,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,13,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
6,15,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
7,19,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
8,21,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
9,23,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
10,25,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
11,29,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
12,31,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
13,33,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
14,35,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
15,37,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
16,39,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
17,41,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
18,43,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
19,45,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
20,47,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
21,49,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
22,53,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
23,55,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
24,59,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
25,65,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
26,67,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
27,71,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
28,73,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
29,77,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
30,79,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
31,81,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
32,83,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
33,85,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
34,87,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
35,89,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
36,91,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
37,93,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
38,95,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
39,97,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
40,99,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
41,101,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
42,103,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
43,105,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
44,107,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
45,109,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
46,113,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
47,115,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
48,119,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
49,121,1,1,,69611,4993,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
50,123,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
51,125,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
52,129,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
53,131,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
54,133,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
55,137,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
56,139,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
57,141,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
58,143,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
59,145,1,1,,69611,4993,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
60,155,1,1,,69611,4993,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
61,157,1,1,,69611,4993,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
62,161,1,1,,69611,4993,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
63,165,1,1,,69611,4993,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
64,167,1,1,,69611,4993,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
65,175,1,1,,69611,4993,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
66,179,1,1,,69611,4993,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
67,180,1,1,,69611,4993,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
68,192,1,1,,69611,4993,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
69,198,1,1,,69611,4993,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in C57BL/6 mice,Other,,
70,218,1,1,,69611,4993,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in C57BL/6 mice,Other,,
71,228,1,1,,69611,4993,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Friend Virus Leukemia (Solid) (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
72,248,1,1,,69611,4993,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
73,250,1,1,,69611,4993,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
74,256,1,1,,69611,4993,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
75,272,1,1,,69611,4993,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intramuscular) in B6D2F1 (BDF1) mice,Other,,
76,284,1,1,,69611,4993,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to Methotrexate; NSC 740 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
77,328,1,1,,69611,4993,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
78,342,1,1,,69611,4993,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma 180 (subcutaneous) in Swiss mice,Other,,
79,357,2,1,,855854,4993,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
80,357,2,1,,11112140,4993,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
81,361,1,2,,855854,4993,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
82,364,1,3,,855854,4993,Active,,,,,Cell Proliferation & Viability (Cytotoxicity) Assay,Confirmatory,,
83,368,2,3,,855854,4993,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
84,371,1,1,,855854,4993,Active,,,,,Human A549 Lung Tumor Cell Growth Inhibition Assay,Screening,,
85,373,1,4,,855854,4993,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
86,374,2,3,,855854,4993,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
87,375,2,3,,855854,4993,Inactive,90108679.0,,,,Mycobacterium tuberculosis Pantothenate Synthetase Assay,Confirmatory,,
88,410,1,5,,11112140,4993,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
89,411,2,1,,855854,4993,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
90,411,2,1,,11112140,4993,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
91,421,1,3,,17389746,4993,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
92,422,1,5,,855854,4993,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
93,425,3,2,,855854,4993,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
94,426,1,2,,17389746,4993,Active,,,,,Cell Viability - Jurkat,Confirmatory,,
95,427,1,1,,17389746,4993,Active,,,,,Cell Viability - Hek293,Confirmatory,,
96,429,1,5,,855854,4993,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
97,429,1,5,,855854,4993,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
98,430,2,4,,855854,4993,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Confirmatory,,
99,431,2,4,,855854,4993,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Confirmatory,,
100,432,2,4,,855854,4993,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
101,433,1,1,,17389746,4993,Active,,,,,Cell Viability - HepG2,Confirmatory,,
102,434,1,2,,17389746,4993,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
103,435,1,2,,17389746,4993,Active,,,,,Cell Viability - SK-N-SH,Confirmatory,,
104,436,2,1,,855854,4993,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
105,438,1,4,,855854,4993,Inactive,223468676.0,5970.0,,,Cellular assay for TNF alpha induced NFkappaB translocation,Screening,,
106,440,3,3,,855854,4993,Inactive,4503779.0,2357.0,,,Primary HTS Assay for Formylpeptide Receptor (FPR) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide-Like-1 (FPRL1) Ligands,Screening,,
107,441,3,3,,855854,4993,Inactive,54112388.0,2358.0,,,Primary HTS Assay for Formylpeptide Receptor-Like-1 (FPRL1) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide Receptor (FPR) Ligands,Screening,,
108,444,1,1,,855854,4993,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
109,444,1,1,,11112140,4993,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
110,445,3,1,,11112140,4993,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
111,445,3,1,,17389746,4993,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
112,446,1,1,,855854,4993,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
113,446,1,1,,11112140,4993,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
114,447,1,1,,11112140,4993,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
115,448,1,2,,11112140,4993,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
116,449,1,5,,855854,4993,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
117,450,1,2,,855854,4993,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
118,450,1,2,,11112140,4993,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
119,451,1,2,,11112140,4993,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
120,454,1,7,,855854,4993,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
121,455,1,7,,855854,4993,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression,Screening,,
122,456,1,7,,855854,4993,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
123,457,1,7,,855854,4993,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression.,Screening,,
124,460,2,2,,855854,4993,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
125,461,1,7,,855854,4993,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression,Screening,,
126,483,1,6,,855854,4993,Inactive,296434520.0,3064.0,,,Aggregation and Clearance of Mutant Huntingtin Protein,Screening,,
127,485,1,8,,855854,4993,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
128,487,1,2,,855854,4993,Inactive,,,,,TNFalpha Induced E-Selectin Expression -  Primary screen,Screening,,
129,488,2,1,,855854,4993,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
130,501,2,2,,855854,4993,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
131,518,2,6,,855854,4993,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
132,521,2,5,,855854,4993,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
133,522,1,2,,855854,4993,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
134,524,1,3,,855854,4993,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
135,525,1,3,,855854,4993,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
136,526,1,1,,11112140,4993,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
137,527,3,1,,855854,4993,Inactive,,,,,Primary HTS Assay for Inhibitors of Bacterial Quorum Sensing,Screening,,
138,528,1,4,,855854,4993,Inactive,67191027.0,3676.0,,,Allosteric Agonists for the VLA-4 Integrin,Screening,,
139,529,1,4,,855854,4993,Inactive,67191027.0,3676.0,,,Allosteric Antagonists for the VLA-4 Integrin,Screening,,
140,530,1,1,,11112140,4993,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
141,530,1,1,,17389746,4993,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
142,538,2,2,,855854,4993,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
143,539,1,2,,855854,4993,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
144,540,1,1,,17389746,4993,Inconclusive,,,,,Cell Viability - N2a,Confirmatory,,
145,541,1,1,,17389746,4993,Inconclusive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
146,542,1,1,,17389746,4993,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
147,543,1,1,,17389746,4993,Active,,,,,Cell Viability - H-4-II-E,Confirmatory,,
148,544,2,1,,17389746,4993,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
149,545,1,1,,17389746,4993,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
150,546,1,1,,17389746,4993,Active,,,,,Cell Viability - Mesenchymal,Confirmatory,,
151,552,1,3,,855854,4993,Inactive,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type),Screening,,
152,555,1,2,,855854,4993,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
153,556,1,3,,855854,4993,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
154,559,2,2,,855854,4993,Inactive,147728.0,,,,RNA polymerase,Screening,,
155,560,1,2,,855854,4993,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
156,561,1,3,,855854,4993,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
157,565,1,4,,855854,4993,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
158,567,1,4,,855854,4993,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
159,568,1,7,,855854,4993,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
160,568,1,7,,855854,4993,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
161,570,1,4,,855854,4993,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
162,571,1,4,,855854,4993,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
163,572,1,5,,855854,4993,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay (Pilot Screen),Screening,,
164,573,1,4,,855854,4993,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
165,574,1,3,,855854,4993,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
166,575,1,4,,855854,4993,Inactive,,,,,Human Endothelial Cell Proliferation Assay,Screening,,
167,576,1,2,,855854,4993,Inactive,67191027.0,3676.0,,,Auto-fluorescence of compounds effecting screening of VLA-4 Integrin,Other,,
168,577,1,1,,855854,4993,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
169,580,1,5,,855854,4993,Inconclusive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay,Screening,,
170,581,2,2,,855854,4993,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
171,583,2,6,,855854,4993,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
172,584,1,3,,11112140,4993,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
173,584,1,3,,17389746,4993,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
174,585,1,4,,11112140,4993,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
175,585,1,4,,17389746,4993,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
176,587,1,5,,855854,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
177,587,1,5,,11112140,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
178,588,1,4,,855854,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
179,588,1,4,,11112140,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
180,589,1,3,,855854,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
181,589,1,3,,11112140,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
182,590,1,3,,855854,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
183,590,1,3,,11112140,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
184,591,1,4,,855854,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
185,591,1,4,,11112140,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
186,592,1,6,,855854,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
187,592,1,6,,11112140,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
188,593,1,4,,855854,4993,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
189,593,1,4,,11112140,4993,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
190,594,1,4,,855854,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
191,594,1,4,,11112140,4993,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
192,595,1,3,,11112140,4993,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
193,595,1,3,,17389746,4993,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
194,596,1,2,,11112140,4993,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
195,596,1,2,,17389746,4993,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
196,597,1,3,,855854,4993,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
197,597,1,3,,11112140,4993,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
198,598,1,4,,855854,4993,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
199,601,1,4,,855854,4993,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance Pilot Screen,Screening,,
200,602,1,4,,855854,4993,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
201,603,1,2,,11112140,4993,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
202,603,1,2,,17389746,4993,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
203,604,1,3,,855854,4993,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
204,605,1,2,,11112140,4993,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
205,605,1,2,,17389746,4993,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
206,606,1,3,,855854,4993,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
207,606,1,3,,855854,4993,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
208,607,1,3,,11112140,4993,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
209,609,1,2,,855854,4993,Inactive,,,,,Chemical Complementation Assay for MKP-3,Screening,,
210,614,1,6,,855854,4993,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
211,615,1,6,,855854,4993,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
212,618,2,6,,855854,4993,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
213,620,2,5,,855854,4993,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
214,622,1,2,,855854,4993,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Negative Modulator Primary Screen,Screening,,
215,623,1,3,,855854,4993,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Positive Modulator: Primary Screen,Screening,,
216,624,1,2,,855854,4993,Inactive,,,,,Measurement of GPCR-mediated thallium flux through GIRK channels: Primary Screen,Screening,,
217,625,1,2,,855854,4993,Inactive,,,,,Discovery of Novel Allosteric Agonists of the M4 Muscarinic Receptor: Primary Screen,Screening,,
218,626,1,3,,855854,4993,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
219,628,2,4,,855854,4993,Inactive,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
220,629,1,3,,855854,4993,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
221,630,1,1,,855854,4993,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
222,631,1,4,,855854,4993,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
223,631,1,4,,855854,4993,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
224,633,1,3,,855854,4993,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
225,639,1,2,,855854,4993,Active,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
226,641,1,4,,855854,4993,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
227,645,1,4,,855854,4993,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
228,648,1,3,,855854,4993,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
229,654,1,1,,17389746,4993,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
230,655,1,1,,17389746,4993,Active,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
231,656,1,1,,17389746,4993,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
232,657,1,1,,17389746,4993,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
233,658,1,1,,17389746,4993,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
234,659,1,1,,17389746,4993,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
235,660,1,1,,17389746,4993,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
236,661,1,1,,17389746,4993,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
237,662,1,1,,11112140,4993,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
238,662,1,1,,17389746,4993,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
239,663,1,1,,17389746,4993,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
240,664,1,1,,17389746,4993,Active,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
241,665,1,1,,17389746,4993,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
242,666,1,1,,17389746,4993,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
243,667,1,1,,17389746,4993,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
244,680,1,10,,855854,4993,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
245,684,1,12,,855854,4993,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
246,686,1,1,,855854,4993,Inactive,,,,,Zebrafish Lipid Metabolism Assay---Primary Screen,Screening,,
247,687,1,17,,855854,4993,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
248,701,1,17,,855854,4993,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
249,708,1,4,,855854,4993,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
250,709,1,2,,855854,4993,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
251,719,1,3,,855854,4993,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
252,731,1,5,,855854,4993,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
253,731,1,5,,855854,4993,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
254,746,1,1,,855854,4993,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
255,750,1,3,,855854,4993,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
256,751,1,3,,855854,4993,Inactive,,,,,Disassembly of the 26S Proteasome (ATP Hydrolysis-dependent),Screening,,
257,757,1,4,,855854,4993,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
258,758,1,4,,855854,4993,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
259,759,1,4,,855854,4993,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
260,760,1,4,,855854,4993,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
261,761,1,4,,855854,4993,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
262,764,1,4,,855854,4993,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
263,770,1,1,,855854,4993,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (24 Hour Treatment Protocol),Screening,,
264,771,1,2,,855854,4993,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (48 Hour Treatment Protocol),Screening,,
265,772,1,2,,855854,4993,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (72 Hour Treatment Protocol),Screening,,
266,774,1,2,,855854,4993,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
267,775,1,3,,855854,4993,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
268,781,1,1,,855854,4993,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
269,782,1,2,,855854,4993,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
270,782,1,2,,855854,4993,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
271,793,1,2,,855854,4993,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
272,795,1,1,,855854,4993,Inactive,,,,,MLSCN Assay for Activators of Prostate Cell Differentiation,Screening,,
273,797,1,1,,855854,4993,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
274,798,2,12,,855854,4993,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
275,799,1,5,,855854,4993,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
276,800,2,11,,855854,4993,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
277,803,1,4,,855854,4993,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
278,804,1,3,,855854,4993,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
279,813,1,4,,855854,4993,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
280,817,1,1,,855854,4993,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
281,818,1,2,,855854,4993,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
282,827,1,2,,855854,4993,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
283,828,1,5,,855854,4993,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
284,834,1,3,,855854,4993,Inactive,,,,,C. albicans biofilm killing,Screening,,
285,841,1,1,,855854,4993,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
286,847,1,2,,855854,4993,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
287,861,1,1,,855854,4993,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
288,862,1,2,,855854,4993,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
289,868,1,3,,855854,4993,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
290,871,1,2,,855854,4993,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
291,873,1,13,,855854,4993,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
292,875,1,2,,11112140,4993,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
293,875,1,2,,17389746,4993,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
294,878,1,2,,855854,4993,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
295,880,2,1,,855854,4993,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
296,880,2,1,,855854,4993,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
297,880,2,1,,11112140,4993,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
298,880,2,1,,11112140,4993,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
299,880,2,1,,17389746,4993,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
300,880,2,1,,17389746,4993,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
301,880,2,1,,26747011,4993,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
302,880,2,1,,26747011,4993,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
303,881,2,2,,11112140,4993,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
304,881,2,2,,17389746,4993,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
305,883,1,3,,11112140,4993,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
306,884,1,2,,11112140,4993,Inactive,13435386.0,1576.0,10.0,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
307,884,1,2,,17389746,4993,Inactive,13435386.0,1576.0,5.0119,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
308,885,1,2,,11112140,4993,Inconclusive,13435386.0,1576.0,10.0,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
309,885,1,2,,17389746,4993,Inconclusive,13435386.0,1576.0,5.0119,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
310,886,1,2,,11112140,4993,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
311,886,1,2,,11112140,4993,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
312,886,1,2,,17389746,4993,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
313,886,1,2,,17389746,4993,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
314,887,1,2,,11112140,4993,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
315,887,1,2,,17389746,4993,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
316,889,1,3,,11112140,4993,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
317,889,1,3,,17389746,4993,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
318,891,1,2,,11112140,4993,Inconclusive,40805836.0,1565.0,7.9433,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
319,892,1,2,,11112140,4993,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
320,892,1,2,,17389746,4993,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
321,893,1,2,,11112140,4993,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
322,893,1,2,,11112140,4993,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
323,893,1,2,,17389746,4993,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
324,893,1,2,,17389746,4993,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
325,894,2,1,,855854,4993,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
326,894,2,1,,11112140,4993,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
327,894,2,1,,17389746,4993,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
328,894,2,1,,26747011,4993,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
329,898,1,1,,855854,4993,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
330,899,1,2,,11112140,4993,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
331,900,1,3,,11112140,4993,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
332,900,1,3,,17389746,4993,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
333,901,1,2,,11112140,4993,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
334,902,1,2,,11112140,4993,Inconclusive,120407068.0,7157.0,7.9433,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
335,902,1,2,,17389746,4993,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
336,910,1,2,,17389746,4993,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
337,912,1,2,,11112140,4993,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
338,912,1,2,,17389746,4993,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
339,914,1,3,,855854,4993,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
340,914,1,3,,11112140,4993,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
341,915,1,3,,855854,4993,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
342,915,1,3,,11112140,4993,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
343,920,1,2,,855854,4993,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
344,921,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
345,923,1,2,,11112140,4993,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
346,923,1,2,,17389746,4993,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
347,924,1,2,,11112140,4993,Inconclusive,120407068.0,7157.0,12.5893,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
348,924,1,2,,17389746,4993,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
349,925,1,2,,11112140,4993,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
350,925,1,2,,17389746,4993,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
351,926,1,2,,11112140,4993,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
352,926,1,2,,17389746,4993,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
353,927,1,3,,11112140,4993,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
354,927,1,3,,17389746,4993,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
355,930,1,2,,17389746,4993,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
356,932,1,4,,855854,4993,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
357,938,1,2,,11112140,4993,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
358,938,1,2,,17389746,4993,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
359,940,1,2,,855854,4993,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
360,940,1,2,,26611904,4993,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
361,946,1,2,,17389746,4993,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
362,947,1,2,,17389746,4993,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
363,948,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
364,950,1,1,,855854,4993,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
365,951,1,1,,855854,4993,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
366,952,1,1,,855854,4993,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
367,955,1,2,,17389746,4993,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
368,960,1,2,,17389746,4993,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
369,961,1,2,,17389746,4993,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
370,962,1,2,,17389746,4993,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
371,963,1,2,,17389746,4993,Inconclusive,,,7.9433,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
372,964,1,2,,17389746,4993,Active,,,7.9433,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
373,965,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
374,966,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
375,967,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
376,968,1,2,,17389746,4993,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-009,Confirmatory,,
377,969,1,2,,17389746,4993,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-011,Confirmatory,,
378,970,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
379,971,1,2,,17389746,4993,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-015,Confirmatory,,
380,972,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
381,973,1,2,,17389746,4993,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-019,Confirmatory,,
382,974,1,2,,17389746,4993,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-021,Confirmatory,,
383,975,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
384,976,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
385,977,1,2,,17389746,4993,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-002,Confirmatory,,
386,978,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
387,979,1,2,,17389746,4993,Active,,,50.1187,Potency,Cell Viability - LYMP2-007,Confirmatory,,
388,980,1,2,,17389746,4993,Inconclusive,,,5.0119,Potency,Cell Viability - LYMP2-008,Confirmatory,,
389,981,1,2,,17389746,4993,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-010,Confirmatory,,
390,982,1,2,,17389746,4993,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-012,Confirmatory,,
391,983,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
392,984,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
393,985,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
394,986,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
395,987,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
396,988,1,2,,17389746,4993,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-024,Confirmatory,,
397,989,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
398,993,1,2,,17389746,4993,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
399,994,1,2,,17389746,4993,Inconclusive,,,7.9433,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
400,995,1,2,,11112140,4993,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
401,995,1,2,,17389746,4993,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
402,1001,2,2,,855854,4993,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
403,1006,1,6,,855854,4993,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
404,1007,1,1,,855854,4993,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
405,1008,1,2,,855854,4993,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
406,1009,1,2,,855854,4993,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
407,1012,1,4,,855854,4993,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
408,1016,1,4,,855854,4993,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
409,1018,2,5,,855854,4993,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
410,1020,1,5,,855854,4993,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
411,1021,1,1,,855854,4993,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
412,1022,1,1,,855854,4993,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
413,1027,1,3,,855854,4993,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
414,1030,2,1,,855854,4993,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
415,1030,2,1,,11112140,4993,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
416,1030,2,1,,17389746,4993,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
417,1030,2,1,,26747011,4993,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
418,1032,1,2,,855854,4993,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
419,1032,1,2,,855854,4993,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
420,1040,1,2,,855854,4993,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
421,1048,1,1,,855854,4993,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
422,1048,1,1,,855854,4993,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
423,1049,1,1,,855854,4993,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
424,1049,1,1,,855854,4993,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
425,1051,1,1,,855854,4993,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
426,1051,1,1,,855854,4993,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
427,1063,1,1,,855854,4993,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
428,1066,1,2,,855854,4993,Active,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
429,1085,1,1,,855854,4993,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
430,1135,1,3,,855854,4993,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
431,1136,1,3,,855854,4993,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
432,1189,1,5,,48414402,4993,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
433,1194,1,3,,48414402,4993,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
434,1195,1,2,,48416502,4993,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
435,1199,1,3,,48414402,4993,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
436,1203,1,3,,855854,4993,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
437,1205,1,4,,48414402,4993,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
438,1208,1,3,,48414402,4993,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
439,1209,2,2,,855854,4993,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
440,1210,1,1,,855854,4993,Inactive,6166154.0,2100.0,,,Estrogen Receptor (beta) binding:  Primary Screen,Screening,,
441,1211,1,1,,855854,4993,Inactive,5821726.0,2099.0,,,Estrogen Receptor (alpha) binding: Primary Screen,Screening,,
442,1214,1,4,,855854,4993,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
443,1216,1,5,,855854,4993,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
444,1217,1,4,,855854,4993,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
445,1220,2,2,,855854,4993,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
446,1222,1,6,,855854,4993,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
447,1229,1,3,,855854,4993,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
448,1233,1,1,,855854,4993,Inactive,9937384.0,,,IC50,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Confirmatory Screen,Confirmatory,,
449,1235,1,2,,855854,4993,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
450,1236,1,1,,855854,4993,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
451,1239,1,3,,855854,4993,Active,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
452,1239,1,3,,855854,4993,Active,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
453,1242,1,1,,855854,4993,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
454,1251,1,1,,855854,4993,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
455,1273,1,1,,855854,4993,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
456,1274,1,2,,855854,4993,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
457,1276,1,1,,855854,4993,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
458,1285,1,1,,855854,4993,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
459,1296,1,1,,855854,4993,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
460,1304,1,2,,855854,4993,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
461,1321,1,2,,855854,4993,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
462,1325,1,2,,855854,4993,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
463,1326,1,4,,855854,4993,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
464,1332,1,1,,49698727,4993,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
465,1359,1,4,,855854,4993,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
466,1362,1,2,,855854,4993,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
467,1376,1,2,,855854,4993,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
468,1377,1,1,,855854,4993,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
469,1379,1,2,,855854,4993,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
470,1379,1,2,,11112140,4993,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
471,1379,1,2,,26747011,4993,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
472,1381,1,1,,855854,4993,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
473,1385,2,2,,855854,4993,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
474,1415,1,2,,855854,4993,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
475,1415,1,2,,855854,4993,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
476,1416,1,2,,855854,4993,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
477,1422,1,1,,855854,4993,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
478,1422,1,1,,26611904,4993,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
479,1423,1,2,,855854,4993,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
480,1423,1,2,,855854,4993,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
481,1424,1,1,,855854,4993,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
482,1430,1,1,,855854,4993,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
483,1434,2,3,,855854,4993,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
484,1434,2,3,,855854,4993,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
485,1439,1,1,,855854,4993,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
486,1439,1,1,,855854,4993,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
487,1440,1,1,,855854,4993,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
488,1440,1,1,,855854,4993,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
489,1441,1,1,,855854,4993,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
490,1441,1,1,,855854,4993,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
491,1443,1,3,,855854,4993,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
492,1445,1,1,,855854,4993,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
493,1446,1,3,,855854,4993,Active,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
494,1448,1,3,,855854,4993,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
495,1452,1,1,,855854,4993,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
496,1452,1,1,,11112140,4993,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
497,1452,1,1,,17389746,4993,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
498,1454,1,1,,11112140,4993,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
499,1454,1,1,,26747011,4993,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
500,1456,1,1,,855854,4993,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
501,1457,1,1,,855854,4993,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
502,1457,1,1,,11112140,4993,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
503,1457,1,1,,17389746,4993,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
504,1457,1,1,,26747011,4993,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
505,1458,1,1,,855854,4993,Inactive,10937869.0,6607.0,1.7783,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
506,1458,1,1,,11112140,4993,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
507,1458,1,1,,17389746,4993,Inactive,10937869.0,6607.0,28.1838,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
508,1458,1,1,,26747011,4993,Inactive,10937869.0,6607.0,35.4813,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
509,1460,1,3,,855854,4993,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
510,1460,1,3,,26747011,4993,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
511,1461,1,2,,855854,4993,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
512,1463,1,1,,855854,4993,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
513,1463,1,1,,26747011,4993,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
514,1465,1,1,,855854,4993,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
515,1466,1,2,,855854,4993,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
516,1467,1,3,,855854,4993,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
517,1467,1,3,,11112140,4993,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
518,1467,1,3,,26747011,4993,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
519,1468,1,1,,855854,4993,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
520,1468,1,1,,26747011,4993,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
521,1469,1,1,,855854,4993,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
522,1469,1,1,,11112140,4993,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
523,1469,1,1,,17389746,4993,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
524,1469,1,1,,26747011,4993,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
525,1469,1,1,,26751532,4993,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
526,1471,2,1,,11112140,4993,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
527,1471,2,1,,17389746,4993,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
528,1471,2,1,,26747011,4993,Unspecified,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
529,1471,2,1,,26751532,4993,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
530,1476,2,1,,855854,4993,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
531,1476,2,1,,11112140,4993,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
532,1476,2,1,,17389746,4993,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
533,1476,2,1,,26747011,4993,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
534,1477,1,1,,855854,4993,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
535,1477,1,1,,11112140,4993,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
536,1477,1,1,,17389746,4993,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
537,1477,1,1,,26747011,4993,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
538,1478,2,1,,855854,4993,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
539,1478,2,1,,11112140,4993,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
540,1478,2,1,,17389746,4993,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
541,1478,2,1,,26747011,4993,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
542,1479,1,2,,855854,4993,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
543,1479,1,2,,11112140,4993,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
544,1479,1,2,,17389746,4993,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
545,1479,1,2,,26747011,4993,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
546,1479,1,2,,26751532,4993,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
547,1481,1,2,,855854,4993,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
548,1486,1,3,,855854,4993,Active,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
549,1487,1,1,,855854,4993,Inconclusive,27436948.0,4000.0,31.6228,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
550,1487,1,1,,11112140,4993,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
551,1490,2,1,,855854,4993,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
552,1490,2,1,,11112140,4993,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
553,1490,2,1,,26747011,4993,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
554,1490,2,1,,26751532,4993,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
555,1496,1,4,,855854,4993,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
556,1496,1,4,,855854,4993,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
557,1509,1,2,,855854,4993,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
558,1510,1,3,,855854,4993,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
559,1511,1,3,,855854,4993,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
560,1515,1,2,,855854,4993,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
561,1519,1,3,,11112140,4993,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
562,1519,1,3,,26747011,4993,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
563,1527,1,3,,855854,4993,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
564,1529,1,1,,855854,4993,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
565,1530,1,1,,855854,4993,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
566,1531,1,1,,855854,4993,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
567,1532,1,1,,855854,4993,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
568,1554,1,1,,855854,4993,Active,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
569,1556,1,4,,855854,4993,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
570,1565,2,2,,855854,4993,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
571,1566,2,3,,855854,4993,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
572,1578,3,2,,855854,4993,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
573,1580,1,1,,8149512,4993,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
574,1581,1,1,,8149512,4993,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
575,1582,1,1,,8149512,4993,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
576,1583,1,1,,8149512,4993,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
577,1584,1,1,,8149512,4993,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
578,1585,1,1,,8149512,4993,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
579,1586,1,1,,8149512,4993,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
580,1587,1,1,,8149512,4993,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
581,1588,1,1,,8149512,4993,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
582,1589,1,1,,8149512,4993,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
583,1590,1,1,,8149512,4993,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
584,1593,1,1,,8149512,4993,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
585,1594,1,1,,8149512,4993,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
586,1595,1,1,,8149512,4993,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
587,1596,1,1,,8149512,4993,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
588,1597,1,1,,8149512,4993,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
589,1598,1,1,,8149512,4993,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
590,1599,1,1,,8149512,4993,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
591,1600,1,1,,8149512,4993,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
592,1601,1,1,,8149512,4993,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
593,1602,1,1,,8149512,4993,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
594,1603,1,1,,8149512,4993,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
595,1604,1,1,,8149512,4993,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
596,1605,1,1,,8149512,4993,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
597,1606,1,1,,8149512,4993,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
598,1607,1,1,,8149512,4993,Active,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
599,1608,1,1,,8149512,4993,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
600,1609,1,1,,8149512,4993,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
601,1610,1,1,,8149512,4993,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
602,1612,1,1,,8149512,4993,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
603,1613,1,1,,8149512,4993,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
604,1614,1,1,,8149512,4993,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
605,1616,1,1,,8149512,4993,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
606,1619,1,2,,855854,4993,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
607,1621,1,2,,855854,4993,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
608,1626,1,2,,855854,4993,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
609,1631,3,1,,855854,4993,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
610,1634,3,1,,855854,4993,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
611,1654,2,2,,855854,4993,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
612,1662,1,2,,855854,4993,Active,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
613,1663,1,2,,855854,4993,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
614,1672,1,3,,855854,4993,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
615,1688,1,1,,855854,4993,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
616,1688,1,1,,26751532,4993,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
617,1700,1,2,,855854,4993,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
618,1706,1,2,,855854,4993,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
619,1721,1,2,,855854,4993,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
620,1722,1,2,,855854,4993,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
621,1766,1,1,,855854,4993,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
622,1766,1,1,,855854,4993,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
623,1766,1,1,,11112140,4993,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
624,1766,1,1,,11112140,4993,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
625,1766,1,1,,26747011,4993,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
626,1766,1,1,,26747011,4993,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
627,1766,1,1,,26751532,4993,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
628,1766,1,1,,26751532,4993,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
629,1768,1,1,,855854,4993,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
630,1768,1,1,,855854,4993,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
631,1768,1,1,,11112140,4993,Inconclusive,18860839.0,4221.0,14.1254,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
632,1768,1,1,,11112140,4993,Inconclusive,56550039.0,4297.0,14.1254,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
633,1768,1,1,,26747011,4993,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
634,1768,1,1,,26747011,4993,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
635,1768,1,1,,26751532,4993,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
636,1768,1,1,,26751532,4993,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
637,1775,1,2,,855854,4993,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
638,1776,1,2,,855854,4993,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
639,1777,3,2,,855854,4993,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
640,1778,3,3,,855854,4993,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
641,1779,2,2,,855854,4993,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
642,1789,1,2,,855854,4993,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
643,1800,1,2,,855854,4993,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
644,1813,1,2,,855854,4993,Active,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
645,1814,1,2,,855854,4993,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
646,1817,2,2,,855854,4993,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
647,1822,1,3,,855854,4993,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
648,1825,1,1,,855854,4993,Active,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
649,1832,2,1,,855854,4993,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
650,1845,1,2,,855854,4993,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
651,1850,2,1,,855854,4993,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
652,1850,2,1,,56422411,4993,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
653,1851,1,2,,11112140,4993,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
654,1851,1,2,1.0,11112140,4993,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
655,1851,1,2,2.0,11112140,4993,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
656,1851,1,2,3.0,11112140,4993,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
657,1851,1,2,4.0,11112140,4993,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
658,1851,1,2,5.0,11112140,4993,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
659,1861,2,1,,855854,4993,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
660,1862,1,4,,855854,4993,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
661,1863,2,1,,855854,4993,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
662,1863,2,1,,56422411,4993,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
663,1865,1,1,,855854,4993,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
664,1865,1,1,,11112140,4993,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
665,1865,1,1,,26747011,4993,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
666,1867,1,4,,855854,4993,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
667,1868,1,4,,855854,4993,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
668,1870,1,4,,855854,4993,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
669,1873,1,4,,855854,4993,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
670,1875,2,1,,855854,4993,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
671,1885,2,1,,855854,4993,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
672,1887,1,4,,855854,4993,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
673,1899,1,3,,56422411,4993,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
674,1900,1,1,,855854,4993,Active,,,3.094,EC50,Luminescence Microorganism-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to SK(-)GAS Group A Streptococcus,Confirmatory,,
675,1902,1,1,,855854,4993,Active,15675770.0,901648.0,3.992,EC50,Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promotor Activity,Confirmatory,,
676,1903,2,3,,855854,4993,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
677,1903,2,3,,56422411,4993,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
678,1906,1,3,,56422411,4993,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
679,1907,1,2,,855854,4993,Active,,,,,Luminescence-based confirmation cell-based assay for cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
680,1910,1,2,,855854,4993,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
681,1914,1,2,,855854,4993,Inactive,15675770.0,901648.0,150.0,EC50,Absorbance Microorganism-Based Dose Response HTS to Identify Inhibitors of Streptokinase Expression,Confirmatory,,
682,1915,1,2,,855854,4993,Active,,,51.168,EC50,Luminescence Microorganism-Based Dose Response HTS to Identify Compounds Cytotoxic to Streptococcus,Confirmatory,,
683,1947,1,2,,56422411,4993,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
684,1948,1,1,,11112140,4993,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
685,1948,1,1,,17389746,4993,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
686,1948,1,1,,26747011,4993,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
687,1950,1,3,,56422411,4993,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
688,1956,1,1,,855854,4993,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
689,1961,2,2,,855854,4993,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
690,1962,1,2,,56422411,4993,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
691,1974,1,2,,56422411,4993,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
692,1979,1,1,,855854,4993,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
693,1984,1,3,,855854,4993,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
694,1985,2,1,,855854,4993,Inactive,,,,IC50,A screen for inhibitors of the PhoP regulon in Salmonella Typhi using a modified counterscreen,Confirmatory,,
695,1986,1,2,,855854,4993,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
696,1987,1,2,,56422411,4993,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
697,1988,1,2,,855854,4993,Active,,,0.2,EC50,Luminescence Cell-Based Dose Confimation HTS to Identify Inhibitors of of 5'UTR Stem-Loop Driven Alpha-Synuclein mRNA Translation in H4 Neuroglioblastoma Cells,Confirmatory,,
698,1990,1,2,,855854,4993,Active,,,3.815,EC50,Luminescence Cell-Based Dose Response HTS to Identify Inhibitors of Luciferase Translation or Activity in H4 Neuroglioblastoma Cells,Confirmatory,,
699,1994,1,2,,855854,4993,Active,,,10.48,EC50,Luminescence Cell-Based Dose Response HTS to Identify Inhibitors of 5'UTR Stem-Loop Driven Prion Protein mRNA Translation in H4 Neuroglioblastoma Cells,Confirmatory,,
700,1996,2,2,,56422411,4993,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
701,2006,3,2,,855854,4993,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
702,2006,3,2,,855854,4993,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
703,2006,3,2,,855854,4993,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
704,2012,3,2,,855854,4993,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
705,2013,2,2,,855854,4993,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
706,2014,3,2,,855854,4993,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
707,2016,1,3,,56422411,4993,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
708,2023,1,3,,56422411,4993,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
709,2025,1,3,,56422411,4993,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
710,2029,1,3,,56422411,4993,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
711,2052,2,1,,56422411,4993,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
712,2057,1,2,,56422411,4993,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
713,2058,3,2,,855854,4993,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
714,2062,1,2,,85209434,4993,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
715,2066,1,4,,56422411,4993,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
716,2071,2,2,,855854,4993,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
717,2073,2,3,,855854,4993,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
718,2073,2,3,,855854,4993,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
719,2094,1,2,,855854,4993,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
720,2094,1,2,,855854,4993,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
721,2094,1,2,,855854,4993,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
722,2097,1,2,,855854,4993,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
723,2098,1,1,,855854,4993,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
724,2099,1,1,,855854,4993,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
725,2100,1,1,,855854,4993,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
726,2101,1,1,,855854,4993,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
727,2101,1,1,,11112140,4993,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
728,2101,1,1,,17389746,4993,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
729,2101,1,1,,26747011,4993,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
730,2107,1,1,,855854,4993,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
731,2107,1,1,,11112140,4993,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
732,2107,1,1,,17389746,4993,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
733,2107,1,1,,26747011,4993,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
734,2112,1,1,,855854,4993,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
735,2112,1,1,,11112140,4993,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
736,2112,1,1,,17389746,4993,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
737,2112,1,1,,26747011,4993,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
738,2120,1,1,,17389746,4993,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
739,2129,1,2,,56422411,4993,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
740,2130,1,3,,56422411,4993,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
741,2147,1,1,,855854,4993,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
742,2147,1,1,,11112140,4993,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
743,2147,1,1,,26747011,4993,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
744,2156,2,2,,855854,4993,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
745,2174,1,3,,56422411,4993,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
746,2177,1,3,,56422411,4993,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
747,2205,1,1,,855854,4993,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
748,2216,1,3,,855854,4993,Inconclusive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
749,2221,1,2,,855854,4993,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
750,2227,1,2,,855854,4993,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
751,2234,1,2,,56422411,4993,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
752,2235,1,2,,56422411,4993,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
753,2237,1,2,,855854,4993,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
754,2239,1,2,,855854,4993,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
755,2240,1,1,,85788820,4993,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
756,2241,1,1,,85788820,4993,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
757,2242,1,1,,855854,4993,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
758,2247,1,2,,855854,4993,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
759,2252,1,1,,855854,4993,Active,,,10.55,EC50,A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhi identified in the primary screen,Confirmatory,,
760,2275,1,1,,85788820,4993,Active,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
761,2280,2,3,,56422411,4993,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
762,2288,1,1,,855854,4993,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
763,2289,1,1,,855854,4993,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
764,2297,1,2,,85858290,4993,Unspecified,,,,,Inhibition Frequency Index,Other,,
765,2297,1,2,,85860317,4993,Unspecified,,,,,Inhibition Frequency Index,Other,,
766,2300,1,3,,56422411,4993,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
767,2302,1,2,,85858290,4993,Inactive,111034851.0,,,,Inhibition of P. falciparum Dd2,Screening,,
768,2302,1,2,,85860317,4993,Inactive,111034851.0,,,,Inhibition of P. falciparum Dd2,Screening,,
769,2303,1,2,,85858290,4993,Active,,,,,Inhibition of HepG2 cell line,Screening,,
770,2303,1,2,,85860317,4993,Active,,,,,Inhibition of HepG2 cell line,Screening,,
771,2304,1,2,,85858290,4993,Inactive,111034851.0,,,,Inhibition of P. falciparum LDH,Screening,,
772,2304,1,2,,85860317,4993,Inactive,111034851.0,,,,Inhibition of P. falciparum LDH,Screening,,
773,2305,1,2,,85858290,4993,Unspecified,,,0.06,XC50_3D7,XC50 for P. falciparum 3D7,Confirmatory,,
774,2305,1,2,,85860317,4993,Unspecified,,,0.03,XC50_3D7,XC50 for P. falciparum 3D7,Confirmatory,,
775,2306,1,2,,85858290,4993,Active,124513266.0,814112.0,,,Inhibition of P. falciparum 3D7,Screening,,
776,2306,1,2,,85860317,4993,Active,124513266.0,814112.0,,,Inhibition of P. falciparum 3D7,Screening,,
777,2313,1,1,,85788820,4993,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
778,2314,1,2,,855854,4993,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
779,2314,1,2,,855854,4993,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
780,2315,1,2,,855854,4993,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
781,2315,1,2,,855854,4993,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
782,2322,1,1,,85788820,4993,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
783,2326,1,1,,855854,4993,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
784,2330,1,1,,85788820,4993,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
785,2380,1,2,,56422411,4993,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
786,2384,1,1,,855854,4993,Active,,,150.0,IC50,A counter screen for small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
787,2391,1,1,,56422411,4993,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
788,2417,1,1,,855854,4993,Inconclusive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
789,2435,1,2,,56422411,4993,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
790,2445,1,2,,56422411,4993,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
791,2451,1,2,,855854,4993,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
792,2451,1,2,,11112140,4993,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
793,2451,1,2,,26747011,4993,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
794,2472,1,2,,855854,4993,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
795,2472,1,2,,11112140,4993,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
796,2472,1,2,,26747011,4993,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
797,2517,2,1,,855854,4993,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
798,2517,2,1,,11112140,4993,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
799,2517,2,1,,17389746,4993,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
800,2517,2,1,,26747011,4993,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
801,2520,1,4,,56422411,4993,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
802,2521,1,3,,56422411,4993,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
803,2523,1,1,,855854,4993,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
804,2524,1,2,,56422411,4993,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
805,2528,1,2,,855854,4993,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
806,2528,1,2,,11112140,4993,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
807,2528,1,2,,26747011,4993,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
808,2528,1,2,,26751532,4993,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
809,2540,1,2,,56422411,4993,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
810,2544,1,2,,56422411,4993,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
811,2546,1,1,,855854,4993,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
812,2546,1,1,,11112140,4993,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
813,2546,1,1,,17389746,4993,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
814,2546,1,1,,26747011,4993,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
815,2546,1,1,,26751532,4993,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
816,2549,1,1,,855854,4993,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
817,2549,1,1,,11112140,4993,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
818,2549,1,1,,17389746,4993,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
819,2549,1,1,,26747011,4993,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
820,2550,1,3,,855854,4993,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
821,2551,1,1,,855854,4993,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
822,2551,1,1,,11112140,4993,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
823,2551,1,1,,17389746,4993,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
824,2551,1,1,,26747011,4993,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
825,2551,1,1,,26751532,4993,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
826,2553,1,2,,855854,4993,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
827,2557,1,3,,56422411,4993,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
828,2563,1,1,,855854,4993,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
829,2599,1,2,,56422411,4993,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
830,2606,1,2,,56422411,4993,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
831,2610,1,2,,855854,4993,Inactive,,,,SAMPLE2_EC50_uM,Fluorescence Cell-Based Dose Response to Characterize Compounds Cytotoxic to RAS-Dependent BJeLR Fibroblast,Confirmatory,,
832,2629,1,1,,56422411,4993,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
833,2631,1,2,,855854,4993,Inactive,,,133.3,EC50_uM,Fluorescence Cell-Based Dose Response to Characterize Compounds Cytotoxic to RAS-Dependent BJ-TERT-LT-ST Fibroblast,Confirmatory,,
834,2642,1,2,,855854,4993,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
835,2648,1,2,,855854,4993,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
836,2662,2,1,,855854,4993,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
837,2674,1,1,,855854,4993,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
838,2675,1,1,,855854,4993,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
839,2676,1,2,,855854,4993,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
840,2685,1,1,,855854,4993,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
841,2690,1,2,,56422411,4993,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
842,2706,1,1,,855854,4993,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
843,2716,1,1,,56422411,4993,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
844,2732,1,1,,855854,4993,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
845,2751,2,2,,56422411,4993,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
846,2796,1,4,,56422411,4993,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
847,2797,1,2,,56422411,4993,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
848,2805,2,2,,56422411,4993,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
849,2806,2,2,,56422411,4993,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
850,2825,1,2,,56422411,4993,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
851,23734,3,3,,103165594,4993,Unspecified,,,,,Micelle/water partition coefficient (Pmic) of the compound was determined,Other,8691461.0,
852,26811,3,3,,103165594,4993,Unspecified,,,,,Partition coefficient (logP),Other,7392035.0,
853,41219,6,2,,103165594,4993,Unspecified,,,250.0,IC50,Cytotoxicity against human breast cancer cells.,Confirmatory,11881993.0,
854,41220,6,2,,103165594,4993,Active,,,40.0,IC50,In vitro cytotoxicity against Plasmodium falciparum infected BC cell line.,Confirmatory,14736247.0,
855,48922,6,2,,103165594,4993,Unspecified,,,,,Minimum inhibitory concentration required to inhibit Candida albicans (in vitro),Other,7658448.0,
856,54410,6,5,,103165594,4993,Unspecified,,,51.5,Ki,Binding affinity towards cytochrome P450 2C9,Confirmatory,14761192.0,
857,55698,10,5,,103165594,4993,Active,118998.0,,2.4,IC50,Compound was tested for inhibition activity against pneumocystis carinii (Pneumocystis carinii) Dihydrofolate reductase,Confirmatory,9526565.0,
858,55702,10,5,,103165594,4993,Active,118998.0,,3.65,IC50,In vitro inhibitory concentration against Pneumocystis carinii dihydrofolate reductase,Confirmatory,9191966.0,
859,55704,10,5,,103165594,4993,Active,118998.0,,3.7,IC50,Inhibition of Pneumocystis carinii Dihydrofolate Reductase,Confirmatory,9357537.0,
860,55705,9,5,,103165594,4993,Active,118998.0,,3.7,IC50,Inhibition of Dihydrofolate reductase of Pneumocystis carinii,Confirmatory,7799402.0,
861,55826,8,2,,103165594,4993,Active,,,3.65,IC50,Inhibition of dihydrofolate reductase DHFR in Pneumocystis carinii.,Confirmatory,11472209.0,
862,55832,9,5,,103165594,4993,Active,118998.0,,3.7,IC50,Inhibitory activity against Pneumocystis carinii Dihydrofolate reductase,Confirmatory,7877140.0,
863,55833,10,5,,103165594,4993,Active,118998.0,,3.65,IC50,Inhibitory activity against Pneumocystis carinii dihydrofolate reductase,Confirmatory,8632434.0,
864,55836,9,5,,103165594,4993,Active,118998.0,,2.8,IC50,Inhibitory activity against dihydrofolate reductase in Pneumocystis carinii at 37 centigrade.,Confirmatory,7490723.0,
865,55851,8,5,,103165594,4993,Active,118998.0,,0.0097,Ki,Binding affinity was reported with purified recombinant Pneumocystis carinii Dihydrofolate reductase,Confirmatory,7490723.0,
866,56164,9,5,,103165594,4993,Active,729370.0,,0.39,IC50,Inhibition of Toxoplasma gondii Dihydrofolate Reductase,Confirmatory,9357537.0,
867,56174,9,5,,103165594,4993,Active,729370.0,,0.39,IC50,Compound was tested for inhibition activity against Toxoplasma gondii (Toxoplasma gondii) Dihydrofolate reductase,Confirmatory,9526565.0,
868,56179,10,5,,103165594,4993,Active,729370.0,,0.39,IC50,Inhibitory concentration against Toxoplasma gondii dihydrofolate reductase,Confirmatory,9191966.0,
869,56182,10,5,,103165594,4993,Active,729370.0,,0.39,IC50,Inhibition of Dihydrofolate reductase of Toxoplasma gondii,Confirmatory,7799402.0,
870,56189,10,5,,103165594,4993,Active,729370.0,,0.39,IC50,Inhibitory activity against dihydrofolate reductase DHFR in Toxoplasma gondii.,Confirmatory,11472209.0,
871,56317,10,5,,103165594,4993,Active,729370.0,,0.39,IC50,Inhibitory activity against Toxoplasma gondii Dihydrofolate reductase,Confirmatory,7877140.0,
872,56318,9,5,,103165594,4993,Active,729370.0,,0.39,IC50,Inhibitory activity against Toxoplasma gondii dihydrofolate reductase,Confirmatory,8632434.0,
873,56349,9,5,,103165594,4993,Active,729370.0,,0.39,IC50,The ability to inhibit Toxoplasma gondii Dihydrofolate reductase was tested,Confirmatory,10090784.0,
874,56350,7,2,,103165594,4993,Active,,,0.011000000000000001,Ki,Inhibition of recombinant Dihydrofolate reductase from humans.,Confirmatory,10543874.0,
875,56459,7,2,,103165594,4993,Active,,,0.098,Ki,Inhibition of recombinant Dihydrofolate reductase from Trypanosoma cruzi.,Confirmatory,10543874.0,
876,56807,9,2,,103165594,4993,Active,,,2.6,IC50,In vitro inhibition of human dihydrofolate reductase,Confirmatory,7658448.0,
877,57074,9,5,,103165594,4993,Active,1169444.0,,5.0,IC50,Inhibition of dihydrofolate reductase in Candida albicans (in vitro).,Confirmatory,7658448.0,
878,57135,9,2,,103165594,4993,Active,,,0.008,Ki,Cytotoxicity by selective inhibition against human dihydrofolate reductase (DHFR).,Confirmatory,11881993.0,
879,57141,7,2,,103165594,4993,Active,,,0.12,Ki,Inhibition of recombinant Dihydrofolate reductase from humans.,Confirmatory,10543874.0,
880,57266,8,5,,103165594,4993,Active,165971782.0,,0.0014,Kd,Thermodynamic dissociation constant of compound for mutant T46A Escherichia coli dihydrofolate reductase,Confirmatory,1495020.0,
881,57267,8,5,,103165594,4993,Active,165971782.0,,0.016,Kd,Thermodynamic dissociation constant of compound for mutant T46N Escherichia coli dihydrofolate reductase,Confirmatory,1495020.0,
882,57268,8,5,,103165594,4993,Active,165971782.0,,0.0015,Kd,Thermodynamic dissociation constant of compound for mutant T46S Escherichia coli dihydrofolate reductase,Confirmatory,1495020.0,
883,57269,8,5,,103165594,4993,Active,165971782.0,,0.013000000000000001,Kd,Thermodynamic dissociation constant of compound for wild type Escherichia coli dihydrofolate reductase,Confirmatory,1495020.0,
884,57405,8,5,,103165594,4993,Active,165971782.0,,0.0012,Ki,Inhibitor constant of compound for mutant T46A Escherichia coli dihydrofolate reductase,Confirmatory,1495020.0,
885,57406,8,5,,103165594,4993,Active,165971782.0,,0.02,Ki,Inhibitor constant of compound for mutant T46N Escherichia coli dihydrofolate reductase,Confirmatory,1495020.0,
886,57407,8,5,,103165594,4993,Active,165971782.0,,0.0052,Ki,Inhibitor constant of compound for mutant T46S Escherichia coli dihydrofolate reductase,Confirmatory,1495020.0,
887,57408,8,5,,103165594,4993,Active,165971782.0,,0.01,Ki,Inhibitor constant of compound for wild type Escherichia coli dihydrofolate reductase,Confirmatory,1495020.0,
888,57588,4,1,,103165594,4993,Unspecified,165971782.0,,3548130000000.0,Ki,Inhibition constant against binding of Escherichia coli dihydrofolate reductase,Confirmatory,3290487.0,
889,57598,3,10,,103165594,4993,Active,165971782.0,,,,Ratio of Kd to Ki of compound for mutant T46A Escherichia coli dihydrofolate reductase,Other,1495020.0,
890,57599,3,10,,103165594,4993,Active,165971782.0,,,,Ratio of Kd to Ki of compound for mutant T46N Escherichia coli dihydrofolate reductase,Other,1495020.0,
891,57600,3,10,,103165594,4993,Active,165971782.0,,,,Ratio of Kd to Ki of compound for mutant T46S Escherichia coli dihydrofolate reductase,Other,1495020.0,
892,57601,3,10,,103165594,4993,Active,165971782.0,,,,Ratio of Kd to Ki of compound for wild type Escherichia coli dihydrofolate reductase,Other,1495020.0,
893,57645,9,1,,103165594,4993,Active,,,1.4,IC50,In vitro inhibitory concentration against rat liver dihydrofolate reductase,Confirmatory,2810335.0,
894,57797,9,1,,103165594,4993,Active,,,1.5,IC50,Compound was tested for inhibition activity against rat liver lipophilic Dihydrofolate reductase (DHFR).,Confirmatory,9526565.0,
895,57813,9,1,,103165594,4993,Active,,,2.3,IC50,In vitro inhibitory concentration against rat liver dihydrofolate reductase,Confirmatory,9191966.0,
896,57817,9,1,,103165594,4993,Active,,,2.3,IC50,Inhibition of rat liver Dihydrofolate Reductase,Confirmatory,9357537.0,
897,57819,9,5,,103165594,4993,Active,81871579.0,24312.0,2.3,IC50,Inhibition of Dihydrofolate reductase (DHFR) of in rat liver,Confirmatory,7799402.0,
898,57826,9,1,,103165594,4993,Active,,,2.3,IC50,Inhibitory activity against dihydrofolate reductase DHFR in rat liver,Confirmatory,11472209.0,
899,57948,7,2,,103165594,4993,Active,,,0.25,Ki,Inhibition of recombinant Dihydrofolate reductase from Leishmania major.,Confirmatory,10543874.0,
900,57968,9,1,,103165594,4993,Active,,,2.3,IC50,Inhibitory activity against rat liver dihydrofolate reductase,Confirmatory,8632434.0,
901,57972,9,1,,103165594,4993,Active,,,2.3,IC50,Inhibitory activity against rat liver Dihydrofolate reductase,Confirmatory,7877140.0,
902,57975,9,2,,103165594,4993,Active,,,2.3,IC50,Inhibitory activity against dihydrofolate reductase in rat.,Confirmatory,7490723.0,
903,58119,3,8,,103165594,4993,Inconclusive,,,,,Thermodynamic dissociation constant of compound for mutant S108 Plasmodium falciparum dihydrofolate reductase; ND=no data,Other,1495020.0,
904,58120,3,7,,103165594,4993,Inconclusive,,,,,Thermodynamic dissociation constant of compound for Plasmodium falciparum dihydrofolate reductase; ND=no data,Other,1495020.0,
905,58121,7,2,,103165594,4993,Active,,,0.002,Ki,Inhibitor constant of compound for mutant S108 N Plasmodium falciparum in dihydrofolate reductase,Confirmatory,1495020.0,
906,58122,7,2,,103165594,4993,Active,,,0.00018999999999999998,Ki,Inhibitor constant of compound for Plasmodium falciparum dihydrofolate reductase,Confirmatory,1495020.0,
907,58123,3,8,,103165594,4993,Inconclusive,,,,,Ratio of Kd to Ki for mutant S108 N Plasmodium falciparum dihydrofolate reductase; ND=no data,Other,1495020.0,
908,58124,3,7,,103165594,4993,Inconclusive,,,,,Ratio of Kd to Ki for Plasmodium falciparum dihydrofolate reductase; ND=no data,Other,1495020.0,
909,58128,7,2,,103165594,4993,Active,,,0.11199999999999999,Ki,Binding affinity towards mutant dihydrofolate reductase (C59R+S108N+I164L DHFR) of Plasmodium falciparum,Confirmatory,14736247.0,
910,58250,7,2,,103165594,4993,Active,,,0.0671,Ki,Binding affinity towards mutant dihydrofolate reductase (N51I+C59R+S108N DHFR) of Plasmodium falciparum,Confirmatory,14736247.0,
911,58251,7,2,,103165594,4993,Active,,,0.385,Ki,Binding affinity towards mutant dihydrofolate reductase (N51I+C59R+S108N+I164L DHFR) of Plasmodium falciparum,Confirmatory,14736247.0,
912,58252,9,2,,103165594,4993,Active,,,0.0015,Ki,Inhibition constant against wild-type PfDHFR (Plasmodium falciparum dihydrofolate reductase),Confirmatory,12825927.0,
913,58253,7,2,,103165594,4993,Active,,,0.0539,Ki,Inhibition of the C59R+S108N mutant of dihydrofolate reductase (DHFR),Confirmatory,11881993.0,
914,58254,7,2,,103165594,4993,Active,,,0.0286,Ki,Inhibition of the S108N mutant of dihydrofolate reductase (DHFR),Confirmatory,11881993.0,
915,58255,7,2,,103165594,4993,Active,,,0.0006,Ki,Inhibition of the wild-type dihydrofolate reductase (DHFR),Confirmatory,11881993.0,
916,58262,3,7,,103165594,4993,Unspecified,,,,,Inhibition of the C59R+S108N mutant of dihydrofolate reductase (DHFR) relative to Pyr.,Other,11881993.0,
917,58267,3,7,,103165594,4993,Unspecified,,,,,Inhibition of the S108N mutant of dihydrofolate reductase (DHFR) relative to Pyr.,Other,11881993.0,
918,58276,3,7,,103165594,4993,Unspecified,,,,,Inhibition of the wild-type dihydrofolate reductase (DHFR)relative to Pyr.,Other,11881993.0,
919,58282,9,2,,103165594,4993,Active,,,0.0036,Ki,Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with double (A16V + S108T) mutations,Confirmatory,12825927.0,
920,58283,9,2,,103165594,4993,Active,,,0.86,Ki,Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with quadruple (N51I + C59R + S108N + I164L) mutations,Confirmatory,12825927.0,
921,58284,9,2,,103165594,4993,Active,,,0.006,Ki,Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with single A16V mutation,Confirmatory,12825927.0,
922,58285,9,2,,103165594,4993,Active,,,0.0014,Ki,Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with single S108T mutation,Confirmatory,12825927.0,
923,58286,9,2,,103165594,4993,Active,,,0.38,Ki,Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with triple (C59R + S108N + I164L) mutations,Confirmatory,12825927.0,
924,65357,4,3,,103165594,4993,Unspecified,,,,,Inhibition of growth of methotrexate-sensitive (MB1417) strain of Escherichia coli cells.,Other,3934385.0,
925,65359,4,3,,103165594,4993,Unspecified,,,,,Inhibition of growth of methotrexate-resistant (MB1428) strain of Escherichia coli cells.,Other,3934385.0,
926,90953,6,2,,103165594,4993,Active,,,0.67,IC50,The ability to inhibit [3H]- uracil incorporation by Toxoplasma gondii in cultures of HEL cells was tested,Confirmatory,10090784.0,
927,90977,3,4,,103165594,4993,Unspecified,,,,,Percentage growth inhibition of Toxoplasma gondii at concentration of 2 ug/mL using an human myelomonocytic cell line THP-1,Other,10853649.0,
928,91139,5,3,,103165594,4993,Unspecified,,,,,Effect of compound on percent survival of human fibroblast cells in culture was determined at 0 uM,Other,15055998.0,
929,91140,5,3,,103165594,4993,Unspecified,,,,,Effect of compound on percent survival of human fibroblast cells in culture was determined at 10 uM,Other,15055998.0,
930,91141,5,3,,103165594,4993,Unspecified,,,,,Effect of compound on percent survival of human fibroblast cells in culture was determined at 25 uM,Other,15055998.0,
931,91142,5,3,,103165594,4993,Unspecified,,,,,Effect of compound on percent survival of human fibroblast cells in culture was determined at 5 uM,Other,15055998.0,
932,91143,5,3,,103165594,4993,Unspecified,,,,,Effect of compound on percent survival of human fibroblast cells in culture was determined at 50 uM,Other,15055998.0,
933,95488,6,2,,103165594,4993,Unspecified,,,109.0,IC50,Cytotoxicity against human epidermoid carcinoma KB cell.,Confirmatory,11881993.0,
934,95845,6,2,,103165594,4993,Unspecified,,,109.0,IC50,In vitro cytotoxicity against Plasmodium falciparum infected KB cell line,Confirmatory,14736247.0,
935,116237,5,2,,103165594,4993,Inconclusive,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at dosage of 160 mg/kg after subcutaneous administration; no data,Other,7009867.0,
936,116238,7,1,,103165594,4993,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after 20 mg/kg subcutaneous dose,Other,7009867.0,
937,116248,5,2,,103165594,4993,Inconclusive,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at dosage of 320 mg/kg after subcutaneous administration; no data,Other,7009867.0,
938,116251,5,2,,103165594,4993,Inconclusive,,,,,Antimalarial effect against trophozoite induced Plasmodium berghei in mice (Mus musculus) at dosage of 40 mg/kg after subcutaneous administration; no data,Other,7009867.0,
939,116373,8,1,,103165594,4993,Inconclusive,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 640 mg/kg subcutaneous dose,Other,7009867.0,
940,116380,6,2,,103165594,4993,Inconclusive,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 80 mg/kg subcutaneous dose; no data,Other,7009867.0,
941,119229,4,3,,103165594,4993,Unspecified,,,,,Antimalarial activity against trophozoite-induced Plasmodium berghei in mice (Mus musculus),Other,7009867.0,
942,119305,4,4,,103165594,4993,Unspecified,,,,,Number of mice cured at a subcutaneous dose of 160 mg/kg.,Other,7009867.0,
943,119306,4,4,,103165594,4993,Unspecified,,,,,Number of mice cured at a subcutaneous dose of 320 mg/kg.,Other,7009867.0,
944,119308,3,5,,103165594,4993,Unspecified,,,,,Number of mice cured at a dose of 40 mg/kg sc,Other,7009867.0,
945,119309,4,4,,103165594,4993,Unspecified,,,,,Number of mice cured at a dose of 640 mg/kg sc,Other,7009867.0,
946,119310,3,4,,103165594,4993,Unspecified,,,,,Number of mice cured at a dose of 80 mg/kg sc,Other,7009867.0,
947,122498,5,2,,103165594,4993,Unspecified,,,,,Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 40 mg/kg; 1 cured at 60 days postinjection.,Other,3881585.0,
948,122508,6,1,,103165594,4993,Unspecified,,,,,Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 5 mg/kg.,Other,3881585.0,
949,122509,5,2,,103165594,4993,Unspecified,,,,,Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 640 mg/kg; 1 cured and 2 toxic death,Other,3881585.0,
950,122524,5,2,,103165594,4993,Unspecified,,,,,Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 80 mg/kg; 3 cured at 60 days postinjection.,Other,3881585.0,
951,124556,7,1,,103165594,4993,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous dose of 10 mg/kg,Other,6227747.0,
952,124678,7,1,,103165594,4993,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 2.5 mg/kg,Other,6227747.0,
953,124688,6,2,,103165594,4993,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 320 mg/kg subcutaneous dose,Other,6227747.0,
954,124692,6,2,,103165594,4993,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 320 mg/kg; 3 toxic deaths after 2-5 days of injection,Other,6227747.0,
955,124700,7,1,,103165594,4993,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 40 mg/kg; 1 survived after 60 days of postinfection,Other,6227747.0,
956,124705,7,1,,103165594,4993,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 5 mg/kg subcutaneous dose,Other,6227747.0,
957,124707,5,2,,103165594,4993,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 640 mg/kg; 1 survived after 60 days of post infection,Other,6227747.0,
958,124709,5,2,,103165594,4993,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 640 mg/kg; 2 toxic deaths after 2-5 days of injection,Other,6227747.0,
959,124835,5,2,,103165594,4993,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 80 mg/kg; 3 survived after 60 days of postinfection,Other,6227747.0,
960,124864,6,1,,103165594,4993,Unspecified,,,,,Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 1.25 mg/kg.,Other,3881585.0,
961,124999,6,1,,103165594,4993,Unspecified,,,,,Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 10 mg/kg.,Other,3881585.0,
962,125005,5,2,,103165594,4993,Unspecified,,,,,Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 160 mg/kg; 5 cured at 60 days postinjection.,Other,3881585.0,
963,125014,6,1,,103165594,4993,Unspecified,,,,,Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 2.5 mg/kg.,Other,3881585.0,
964,125020,6,1,,103165594,4993,Unspecified,,,,,Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 20 mg/kg.,Other,3881585.0,
965,125024,5,2,,103165594,4993,Unspecified,,,,,Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 320 mg/kg; 2 cured and 3 toxic death,Other,3881585.0,
966,138101,3,4,,103165594,4993,Unspecified,,,,,"Dose needed to increase the survival of treated animals(mouse), to twice the number of days",Other,11689078.0,
967,157697,4,3,,103165594,4993,Active,,,2.5,IC50,Anti-malarial activity against Plasmodium falciparum Dd2,Confirmatory,12699750.0,
968,157842,6,3,,103165594,4993,Active,,,30.9,IC50,Antiplasmodial activity IC50 against Plasmodium falciparum K1CB1 DHFR double-mutant (C59R/S10),Confirmatory,11881993.0,
969,158038,4,3,,103165594,4993,Active,,,2.5,IC50,Inhibitory concentration against multidrug-resistant Plasmodium falciparum Dd2.,Confirmatory,12217353.0,
970,158189,6,2,,103165594,4993,Active,,,0.08,IC50,In vitro antiplasmodial activity (IC50) against Plasmodium falciparum wtTM4/8.2,Confirmatory,11881993.0,
971,158540,6,3,,103165594,4993,Active,,,41.7,IC50,In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase C59R+S108N/I164L (Csl-2) mutant,Confirmatory,14736247.0,
972,158541,6,3,,103165594,4993,Unspecified,,,100.0,IC50,In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase CN51I/C59R/S108N/I164L (V1/S) mutant,Confirmatory,14736247.0,
973,158542,6,3,,103165594,4993,Unspecified,,,73.5,IC50,In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase N51I/C59R/S108N (W2),Confirmatory,14736247.0,
974,158543,6,3,,103165594,4993,Active,,,0.08,IC50,In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase wild type (TM4/8.2),Confirmatory,14736247.0,
975,158556,4,3,,103165594,4993,Active,,,0.0012,IC50,In vitro inhibition of Plasmodium falciparum HB3 (S108N) culture,Confirmatory,9554869.0,
976,158557,4,3,,103165594,4993,Active,,,0.0102,IC50,In vitro inhibition of Plasmodium falciparum K1 (S108N + C59R) culture,Confirmatory,9554869.0,
977,158715,4,4,,103165594,4993,Active,,,2.5,IC50,Inhibition against Plasmodium falciparum Dd2 in erythrocytes in semiautomated micro dilution assay,Confirmatory,12798326.0,
978,158849,8,1,,103165594,4993,Active,,,2.5,IC50,Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes,Confirmatory,11212126.0,
979,158852,4,4,,103165594,4993,Active,,,0.03,IC50,Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes by semiautomated micro dilution,Confirmatory,12565929.0,
980,158864,4,3,,103165594,4993,Active,,,0.003,IC50,Antimalarial activity against Plasmodium falciparum 3D7 in erythrocytes,Confirmatory,11844668.0,
981,158865,4,3,,103165594,4993,Active,,,2.5,IC50,Antimalarial activity against Plasmodium falciparum Dd2 in erythrocytes,Confirmatory,11844668.0,
982,159001,6,2,,103165594,4993,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum K1,Other,11689078.0,
983,159183,3,3,,103165594,4993,Unspecified,,,,,Antiplasmodial activity (IC50) compared to Pyr against Plasmodium falciparum K1CB1 DHFR double-mutant (C59R/S108N),Other,11881993.0,
984,159184,3,3,,103165594,4993,Unspecified,,,,,In vitro relative antiplasmodial activity (IC50) compared to Pyr against Plasmodium falciparum TM4/8.2 wild-type,Other,11881993.0,
985,159446,6,1,,103165594,4993,Unspecified,,,,,Antimalarial activity as survivor numbers at day 60 against drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 160 mg/kg subcutaneous dose after 72 hr,Other,6502605.0,
986,159452,6,1,,103165594,4993,Unspecified,,,,,Antimalarial activity as survivor numbers at day 60 against drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 20 mg/kg subcutaneous dose after 72 hr,Other,6502605.0,
987,159577,6,1,,103165594,4993,Unspecified,,,,,Antimalarial activity as survivor numbers at day 60 for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 320 mg/kg subcutaneous dose over 72 hr,Other,6502605.0,
988,159579,6,1,,103165594,4993,Unspecified,,,,,Antimalarial activity as toxic deaths 2-5 days post infection for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 320 mg/kg subcutaneous dose over 72 hr,Other,6502605.0,
989,159582,6,1,,103165594,4993,Unspecified,,,,,Antimalarial activity as change in MST for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 40 mg/kg subcutaneous dose over 72 hr,Other,6502605.0,
990,159590,6,1,,103165594,4993,Unspecified,,,,,Antimalarial activity as survivor number at day 60 for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 640 mg/kg subcutaneous dose over 72 hr,Other,6502605.0,
991,159707,6,1,,103165594,4993,Unspecified,,,,,Antimalarial activity as toxic deaths 2-5 days post infection for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 640 mg/kg subcutaneous dose over 72 hr,Other,6502605.0,
992,159711,6,1,,103165594,4993,Unspecified,,,,,Antimalarial activity as survivor numbers at day 60 for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 80 mg/kg subcutaneous dose over 72 hr,Other,6502605.0,
993,159736,3,3,,103165594,4993,Unspecified,,,,,Compound was tested in vivo for antimalarial activity against Plasmodium berghei in mice (Mus musculus) after 6 days of administration (ED90 is the dose necessary to reduce the percentage of infected cells to 10% of the level found in the infected untreated controls),Other,11689078.0,
994,159855,3,3,,103165594,4993,Unspecified,,,,,Dose required by the animals(mouse) to survive after 31 days,Other,11689078.0,
995,189629,3,3,,103165594,4993,Unspecified,,,,,The capillary permeability of radioligand was measured in Rat brain,Other,7392035.0,
996,210619,6,2,,103165594,4993,Active,,,0.4,IC50,Inhibition of Toxoplasma gondii cell growth,Confirmatory,8632434.0,
997,210626,5,3,,103165594,4993,Unspecified,,,,,Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 0 uM,Other,15055998.0,
998,210627,5,3,,103165594,4993,Unspecified,,,,,Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 10 uM,Other,15055998.0,
999,210628,5,3,,103165594,4993,Unspecified,,,,,Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 25 uM,Other,15055998.0,
1000,210629,5,3,,103165594,4993,Unspecified,,,,,Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 5 uM,Other,15055998.0,
1001,210630,5,3,,103165594,4993,Unspecified,,,,,Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 50 uM,Other,15055998.0,
1002,211987,7,2,,103165594,4993,Active,,,0.0717,Ki,Binding affinity was evaluated as inhibition of mutant (C59R + S108N) Plasmodium falciparum DHFR-TS.,Confirmatory,9554869.0,
1003,211988,7,2,,103165594,4993,Active,,,0.0015,Ki,Binding affinity was evaluated as inhibition of recombinant wild type (WT) Plasmodium falciparum DHFR-TS.,Confirmatory,9554869.0,
1004,215506,6,2,,103165594,4993,Active,,,7.0,IC50,Inhibition of Trypanosoma brucei rhodesiense growth,Confirmatory,10543874.0,
1005,216031,6,2,,103165594,4993,Active,,,32.0,IC50,In vitro cytotoxicity against Plasmodium falciparum infected vero cell line.,Confirmatory,14736247.0,
1006,219249,7,2,,103165594,4993,Active,,,0.0006,Ki,Binding affinity towards wild-type dihydrofolate reductase of Plasmodium falciparum.,Confirmatory,14736247.0,
1007,227718,7,1,,103165594,4993,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
1008,229040,6,2,,103165594,4993,Active,,,32.0,IC50,Cytotoxicity by the selective inhibition against African green monkey kidney fibroblast (vero cells).,Confirmatory,11881993.0,
1009,229684,3,9,,103165594,4993,Unspecified,118998.0,,,,Relative affinity for dihydrofolate reductase of rat liver and Pneumocystis carinii,Other,7799402.0,
1010,229684,3,9,,103165594,4993,Unspecified,81871579.0,24312.0,,,Relative affinity for dihydrofolate reductase of rat liver and Pneumocystis carinii,Other,7799402.0,
1011,229685,3,9,,103165594,4993,Unspecified,729370.0,,,,Relative affinity for dihydrofolate reductase of rat liver and Toxoplasma gondii,Other,7799402.0,
1012,229685,3,9,,103165594,4993,Unspecified,81871579.0,24312.0,,,Relative affinity for dihydrofolate reductase of rat liver and Toxoplasma gondii,Other,7799402.0,
1013,229767,3,7,,103165594,4993,Unspecified,,,,,Ratio of Inhibition of the C59R+S108N mutant of dihydrofolate reductase (DHFR) to inhibition of wild type dihydrofolate reductase.,Other,11881993.0,
1014,229768,3,7,,103165594,4993,Unspecified,,,,,Ratio of Inhibition of the S108N mutant of dihydrofolate reductase (DHFR) to inhibition of wild type dihydrofolate reductase.,Other,11881993.0,
1015,229964,4,3,,103165594,4993,Unspecified,,,,,IC50 ratio against Plasmodium falciparum K1CB1/TM4,Other,11881993.0,
1016,231127,3,3,,103165594,4993,Unspecified,,,,,Ratio of the inhibitory concentration against [3H]-uracil incorporation into nuclear DNA and T. gondii(Tg) DHFR; IC50 ([3H]-uracil incorporation) / IC50(Tg),Other,10090784.0,
1017,231312,3,7,,103165594,4993,Unspecified,,,,,Ratio of binding affinity for mutant (C59R+S108N+I164L) to that of wild type dihydrofolate reductase,Other,14736247.0,
1018,231313,3,7,,103165594,4993,Unspecified,,,,,Ratio of binding affinity for mutant (N51I+C59R+S108N) to that of wild type dihydrofolate reductase,Other,14736247.0,
1019,231314,3,7,,103165594,4993,Unspecified,,,,,Ratio of binding affinity for mutant (N51I+C59R+S108N+I164L) to that of wild type dihydrofolate reductase,Other,14736247.0,
1020,232422,3,3,,103165594,4993,Unspecified,,,,,Ratio of inhibition of Human DHFR to Inhibition of the C59R+S108N mutant of dihydrofolate reductase (DHFR),Other,11881993.0,
1021,232423,3,3,,103165594,4993,Unspecified,,,,,Ratio of inhibition of Human DHFR to inhibition of wild type DHFR.,Other,11881993.0,
1022,232440,3,3,,103165594,4993,Unspecified,,,,,Ratio of inhibitions against mutant and wild type (WT) Plasmodium falciparum DHFR-TS.,Other,9554869.0,
1023,232759,3,9,,103165594,4993,Unspecified,118998.0,,,,Selectivity index measured as the ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR.,Other,9191966.0,
1024,232759,3,9,,103165594,4993,Unspecified,81871579.0,24312.0,,,Selectivity index measured as the ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR.,Other,9191966.0,
1025,232760,3,5,,103165594,4993,Unspecified,,,,,Selectivity index measured as the ratio of IC50 for rat liver DHFR to IC50 for Toxoplasma gondii DHFR.,Other,9191966.0,
1026,232860,4,4,,103165594,4993,Unspecified,,,,,Safety ratio is cytotoxicity to KB cells/IC50 K1.,Other,11881993.0,
1027,232861,4,4,,103165594,4993,Unspecified,,,,,Safety ratio is cytotoxicity to KB cells/IC50 TM4.,Other,11881993.0,
1028,232867,3,4,,103165594,4993,Unspecified,,,,,Safety ratio is cytotoxicity to vero cells/IC50 K1.,Other,11881993.0,
1029,232870,4,3,,103165594,4993,Unspecified,,,,,Safety ratio as cytotoxicity in vero cells relative to IC50 TM4,Other,11881993.0,
1030,233406,3,5,,103165594,4993,Unspecified,,,,,Ratio for IC50 of mammalian DHFR to IC50 of Pneumocystis carinii DHFR,Other,7490723.0,
1031,233450,3,3,,103165594,4993,Unspecified,,,,,Selectivity ratio of IC50 (rat liver)/IC50 (Pneumocystis carinii),Other,9357537.0,
1032,233452,3,3,,103165594,4993,Unspecified,,,,,Selectivity ratio of IC50 (rat liver)/IC50 (Toxoplasma gondii,Other,9357537.0,
1033,233571,3,5,,103165594,4993,Unspecified,,,,,"The ratio of SD90 of the quinine hydrochloride, to the SD90 of the test substance for the Dose of 0.28 mg/kg",Other,7009867.0,
1034,233652,4,9,,103165594,4993,Unspecified,118998.0,,,,Selectivity ratio of IC50(rat liver)/IC50(Pneumocystis carinii),Other,11472209.0,
1035,233652,4,9,,103165594,4993,Unspecified,81871579.0,24312.0,,,Selectivity ratio of IC50(rat liver)/IC50(Pneumocystis carinii),Other,11472209.0,
1036,233653,4,9,,103165594,4993,Unspecified,729370.0,,,,Selectivity ratio of IC50(rat liver)/IC50(Toxoplasma gondii),Other,11472209.0,
1037,233653,4,9,,103165594,4993,Unspecified,81871579.0,24312.0,,,Selectivity ratio of IC50(rat liver)/IC50(Toxoplasma gondii),Other,11472209.0,
1038,234269,3,9,,103165594,4993,Unspecified,118998.0,,,,Ratio of IC50 rat liver DHFR vs IC50 of Pneumocystis carinii DHFR,Other,8632434.0,
1039,234269,3,9,,103165594,4993,Unspecified,81871579.0,24312.0,,,Ratio of IC50 rat liver DHFR vs IC50 of Pneumocystis carinii DHFR,Other,8632434.0,
1040,234270,3,5,,103165594,4993,Unspecified,,,,,Ratio of IC50 rat liver DHFR vs IC50 of Toxoplasma gondii DHFR,Other,8632434.0,
1041,234733,3,9,,103165594,4993,Unspecified,118998.0,,,,Selectivity ratio of IC50 value against rat liver DHFR to that of Pneumocystis carinii DHFR,Other,7877140.0,
1042,234733,3,9,,103165594,4993,Unspecified,81871579.0,24312.0,,,Selectivity ratio of IC50 value against rat liver DHFR to that of Pneumocystis carinii DHFR,Other,7877140.0,
1043,234735,3,9,,103165594,4993,Unspecified,729370.0,,,,Selectivity ratio of IC50 value against rat liver DHFR and Toxoplasma gondii DHFR,Other,7877140.0,
1044,234735,3,9,,103165594,4993,Unspecified,81871579.0,24312.0,,,Selectivity ratio of IC50 value against rat liver DHFR and Toxoplasma gondii DHFR,Other,7877140.0,
1045,235838,3,4,,103165594,4993,Unspecified,,,,,Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum Csl-2 infected BC cells,Other,14736247.0,
1046,235839,3,4,,103165594,4993,Unspecified,,,,,Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum Csl-2 infected KB cells,Other,14736247.0,
1047,235840,3,4,,103165594,4993,Unspecified,,,,,Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum Csl-2 infected Vero cells,Other,14736247.0,
1048,235841,3,4,,103165594,4993,Unspecified,,,,,Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum TM4/8.2 infected BC cells,Other,14736247.0,
1049,235842,3,4,,103165594,4993,Unspecified,,,,,Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum TM4/8.2 infected KB cells,Other,14736247.0,
1050,235843,3,4,,103165594,4993,Unspecified,,,,,Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum TM4/8.2 infected Vero cells,Other,14736247.0,
1051,235844,3,4,,103165594,4993,Unspecified,,,,,Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum V1/S infected BC cells,Other,14736247.0,
1052,235845,3,4,,103165594,4993,Unspecified,,,,,Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum V1/S infected KB cells,Other,14736247.0,
1053,235846,3,4,,103165594,4993,Unspecified,,,,,Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum V1/S infected Vero cells,Other,14736247.0,
1054,235849,3,3,,103165594,4993,Unspecified,,,,,Selectivity ratio is the ratio between the IC50 values of rat liver and Pneumocystis carinii,Other,9526565.0,
1055,235851,3,3,,103165594,4993,Unspecified,,,,,Selectivity ratio is the ratio between the IC50 values of rat liver and Toxoplasma gondii,Other,9526565.0,
1056,238767,7,2,,103165594,4993,Active,,,0.0008699999999999999,Ki,Inhibition constant against Plasmodium falciparum dihydrofolate reductase,Confirmatory,15293997.0,
1057,245149,6,2,,103165594,4993,Unspecified,,,,,Minimum inhibitory concentration against schizont maturation in Plasmodium falciparum NF-54,Other,15878272.0,
1058,245369,6,2,,103165594,4993,Unspecified,,,,,In vitro minimum inhibitory concentration against Plasmodium falciparum NF54 over 40 hours,Other,15925306.0,
1059,245657,6,2,,103165594,4993,Unspecified,,,,,Minimum inhibitory concentration against schizont maturation of Plasmodium falciparum NF54 ring stage after 40 h,Other,15780626.0,
1060,247034,5,1,,103165594,4993,Active,,,0.039,ED50,"Effective dose against chloroquine-sensitive, pyrimethamine-sensitive, mefloquine-sensitive Plasmodium falciparum 3D7",Confirmatory,15916422.0,
1061,247035,5,1,,103165594,4993,Active,,,16.0,ED50,"Effective dose against chloroquine-resistant, pyrimethamine-resistant, mefloquine-resistant Plasmodium falciparum Dd2",Confirmatory,15916422.0,
1062,247036,5,1,,103165594,4993,Active,,,0.002,ED50,"Effective dose against chloroquine-sensitive, pyrimethamine-sensitive, mefloquine-sensitive Plasmodium falciparum HB3",Confirmatory,15916422.0,
1063,247058,5,1,,103165594,4993,Active,,,25.0,ED50,"Effective dose against chloroquine-resistant, pyrimethamine-resistant, mefloquine-sensitive Plasmodium falciparum K1",Confirmatory,15916422.0,
1064,247087,5,2,,103165594,4993,Inconclusive,,,,,"Effective dose against chloroquine-resistant, pyrimethamine-resistant, mefloquine-sensitive Plasmodium falciparum W2; Not determined",Other,15916422.0,
1065,248631,6,2,,103165594,4993,Active,,,0.005,IC50,Inhibitory concentration against cycloguanil sensitive Plasmodium falciparum FJB-D4,Confirmatory,15686886.0,
1066,248632,6,2,,103165594,4993,Active,,,0.0016,IC50,Inhibitory concentration against cycloguanil sensitive Plasmodium falciparum FJB-D9,Confirmatory,15686886.0,
1067,248852,8,2,,103165594,4993,Unspecified,,,,,"In vitro antimalarial activity for DHFR wild-type, chloroquine and pyrimethamine-resistant Plasmodium falciparum W2",Other,15828818.0,
1068,248853,8,2,,103165594,4993,Unspecified,,,,,"In vitro antimalarial activity for DHFR wild-type, chloroquine and pyrimethamine-sensitive Plasmodium falciparum D6",Other,15828818.0,
1069,249023,5,2,,103165594,4993,Active,,,,,Inhibitory concentration against cycloguanil sensitive Plasmodium falciparum FJB-D4,Other,15686886.0,
1070,249024,5,2,,103165594,4993,Active,,,,,Inhibitory concentration sensitive Plasmodium falciparum FJB-D9,Other,15686886.0,
1071,268782,12,2,,103165594,4993,Unspecified,,,1000.0,IC50,Inhibition of Cryptosporidium hominis DHFR,Confirmatory,16750361.0,
1072,268783,9,2,,103165594,4993,Active,,,0.08,IC50,Inhibition of Plasmodium falciparum DHFR,Confirmatory,16750361.0,
1073,268784,9,5,,103165594,4993,Inconclusive,118998.0,,,IC50,Inhibition of Pneumocystis carinii DHFR,Confirmatory,16750361.0,
1074,279386,4,3,,103165594,4993,Active,,,0.01001,IC50,Growth inhibition of Plasmodium falciparum 3D7 ring stage in infected erythrocytes after 72 hrs in DAPI fluorimetry,Confirmatory,17116676.0,
1075,279387,4,3,,103165594,4993,Active,,,0.04988,IC50,Growth inhibition of Plasmodium falciparum HB3 ring stage in infected erythrocytes after 72 hrs in DAPI fluorimetry,Confirmatory,17116676.0,
1076,279388,4,3,,103165594,4993,Active,,,0.0441,IC50,Growth inhibition of Plasmodium falciparum Dd2 ring stage infected erythrocytes after 72 hrs by DAPI fluorimetry,Confirmatory,17116676.0,
1077,300109,3,3,,103165594,4993,Unspecified,,,,,Antiparasitemia activity against Plasmodium berghei infected mice (Mus musculus) at 30 mg/kg subcutaneous dose for 4 days,Other,17548196.0,
1078,300110,3,3,,103165594,4993,Unspecified,,,,,Antiparasitemia activity against Plasmodium berghei infected mice (Mus musculus) at 30 mg/kg peroral dose for 4 days,Other,17548196.0,
1079,320500,7,2,,103165594,4993,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum NF54 after 36-40 hrs,Other,18039570.0,
1080,322126,8,2,,103165594,4993,Inconclusive,,,,,In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
1081,322127,8,2,,103165594,4993,Inconclusive,,,,,In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
1082,322128,8,2,,103165594,4993,Inconclusive,,,,,In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs by SYBR green fluorescence assay,Other,17371812.0,
1083,322129,8,2,,103165594,4993,Inconclusive,,,,,In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green fluorescence assay,Other,17371812.0,
1084,322130,8,2,,103165594,4993,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
1085,322131,8,2,,103165594,4993,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
1086,322132,8,2,,103165594,4993,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
1087,322133,8,2,,103165594,4993,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
1088,322134,8,2,,103165594,4993,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum D6 as reduced [3H]hypoxanthine uptake after 72 hrs,Other,17371812.0,
1089,322135,8,2,,103165594,4993,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum W2 as reduced [3H]hypoxanthine uptake after 72 hrs,Other,17371812.0,
1090,341462,9,5,,103165594,4993,Active,118992.0,1719.0,6.0,IC50,Inhibition of human dihydrofolate reductase,Confirmatory,18605720.0,
1091,341462,9,5,,103165594,4993,Active,118992.0,573971.0,6.0,IC50,Inhibition of human dihydrofolate reductase,Confirmatory,18605720.0,
1092,341469,6,2,,103165594,4993,Active,,,2.0,IC50,Inhibition of Escherichia coli dihydrofolate reductase,Confirmatory,18605720.0,
1093,341470,10,5,,103165594,4993,Active,729370.0,,0.08,IC50,Inhibition of Toxoplasma gondii dihydrofolate reductase,Confirmatory,18605720.0,
1094,341471,3,3,,103165594,4993,Unspecified,,,,,Selectivity for Escherichia coli dihydrofolate reductase over human dihydrofolate reductase,Other,18605720.0,
1095,341472,3,3,,103165594,4993,Unspecified,,,,,Selectivity for sToxoplasma gondii dihydrofolate reductase over human dihydrofolate reductase,Other,18605720.0,
1096,343762,3,4,,103165594,4993,Unspecified,,,,,"Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 5 uM after 18 hrs by [5,6-13H]uracil incorporation assay",Other,18563892.0,
1097,343763,3,4,,103165594,4993,Unspecified,,,,,"Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 10 uM after 18 hrs by [5,6-13H]uracil incorporation assay",Other,18563892.0,
1098,343764,3,4,,103165594,4993,Unspecified,,,,,"Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 25 uM after 18 hrs by [5,6-13H]uracil incorporation assay",Other,18563892.0,
1099,343765,3,4,,103165594,4993,Unspecified,,,,,"Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 50 uM after 18 hrs by [5,6-13H]uracil incorporation assay",Other,18563892.0,
1100,343766,6,2,,103165594,4993,Active,,,5.9,IC50,"Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival after 18 hrs by [5,6-13H]uracil incorporation assay",Confirmatory,18563892.0,
1101,344037,3,4,,103165594,4993,Unspecified,,,,,Toxicity against human foreskin fibroblasts at 5 uM after 48 hrs by MTT method,Other,18563892.0,
1102,344038,3,4,,103165594,4993,Unspecified,,,,,Toxicity against human foreskin fibroblasts at 10 uM after 48 hrs by MTT method,Other,18563892.0,
1103,344039,3,4,,103165594,4993,Unspecified,,,,,Toxicity against human foreskin fibroblasts at 25 uM after 48 hrs by MTT method,Other,18563892.0,
1104,344040,3,4,,103165594,4993,Unspecified,,,,,Toxicity against human foreskin fibroblasts at 50 uM after 48 hrs by MTT method,Other,18563892.0,
1105,356776,3,4,,103165594,4993,Active,311033393.0,3073.0,,,Activation of beta Hex A alpha G269S/c.1278insTACT mutant isolated from Tay-Sachs disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1106,356777,3,4,,103165594,4993,Active,311033393.0,3073.0,,,Activation of beta Hex A alpha IVS9 + 1G>A/IVS8-7G>A mutant isolated from Tay-Sachs disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1107,356780,3,4,,103165594,4993,Active,311033393.0,3073.0,,,Activation of beta Hex A alphaG269S mutant isolated from Tay-Sachs disease patient assessed as increase in activator-[3H]GM2 complex hydrolysis at 3 ug/ml relative to control,Other,17237499.0,
1108,356781,3,4,,103165594,4993,Active,311033393.0,3073.0,,,Activation of beta Hex A alphaG269S mutant isolated from Tay-Sachs disease patient assessed as increase in 4-methylumbelliferyl-7-(6-sulfo-2-acetamido-2-deoxy)-beta-D-glucopyranoside hydrolysis at 3 ug/ml relative to control,Other,17237499.0,
1109,356782,3,4,,103165594,4993,Active,311033393.0,3073.0,,,Increase in thermostability of beta Hex A betaR505Q mutant isolated from Sandhoff disease patient assessed as residual enzyme activity at 3 ug/ml at 37 degC after 30 mins relative to control,Other,17237499.0,
1110,356783,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-C137Y/C137Y mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1111,356785,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-C137Y/C137Y mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1112,356787,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-T150P/P417L mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1113,356789,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-T150P/P417L mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1114,356791,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-G353R/IVS12-26G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1115,356793,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-G353R/IVS12-26G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1116,356795,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-P417L/delta16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1117,356797,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-P417L/delta16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1118,356799,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-R505Q/IVS11 + 5G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1119,356801,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-R505Q/IVS11 + 5G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1120,356803,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-P504S/delta16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1121,356805,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-P504S/delta16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control,Other,17237499.0,
1122,356807,5,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Activation of on beta Hex A beta C137Y/C137Y mutant in postnuclear supernatant of fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity per mg of protein at 3 mg/ml by relative to control,Other,17237499.0,
1123,356808,5,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Activation of on beta Hex A beta C137Y/C137Y mutant in postnuclear supernatant of fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity per mg of protein at 3 mg/ml by relative to control,Other,17237499.0,
1124,356809,5,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Activation of on beta Hex A beta C137Y/C137Y mutant in enriched lysosomal fraction of fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity per mg of protein at 3 mg/ml by relative to control,Other,17237499.0,
1125,356810,5,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Activation of on beta Hex A beta C137Y/C137Y mutant in enriched lysosomal fraction of fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity per mg of protein at 3 mg/ml by relative to control,Other,17237499.0,
1126,356811,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A alpha G269S/c.1278ins TACT mutant in fibroblasts from Tay-Sachs disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1127,356812,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A alpha G269S/IV6 + 1G>A mutant in fibroblasts from Tay-Sachs disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1128,356813,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A alpha IVS9 + 1G>A/IVS8-7G>A mutant in fibroblasts from Tay-Sachs disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1129,356814,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Activation of on beta Hex A beta R505Q/IVS11 + 5G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1130,356815,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Activation of on beta Hex A beta R505Q/delta-16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1131,356816,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-C137Y/C137Y mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1132,356817,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta G353R/IVS12-26G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1133,356818,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta-T150P/P417L mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1134,356819,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta delta16kb/P417L mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1135,356820,3,4,,103165594,4993,Unspecified,311033393.0,3073.0,,,Pharmacological chaperone effect on beta Hex A beta P504S/delta16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control,Other,17237499.0,
1136,361326,6,2,,103165594,4993,Active,,,5.0,IC50,Inhibition of beta-hexosaminidase A at pH 4.3 assessed as residual enzyme activity,Confirmatory,17237499.0,
1137,361327,6,2,,103165594,4993,Active,,,5.0,IC50,Inhibition of beta-hexosaminidase B at pH 4.3 assessed as residual enzyme activity,Confirmatory,17237499.0,
1138,361328,6,2,,103165594,4993,Active,,,13.0,Ki,Inhibition of beta-hexosaminidase A at pH 4.5 by competitive binding assay,Confirmatory,17237499.0,
1139,361329,6,2,,103165594,4993,Active,,,2.0,IC50,Inhibition of beta-hexosaminidase A at pH 6.5 by competitive binding assay,Confirmatory,17237499.0,
1140,361330,3,4,,103165594,4993,Inactive,311033393.0,3073.0,,,Effect on acid phosphatase in fibroblasts with Hex A alpha-G269S/ins1278TACT mutation isolated from Tay-Sachs disease patient,Other,17237499.0,
1141,361331,3,4,,103165594,4993,Inactive,311033393.0,3073.0,,,Effect on beta-galactosidase in fibroblasts with Hex A alpha-G269S/ins1278TACT mutation isolated from Tay-Sachs disease patient,Other,17237499.0,
1142,372372,7,1,,103165594,4993,Active,,,0.21,EC50,Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay,Confirmatory,17698618.0,
1143,372373,7,1,,103165594,4993,Active,,,0.29,EC50,Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-1 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay,Confirmatory,17698618.0,
1144,372374,7,1,,103165594,4993,Active,,,0.27,EC50,Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-6 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay,Confirmatory,17698618.0,
1145,372375,7,1,,103165594,4993,Active,,,0.24,EC50,Antiparasitic activity against artemisinin-resistant Toxoplasma gondii STL500-10A infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay,Confirmatory,17698618.0,
1146,373624,4,3,,103165594,4993,Active,,,0.00107,Ki,"Inhibition of pyrimethamine-resistant form-3 Plasmodium falciparum N51I, C59R, S108N, I164L, I150V, N182I, N201D mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay",Confirmatory,17875995.0,
1147,373625,4,4,,103165594,4993,Active,,,0.00085,Ki,"Inhibition of pyrimethamine-resistant form-2 Plasmodium falciparum N51I, C59R, S108N, I164L, K96N mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay",Confirmatory,17875995.0,
1148,373626,4,3,,103165594,4993,Active,,,0.00124,Ki,"Inhibition of pyrimethamine-resistant form-1 Plasmodium falciparum N51I, C59R, S108N, I164L, D187A mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay",Confirmatory,17875995.0,
1149,373627,4,3,,103165594,4993,Active,,,0.0155,Ki,"Inhibition of WR99210-resistant form-3 Plasmodium falciparum N51I, C59R, N108T, I164L mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay",Confirmatory,17875995.0,
1150,373628,4,3,,103165594,4993,Active,,,0.0035700000000000003,Ki,"Inhibition of WR99210-resistant form-1 Plasmodium falciparum I51N, C59R, N108S, I164L mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay",Confirmatory,17875995.0,
1151,373629,4,3,,103165594,4993,Active,,,0.0019,Ki,"Inhibition of Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay",Confirmatory,17875995.0,
1152,373630,3,3,,103165594,4993,Inconclusive,,,,,"Inhibition of WR99210-resistant form-A Plasmodium falciparum DHFR-TS I51N, C59R, N108S, L164I, D54N mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay",Other,17875995.0,
1153,373631,4,3,,103165594,4993,Active,,,0.0021,Ki,"Inhibition of Plasmodium falciparum DHFR-TS QM template N51I, C59R, S108N, I164L mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay",Confirmatory,17875995.0,
1154,373632,6,2,,103165594,4993,Active,,,0.17,IC50,"Inhibition of Plasmodium falciparum DHFR-TS QM template N51I, C59R, S108N, I164L mutant expressed in Escherichia coli BL21(DE3)",Confirmatory,17875995.0,
1155,373633,6,2,,103165594,4993,Active,,,7.2,IC50,"Inhibition of WR99210-resistant form-A Plasmodium falciparum DHFR-TS I51N, C59R, N108S, L164I, D54N mutant expressed in Escherichia coli BL21(DE3)",Confirmatory,17875995.0,
1156,373634,6,2,,103165594,4993,Active,,,0.42,IC50,"Inhibition of Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant expressed in Escherichia coli BL21(DE3)",Confirmatory,17875995.0,
1157,373635,3,3,,103165594,4993,Unspecified,,,,,"Ratio of IC50 for WR99210-resistant form-A Plasmodium falciparum DHFR-TS I51N, C59R, N108S, L164I, D54N mutant to IC50 for Plasmodium falciparum DHFR-TS QM template N51I, C59R, S108N, I164L mutant",Other,17875995.0,
1158,373636,6,2,,103165594,4993,Active,,,0.09,IC50,"Inhibition of WR99210-resistant form-1 Plasmodium falciparum I51N, C59R, N108S, I164L mutant expressed in Escherichia coli BL21(DE3)",Confirmatory,17875995.0,
1159,373637,6,2,,103165594,4993,Active,,,0.01,IC50,"Inhibition of WR99210-resistant form-2 Plasmodium falciparum N51I, C59R, N108S, I164L mutant expressed in Escherichia coli BL21(DE3)",Confirmatory,17875995.0,
1160,373638,6,2,,103165594,4993,Active,,,1.82,IC50,"Inhibition of WR99210-resistant form-3 Plasmodium falciparum N51I, C59R, N108T, I164L mutant expressed in Escherichia coli BL21(DE3)",Confirmatory,17875995.0,
1161,373639,6,2,,103165594,4993,Active,,,0.87,IC50,"Inhibition of pyrimethamine-resistant form-1 Plasmodium falciparum N51I, C59R, S108N, I164L, D187A mutant expressed in Escherichia coli BL21(DE3)",Confirmatory,17875995.0,
1162,373640,6,3,,103165594,4993,Active,,,2.48,IC50,"Inhibition of pyrimethamine-resistant form-2 Plasmodium falciparum N51I, C59R, S108N, I164L, K96N mutant expressed in Escherichia coli BL21(DE3)",Confirmatory,17875995.0,
1163,373641,6,2,,103165594,4993,Active,,,3.47,IC50,"Inhibition of pyrimethamine-resistant form-3 Plasmodium falciparum N51I, C59R, S108N, I164L, I150V, N182I, N201D mutant expressed in Escherichia coli BL21(DE3)",Confirmatory,17875995.0,
1164,373642,3,3,,103165594,4993,Unspecified,,,,,"Ratio of IC50 for WR99210-resistant form-1 Plasmodium falciparum I51N, C59R, N108S, I164L mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant",Other,17875995.0,
1165,373643,3,3,,103165594,4993,Unspecified,,,,,"Ratio of IC50 for WR99210-resistant form-2 Plasmodium falciparum N51I, C59R, N108S, I164L mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant",Other,17875995.0,
1166,373644,3,3,,103165594,4993,Unspecified,,,,,"Ratio of IC50 for WR99210-resistant form-3 Plasmodium falciparum N51I, C59R, N108T, I164L mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant",Other,17875995.0,
1167,373645,3,3,,103165594,4993,Unspecified,,,,,"Ratio of IC50 for pyrimethamine-resistant form-1 Plasmodium falciparum N51I, C59R, S108N, I164L, D187A mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant",Other,17875995.0,
1168,373646,3,3,,103165594,4993,Unspecified,,,,,"Ratio of IC50 for pyrimethamine-resistant form-2 Plasmodium falciparum N51I, C59R, S108N, I164L, K96N mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant",Other,17875995.0,
1169,373647,3,3,,103165594,4993,Unspecified,,,,,"Ratio of IC50 for pyrimethamine-resistant form-3 Plasmodium falciparum N51I, C59R, S108N, I164L, I150V, N182I, N201D mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant",Other,17875995.0,
1170,373648,4,3,,103165594,4993,Active,,,0.007259999999999999,Ki,"Inhibition of WR99210-resistant form-2 Plasmodium falciparum N51I, C59R, N108S, I164L mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay",Confirmatory,17875995.0,
1171,394668,8,2,,103165594,4993,Unspecified,,,,,Antiplasmodial activity against Plasmodium falciparum,Other,17682097.0,
1172,394669,8,2,,103165594,4993,Unspecified,,,,,Antiplasmodial activity against Plasmodium vivax,Other,17682097.0,
1173,394670,8,2,,103165594,4993,Unspecified,,,,,Antimalarial activity as inhibition of schizont maturation against Plasmodium malariae Thai after 40 - 70 hrs,Other,17682097.0,
1174,427682,6,2,,103165594,4993,Active,,,5.0,IC50,Cytotoxicity against human K562 cells after 72 hrs by flow cytometry,Confirmatory,19482476.0,
1175,427683,6,2,,103165594,4993,Active,,,30.0,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,19482476.0,
1176,427686,6,2,,103165594,4993,Active,,,2.0,IC50,Antitoxoplasmic activity against Toxoplasma gondii tachyzoites infected in HFF assessed as beta-galactosidase activity after 96 hrs by colorimetric microtiter assay,Confirmatory,19482476.0,
1177,428940,3,3,,103165594,4993,Unspecified,,,,,"Antiprotozoal activity against 100Toxoplasma gondii RH tachyzoites infected in CBA/J mouse survival at 5 mg/kg, po administered 2 hrs postinfection for 7 consecutive days",Other,17923491.0,
1178,434955,1,2,,56422411,4993,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1179,434959,1,1,,85788820,4993,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
1180,434962,1,2,,56422411,4993,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1181,434973,1,3,,56422411,4993,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1182,434989,1,1,,56422411,4993,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1183,435003,1,3,,56422411,4993,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1184,435022,2,2,,56422411,4993,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1185,435030,1,2,,56422411,4993,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1186,435030,1,2,,56422411,4993,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1187,436208,3,4,,103165594,4993,Unspecified,,,,,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in type B+ human erythrocytes assessed as reduction of hemozoin formation at IC50 after 48 hrs relative to control,Other,19269069.0,
1188,436211,3,4,,103165594,4993,Unspecified,,,,,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in type B+ human erythrocytes assessed as inhibition of sorbitol-induced hemolysis at 10 nM after 15 min by spectrophotometry,Other,19269069.0,
1189,442355,8,2,,103165594,4993,Active,,,1.5,IC50,Antitoxoplasmic activity against Toxoplasma gondii PRU-betaGal tachyzoite after 96 hrs by colorimetric microtiter assay,Confirmatory,19926173.0,
1190,444879,7,1,,103165594,4993,Active,,,26.6,ED50,Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 blood stream form by Alamar blue assay,Confirmatory,19916554.0,
1191,444882,3,3,,103165594,4993,Unspecified,,,,,Ratio of ED50 for Trypanosoma brucei brucei Lister 427 to Ki for Leishmania major DHFR,Other,19916554.0,
1192,449703,5,2,,103165594,4993,Active,,,0.0319,EC50,NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay,Confirmatory,18579783.0,
1193,449704,5,2,,103165594,4993,Active,,,0.01456,EC50,NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay,Confirmatory,18579783.0,
1194,449705,5,2,,103165594,4993,Active,,,45.62,CC50,NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7),Confirmatory,18579783.0,
1195,449706,5,2,,103165594,4993,Unspecified,,,,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.",Other,18579783.0,
1196,449728,1,2,,56422411,4993,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1197,449739,1,2,,855854,4993,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
1198,449762,1,2,,56422411,4993,Inconclusive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1199,449763,1,3,,56422411,4993,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1200,449768,1,1,,855854,4993,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1201,459260,5,2,,103165594,4993,Active,,,0.7,IC50,Antimicrobial activity against Toxoplasma gondii infected in HEL cells assessed as inhibition of parasite growth by [3H]uracil incorporation assay,Confirmatory,20117005.0,
1202,463073,1,2,,855854,4993,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
1203,463075,1,1,,855854,4993,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
1204,463079,1,2,,56422411,4993,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1205,463082,1,1,,56422411,4993,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1206,463104,1,2,,56422411,4993,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1207,463111,1,1,,855854,4993,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1208,463115,1,1,,855854,4993,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
1209,463141,1,2,,56422411,4993,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1210,463165,1,1,,855854,4993,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1211,463187,1,1,,855854,4993,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
1212,463189,1,1,,855854,4993,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1213,463190,1,2,,56422411,4993,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1214,463193,1,1,,855854,4993,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
1215,463195,1,2,,56422411,4993,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1216,463210,1,2,,56422411,4993,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1217,463212,1,1,,56422411,4993,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1218,463254,1,1,,855854,4993,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1219,478201,3,3,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 5 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting",Other,20456959.0,
1220,478202,3,3,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 10 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting",Other,20456959.0,
1221,478203,3,3,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 25 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting",Other,20456959.0,
1222,478204,3,3,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 50 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting",Other,20456959.0,
1223,478209,3,3,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 5 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting",Other,20456959.0,
1224,478210,3,3,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 10 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting",Other,20456959.0,
1225,478211,3,3,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 25 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting",Other,20456959.0,
1226,478212,3,3,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 50 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting",Other,20456959.0,
1227,478213,5,3,,103165594,4993,Active,,,16.1,IC50,Cytotoxicity against human CRL1634 cells after 48 hrs by MTT assay,Confirmatory,20456959.0,
1228,485270,1,1,,56422411,4993,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1229,485272,1,1,,56422411,4993,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1230,485273,2,1,,56422411,4993,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1231,485275,1,3,,56422411,4993,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1232,485281,1,1,,855854,4993,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1233,485281,1,1,,11112140,4993,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1234,485290,1,1,,855854,4993,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1235,485290,1,1,,11112140,4993,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1236,485290,1,1,,17389746,4993,Inactive,20150581.0,,79.4328,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1237,485290,1,1,,26747011,4993,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1238,485290,1,1,,26751532,4993,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1239,485294,1,1,,855854,4993,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1240,485297,1,1,,855854,4993,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1241,485298,1,1,,855854,4993,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1242,485313,1,2,,855854,4993,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1243,485314,1,1,,855854,4993,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1244,485341,1,1,,855854,4993,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1245,485344,1,1,,855854,4993,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1246,485346,1,1,,56422411,4993,Active,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1247,485346,1,1,,56422411,4993,Active,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1248,485347,1,2,,855854,4993,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1249,485349,1,1,,855854,4993,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1250,485350,1,2,,92124196,4993,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1251,485350,1,2,,92125099,4993,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1252,485353,2,1,,855854,4993,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1253,485358,1,1,,855854,4993,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1254,485360,1,1,,855854,4993,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
1255,485364,1,1,,855854,4993,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1256,485367,1,2,,855854,4993,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1257,488806,1,2,,855854,4993,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
1258,488837,1,1,,855854,4993,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1259,488839,1,1,,56422411,4993,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1260,488839,1,1,,56422411,4993,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1261,488847,1,3,,56422411,4993,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1262,488862,1,1,,56422411,4993,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1263,488890,1,2,,56422411,4993,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1264,488895,1,2,,56422411,4993,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1265,488896,1,1,,56422411,4993,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1266,488899,1,1,,56422411,4993,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1267,488922,1,2,,855854,4993,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1268,488965,1,2,,56422411,4993,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1269,488966,1,1,,56422411,4993,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1270,488975,1,2,,56422411,4993,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1271,488977,1,2,,56422411,4993,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1272,489028,1,2,,56422411,4993,Inactive,88702791.0,4194.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1273,489028,1,2,,56422411,4993,Inactive,89993689.0,4193.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1274,489030,2,1,,56422411,4993,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1275,489031,2,1,,56422411,4993,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1276,492947,1,1,,855854,4993,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1277,492953,1,1,,56422411,4993,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1278,492956,1,1,,56422411,4993,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1279,492967,1,2,,92125099,4993,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1280,492967,1,2,,99301740,4993,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1281,492972,1,1,,56422411,4993,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1282,493005,1,1,,56422411,4993,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1283,493008,1,1,,56422411,4993,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1284,493008,1,1,,56422411,4993,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1285,493008,1,1,,56422411,4993,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1286,493008,1,1,,56422411,4993,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1287,493011,1,1,,56422411,4993,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1288,493012,1,1,,56422411,4993,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1289,493014,1,1,,855854,4993,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1290,493027,1,2,,56422411,4993,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1291,493027,1,2,,56422411,4993,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1292,493033,1,2,,92124196,4993,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1293,493033,1,2,,92125099,4993,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1294,493035,1,2,,56422411,4993,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1295,493035,1,2,,56422411,4993,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1296,493036,1,2,,56422411,4993,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1297,493056,1,1,,855854,4993,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1298,493084,1,1,,855854,4993,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1299,493087,1,1,,56422411,4993,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1300,493091,1,1,,56422411,4993,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1301,493098,1,1,,56422411,4993,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1302,493131,1,1,,56422411,4993,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1303,493140,1,1,,103913983,4993,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
1304,493160,1,1,,56422411,4993,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1305,493162,1,2,,99301740,4993,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1306,493187,1,2,,56422411,4993,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1307,493244,1,1,,56422411,4993,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1308,493244,1,1,,56422411,4993,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1309,493244,1,1,,56422411,4993,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1310,493244,1,1,,56422411,4993,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1311,496819,4,2,,103165594,4993,Unspecified,,,100.0,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
1312,496824,4,2,,103165594,4993,Unspecified,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
1313,497005,4,2,,103165594,4993,Unspecified,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
1314,504326,1,2,,56422411,4993,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1315,504326,1,2,,56422411,4993,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1316,504327,1,1,,855854,4993,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1317,504327,1,1,,11112140,4993,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1318,504329,1,1,,56422411,4993,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1319,504332,1,1,,855854,4993,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1320,504332,1,1,,11112140,4993,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1321,504333,1,1,,855854,4993,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1322,504339,1,1,,56422411,4993,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1323,504357,1,1,,56422411,4993,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1324,504357,1,1,,56422411,4993,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1325,504408,2,1,,855854,4993,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1326,504411,1,1,,56422411,4993,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1327,504414,1,1,,56422411,4993,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1328,504414,1,1,,56422411,4993,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1329,504423,1,1,,56422411,4993,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1330,504441,1,1,,56422411,4993,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1331,504444,1,1,,56422411,4993,Inconclusive,224028257.0,4780.0,11.5821,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1332,504454,1,3,,56422411,4993,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1333,504459,1,3,,855854,4993,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method from Validation Set,Screening,,
1334,504462,1,1,,56422411,4993,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1335,504466,1,1,,855854,4993,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1336,504467,1,1,,855854,4993,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1337,504490,1,2,,56422411,4993,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1338,504523,1,1,,56422411,4993,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1339,504523,1,1,,56422411,4993,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1340,504541,1,1,,855854,4993,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
1341,504558,1,1,,56422411,4993,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1342,504577,2,2,,56422411,4993,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1343,504582,2,1,,56422411,4993,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1344,504594,1,1,,56422411,4993,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1345,504600,1,2,,855854,4993,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1346,504621,1,1,,56422411,4993,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1347,504634,1,1,,56422411,4993,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1348,504648,1,1,,56422411,4993,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1349,504651,1,1,,855854,4993,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1350,504652,1,1,,855854,4993,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1351,504660,1,1,,855854,4993,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1352,504690,1,3,,56422411,4993,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1353,504692,2,2,,56422411,4993,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1354,504700,1,1,,56422411,4993,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1355,504700,1,1,,56422411,4993,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1356,504706,1,1,,855854,4993,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1357,504707,1,1,,56422411,4993,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1358,504707,1,1,,56422411,4993,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1359,504720,1,1,,56422411,4993,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1360,504734,1,1,,56422411,4993,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1361,504749,1,3,,26751532,4993,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1362,504749,1,3,,104171273,4993,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1363,504749,1,3,1.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1364,504749,1,3,2.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1365,504749,1,3,3.0,104171273,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1366,504749,1,3,4.0,26751532,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1367,504749,1,3,5.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1368,504749,1,3,6.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1369,504749,1,3,7.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1370,504749,1,3,8.0,26751532,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1371,504749,1,3,9.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1372,504749,1,3,10.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1373,504749,1,3,11.0,26751532,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1374,504749,1,3,12.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1375,504749,1,3,13.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1376,504749,1,3,14.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1377,504749,1,3,15.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1378,504749,1,3,16.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1379,504749,1,3,17.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1380,504749,1,3,18.0,26751532,4993,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1381,504749,1,3,19.0,26751532,4993,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1382,504749,1,3,20.0,104171273,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1383,504749,1,3,21.0,26751532,4993,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1384,504749,1,3,22.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1385,504749,1,3,23.0,104171273,4993,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1386,504749,1,3,24.0,26751532,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1387,504749,1,3,25.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1388,504749,1,3,26.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1389,504749,1,3,27.0,104171273,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1390,504749,1,3,28.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1391,504749,1,3,29.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1392,504749,1,3,30.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1393,504749,1,3,31.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1394,504749,1,3,32.0,26751532,4993,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1395,504749,1,3,33.0,104171273,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1396,504749,1,3,34.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1397,504749,1,3,35.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1398,504749,1,3,36.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1399,504749,1,3,37.0,26751532,4993,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1400,504749,1,3,38.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1401,504749,1,3,39.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1402,504749,1,3,40.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1403,504749,1,3,41.0,104171273,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1404,504749,1,3,42.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1405,504749,1,3,43.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1406,504749,1,3,44.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1407,504749,1,3,45.0,104171273,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1408,504749,1,3,46.0,26751532,4993,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1409,504749,1,3,47.0,26751532,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1410,504749,1,3,48.0,26751532,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1411,504749,1,3,49.0,26751532,4993,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1412,504749,1,3,50.0,104171273,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1413,504749,1,3,51.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1414,504749,1,3,52.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1415,504749,1,3,53.0,104171273,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1416,504749,1,3,54.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1417,504749,1,3,55.0,104171273,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1418,504749,1,3,56.0,26751532,4993,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1419,504749,1,3,57.0,26751532,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1420,504749,1,3,58.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1421,504749,1,3,59.0,104171273,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1422,504749,1,3,60.0,104171273,4993,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1423,504749,1,3,61.0,26751532,4993,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1424,504766,2,1,,56422411,4993,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1425,504770,1,2,,92124196,4993,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1426,504775,1,1,,56422411,4993,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1427,504803,1,1,,56422411,4993,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1428,504810,1,2,,855854,4993,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1429,504812,1,2,,855854,4993,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1430,504832,1,1,,855854,4993,Active,,,0.0828,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1431,504832,1,1,,104171273,4993,Active,,,0.0338,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1432,504834,1,1,,855854,4993,Inconclusive,,,0.0657,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1433,504834,1,1,,104171273,4993,Active,,,4.2562,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1434,504842,1,1,,855854,4993,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1435,504845,1,1,,56422411,4993,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1436,504847,1,1,,11112140,4993,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1437,504847,1,1,,56422411,4993,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1438,504847,1,1,,104171273,4993,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1439,504865,1,1,,11112140,4993,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1440,504865,1,1,,104171273,4993,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1441,504884,1,2,,56422411,4993,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1442,504891,1,1,,56422411,4993,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1443,504894,1,1,,56422411,4993,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1444,504937,1,2,,56422411,4993,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1445,510926,2,4,,103165594,4993,Unspecified,,,20.0,IC50,Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green based fluorescence assay,Confirmatory,20813948.0,
1446,510927,2,4,,103165594,4993,Unspecified,,,20.0,IC50,Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone1 bearing P-type ATPase4 I398F and P990R mutations after 72 hrs by SYBR green based fluorescence assay,Confirmatory,20813948.0,
1447,510928,2,4,,103165594,4993,Unspecified,,,20.0,IC50,Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone2 bearing P-type ATPase4 T418N and P990R mutations after 72 hrs by SYBR green based fluorescence assay,Confirmatory,20813948.0,
1448,510929,2,4,,103165594,4993,Unspecified,,,20.0,IC50,Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone3 bearing P-type ATPase4 D1247Y mutations after 72 hrs by SYBR green based fluorescence assay,Confirmatory,20813948.0,
1449,515780,5,1,,103165594,4993,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
1450,518312,2,3,,103165594,4993,Active,,,0.371,IC50,"Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum clinical isolate harboring S108N, N51I mutation in DHFR assessed as decrease in parasitaemia",Confirmatory,20350951.0,
1451,518313,2,3,,103165594,4993,Active,,,0.371,IC50,"Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum clinical isolate harboring S108N, C59R mutation in DHFR assessed as decrease in parasitaemia",Confirmatory,20350951.0,
1452,518314,2,3,,103165594,4993,Active,,,0.77828,IC50,"Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum clinical isolate harboring S108N, N51I, C59R mutation in DHFR assessed as decrease in parasitaemia",Confirmatory,20350951.0,
1453,518315,2,3,,103165594,4993,Active,,,3.6907900000000002,IC50,"Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum V1/S harboring S108N, N51I, C59R, I164L mutation in DHFR assessed as decrease in parasitaemia",Confirmatory,20350951.0,
1454,518561,2,3,,103165594,4993,Active,,,0.00059,Ki,Binding affinity to wild type Plasmodium falciparum DHFR by competitive binding assay,Confirmatory,20350951.0,
1455,518562,2,3,,103165594,4993,Active,,,0.385,Ki,"Binding affinity to recombinant Plasmodium falciparum V1/S DHFR S108N, N51I, C59R, I164L mutant by competitive binding assay",Confirmatory,20350951.0,
1456,518563,6,5,,103165594,4993,Active,118992.0,1719.0,0.0308,Ki,Binding affinity to human recombinant DHFR expressed in Escherichia coli BL21(DE3) by competitive binding assay,Confirmatory,20350951.0,
1457,518563,6,5,,103165594,4993,Active,118992.0,573971.0,0.0308,Ki,Binding affinity to human recombinant DHFR expressed in Escherichia coli BL21(DE3) by competitive binding assay,Confirmatory,20350951.0,
1458,518564,1,3,,103165594,4993,Unspecified,,,,,Selectivity ratio of Ki for human recombinant DHFR to Ki for wild type Plasmodium falciparum DHFR,Other,20350951.0,
1459,518565,2,3,,103165594,4993,Unspecified,,,,,"Selectivity ratio of Ki for recombinant Plasmodium falciparum V1/S DHFR S108N, N51I, C59R, I164L mutant to Ki for wild type Plasmodium falciparum DHFR",Other,20350951.0,
1460,519610,5,2,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA",Other,18212105.0,
1461,519611,5,2,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA",Other,18212105.0,
1462,519612,5,2,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA",Other,18212105.0,
1463,519613,5,2,,103165594,4993,Unspecified,,,,,Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA,Other,18212105.0,
1464,519614,5,2,,103165594,4993,Unspecified,,,,,Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA,Other,18212105.0,
1465,519615,5,2,,103165594,4993,Unspecified,,,,,Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA,Other,18212105.0,
1466,519616,5,2,,103165594,4993,Unspecified,,,,,Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA,Other,18212105.0,
1467,519617,5,2,,103165594,4993,Unspecified,,,,,Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA,Other,18212105.0,
1468,519618,5,2,,103165594,4993,Unspecified,,,,,Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA,Other,18212105.0,
1469,519619,5,2,,103165594,4993,Unspecified,,,,,Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA,Other,18212105.0,
1470,519620,2,3,,103165594,4993,Inconclusive,,,,,Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-TOU infected in human MRC-5 cells after 72 hrs by ELISA,Other,18212105.0,
1471,519621,5,2,,103165594,4993,Unspecified,,,,,Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA,Other,18212105.0,
1472,519622,5,2,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA",Other,18212105.0,
1473,519623,5,2,,103165594,4993,Unspecified,,,,,Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA,Other,18212105.0,
1474,519624,5,2,,103165594,4993,Unspecified,,,,,Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA,Other,18212105.0,
1475,519625,5,2,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA",Other,18212105.0,
1476,519626,4,2,,103165594,4993,Unspecified,,,,,"Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA",Other,18212105.0,
1477,529905,2,3,,103165594,4993,Active,,,2.512,IC50,"Antiplasmodial activity against Plasmodium falciparum harboring K1 allele group of msp1, 3D7 allele group of msp2 gene and 94 bp of 7A11, 196bp of C4M79 and 336bp of C4M69 locus measured on day 23 by [3H]hypoxanthine incorporation assay",Confirmatory,18411319.0,
1478,540209,4,3,,103165594,4993,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
1479,540210,4,3,,103165594,4993,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
1480,540211,2,5,,103165594,4993,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
1481,540212,4,3,,103165594,4993,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
1482,540213,4,3,,103165594,4993,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
1483,540253,1,1,,56422411,4993,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1484,540253,1,1,,56422411,4993,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1485,540253,1,1,,56422411,4993,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1486,540256,1,2,,855854,4993,Active,,,3.2643,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1487,540263,1,1,,56422411,4993,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1488,540263,1,1,,56422411,4993,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1489,540267,1,1,,56422411,4993,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1490,540275,1,1,,855854,4993,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
1491,540276,1,2,,855854,4993,Inconclusive,420597.0,,5.1735,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1492,540276,1,2,,11112140,4993,Inconclusive,420597.0,,5.1735,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1493,540276,1,2,,17389746,4993,Inconclusive,420597.0,,5.1735,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1494,540276,1,2,,26747011,4993,Inconclusive,420597.0,,5.1735,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1495,540276,1,2,,26747012,4993,Inconclusive,420597.0,,5.1735,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1496,540276,1,2,,26751532,4993,Inconclusive,420597.0,,5.1735,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1497,540276,1,2,,50100376,4993,Inconclusive,420597.0,,5.1735,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1498,540276,1,2,,50104113,4993,Inconclusive,420597.0,,5.1735,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1499,540276,1,2,,104171273,4993,Inconclusive,420597.0,,5.1735,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1500,540277,1,1,,855854,4993,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
1501,540295,1,1,,56422411,4993,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1502,540299,1,2,,92124196,4993,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1503,540299,1,2,,92125099,4993,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1504,540303,1,1,,56422411,4993,Inconclusive,6679377.0,18792.0,0.7079,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1505,540303,1,1,,56422411,4993,Inconclusive,7242179.0,18793.0,0.7079,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1506,540303,1,1,,56422411,4993,Inconclusive,257471003.0,18815.0,0.7079,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1507,540308,1,1,,56422411,4993,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1508,540317,1,1,,56422411,4993,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1509,540336,1,1,,56422411,4993,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1510,540336,1,1,,56422411,4993,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1511,540364,1,2,,56422411,4993,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1512,543835,2,3,,103165594,4993,Unspecified,,,,,"Antimalarial activity against chloroquine-sensitive Plasmodium berghei ATCC 50175 infected in ICR mouse assessed as parasitemia at 1.2 mg/kg/day, po pretreated for 4 days before infection and measured after 72 hrs (Rvb = 4.6+/-0.21 %)",Other,18625780.0,
1513,543839,2,3,,103165594,4993,Unspecified,,,,,"Antimalarial activity against chloroquine-sensitive Plasmodium berghei ATCC 50175 infected in ICR mouse assessed as chemosuppression of parasitemia at 1.2 mg/kg/day, po pretreated for 4 days before infection and measured after 72 hrs",Other,18625780.0,
1514,543852,2,3,,103165594,4993,Inconclusive,,,,,"Antimalarial activity against chloroquine-sensitive Plasmodium berghei ATCC 50175 infected in ICR mouse assessed as chemosuppression of parasitemia at 1.2 mg/kg/day, po administered 24 hrs post-treatment measured after 4 days",Other,18625780.0,
1515,543853,2,3,,103165594,4993,Inconclusive,,,,,"Antimalarial activity against chloroquine-sensitive Plasmodium berghei ATCC 50175 infected in ICR mouse assessed as parasitemia at 1.2 mg/kg/day, po administered 24 hrs post-treatment measured after 4 days (Rvb = 56.3+/-0.16 %)",Other,18625780.0,
1516,549612,2,4,,103165594,4993,Inactive,,,,,"Antimalarial activity against mefloquine-resistant, chloroquine-sensitive Plasmodium falciparum D6 assessed as inhibition of [3H]hypoxanthine uptake in presence of 1 mM folinic acid",Other,21168330.0,
1517,549613,2,3,,103165594,4993,Inactive,,,,,Antimalarial activity against multidrug-resistant Plasmodium falciparum TM91C235 assessed as inhibition of [3H]hypoxanthine uptake in presence of 1 mM folinic acid,Other,21168330.0,
1518,554322,2,4,,103165594,4993,Unspecified,,,,,Antileishmanial activity against Leishmania mexicana MHOM/BZ/84/BEL46 assessed as growth at 50 ug/ml by Alamar blue assay,Other,21126022.0,
1519,554324,2,4,,103165594,4993,Unspecified,,,,,Antileishmanial activity against Leishmania major MHOM/SU/73/5-ASKH assessed as growth at 50 ug/ml by Alamar blue assay,Other,21126022.0,
1520,554326,5,1,,103165594,4993,Unspecified,,,,,Cytotoxicity against human MRC5 cells after 72 hrs by Alamar blue assay,Other,21126022.0,
1521,559547,3,2,,103165594,4993,Active,,,6.929139999999999,IC50,"Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum V1S expressing DHFR quadruple mutant with point mutations at codons 108, 51, 59 and 164 gene by [3H]hypoxanthine incorporation assay",Confirmatory,19528269.0,
1522,559548,2,4,,103165594,4993,Active,,,0.0039,IC50,Antimalarial activity against pyrimethamine-sensitive Plasmodium falciparum 3D7 expressing wild type DHFR by [3H]hypoxanthine incorporation assay,Confirmatory,19528269.0,
1523,559549,2,3,,103165594,4993,Active,,,0.73326,IC50,Antimalarial activity against Plasmodium falciparum Kenyan isolates by [3H]hypoxanthine incorporation assay,Confirmatory,19528269.0,
1524,560256,2,3,,103165594,4993,Active,,,0.371,IC50,Antimalarial activity against Plasmodium falciparum Kenyan isolates expressing DHFR Ser108Asn and Cys59Arg or Ser108Asn and Asn51Ile double mutant by [3H]hypoxanthine incorporation assay,Confirmatory,19528269.0,
1525,560257,2,3,,103165594,4993,Active,,,0.77828,IC50,"Antimalarial activity against Plasmodium falciparum Kenyan isolates expressing DHFR Ser108Asn, Asn51Ile and Cys59Arg triple mutant by [3H]hypoxanthine incorporation assay",Confirmatory,19528269.0,
1526,560258,3,2,,103165594,4993,Active,,,3.6907900000000002,IC50,"Antimalarial activity against Plasmodium falciparum isolate Kil-164 expressing DHFR Ser108Asn, Asn51Ile, Cys59Arg and Ile164Leu quadruple mutant by [3H]hypoxanthine incorporation assay",Confirmatory,19528269.0,
1527,562110,2,4,,103165594,4993,Active,,,5.0,IC50,Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay,Confirmatory,19364853.0,
1528,565414,2,3,,103165594,4993,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum Pf3D70087/N9 infected in immunodeficient HM-IL2Rgamma null mouse after 7 days,Other,19596869.0,
1529,565415,2,3,,103165594,4993,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum Pf3D70087/N9 infected in immunodeficient HM-beta2 m null mouse after 7 days,Other,19596869.0,
1530,565416,2,3,,103165594,4993,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum PfV1S0176/N10 infected in immunodeficient HM-IL2Rgamma null mouse after 7 days,Other,19596869.0,
1531,571507,3,3,,103165594,4993,Active,,,0.05,IC50,Inhibition of Babesia gibsoni Dihydrofolate reductase-thymidylate synthase expressed in Escherichia coli BL21,Confirmatory,18794380.0,
1532,571510,3,3,,103165594,4993,Active,,,,,Antiparasitic activity against Babesia gibsoni infected in dog erythrocytes assessed as growth inhibition at 20 uM by Giemsa staining based microscopy,Other,18794380.0,
1533,571511,1,3,,103165594,4993,Active,,,,,Antiparasitic activity against Babesia gibsoni infected in dog erythrocytes assessed as growth inhibition at 80 uM by Giemsa staining based microscopy,Other,18794380.0,
1534,576697,2,4,,103165594,4993,Active,,,2.8000000000000003e-05,IC50,Antimalarial activity against Plasmodium falciparum D6 infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs,Confirmatory,20566761.0,
1535,576698,2,3,,103165594,4993,Active,,,0.14261,IC50,"Antimalarial activity against Plasmodium falciparum TM91c235 harboring DHFR F57L, S58R, T61M, S117T mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs",Confirmatory,20566761.0,
1536,576699,2,4,,103165594,4993,Active,,,5.5e-05,IC50,Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs,Confirmatory,20566761.0,
1537,576700,2,4,,103165594,4993,Active,,,0.0025,IC50,Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs,Confirmatory,20566761.0,
1538,576701,2,4,,103165594,4993,Active,,,0.00366,IC50,Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L and S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs,Confirmatory,20566761.0,
1539,576702,2,4,,103165594,4993,Active,,,0.00626,IC50,Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R and S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs,Confirmatory,20566761.0,
1540,576703,2,4,,103165594,4993,Active,,,0.00281,IC50,"Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R, T61M and S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs",Confirmatory,20566761.0,
1541,576704,2,4,,103165594,4993,Active,,,0.46734,IC50,"Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L, S58R, T61M, S117T mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs",Confirmatory,20566761.0,
1542,576705,2,4,,103165594,4993,Unspecified,,,,,Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR,Other,20566761.0,
1543,576706,2,4,,103165594,4993,Unspecified,,,,,Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L and S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR,Other,20566761.0,
1544,576707,2,4,,103165594,4993,Unspecified,,,,,Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R and S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR,Other,20566761.0,
1545,576708,2,4,,103165594,4993,Unspecified,,,,,"Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R, T61M and S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR",Other,20566761.0,
1546,576709,2,4,,103165594,4993,Unspecified,,,,,"Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L, S58R, T61M, S117T mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR",Other,20566761.0,
1547,576710,1,3,,103165594,4993,Unspecified,,,,,"Ratio of IC50 for Plasmodium falciparum TM91c235 harboring DHFR F57L, S58R, T61M, S117T mutant to IC50 for Plasmodium falciparum D6",Other,20566761.0,
1548,588209,2,3,,103165594,4993,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
1549,588210,2,4,,103165594,4993,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
1550,588211,2,3,,103165594,4993,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
1551,588212,2,3,,103165594,4993,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
1552,588213,2,3,,103165594,4993,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
1553,588334,1,1,,56422411,4993,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1554,588335,1,1,,56422411,4993,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1555,588342,1,1,,855854,4993,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
1556,588352,1,2,,56422411,4993,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1557,588354,1,1,,56422411,4993,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1558,588358,1,2,,56422411,4993,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1559,588368,1,2,,855854,4993,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
1560,588391,1,1,,56422411,4993,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1561,588405,1,1,,56422411,4993,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1562,588413,1,2,,56422411,4993,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1563,588436,1,1,,56422411,4993,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1564,588453,1,1,,56422411,4993,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1565,588453,1,1,,124881963,4993,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1566,588453,1,1,,124881964,4993,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1567,588456,1,1,,56422411,4993,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1568,588456,1,1,,124881963,4993,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1569,588456,1,1,,124881964,4993,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1570,588458,1,1,,56422411,4993,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1571,588459,1,2,,855854,4993,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
1572,588459,1,2,,855854,4993,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
1573,588459,1,2,,855854,4993,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
1574,588460,1,2,,855854,4993,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
1575,588460,1,2,,855854,4993,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
1576,588460,1,2,,855854,4993,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
1577,588461,1,2,,855854,4993,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
1578,588461,1,2,,855854,4993,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
1579,588461,1,2,,855854,4993,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
1580,588473,1,1,,56422411,4993,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1581,588473,1,1,,56422411,4993,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1582,588475,1,2,,56422411,4993,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1583,588475,1,2,,56422411,4993,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1584,588478,1,2,,124801059,4993,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1585,588489,1,1,,56422411,4993,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1586,588492,1,1,,56422411,4993,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1587,588493,1,2,,56422411,4993,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1588,588497,1,2,,56422411,4993,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1589,588497,1,2,,56422411,4993,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1590,588497,1,2,,56422411,4993,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1591,588499,1,3,,56422411,4993,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1592,588499,1,3,,56422411,4993,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1593,588499,1,3,,56422411,4993,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1594,588501,1,2,,56422411,4993,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1595,588501,1,2,,56422411,4993,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1596,588501,1,2,,56422411,4993,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1597,588506,1,2,,855854,4993,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
1598,588511,1,2,,56422411,4993,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1599,588513,1,1,,17389746,4993,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1600,588513,1,1,,26751532,4993,Inconclusive,348019627.0,2099.0,7.0795,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1601,588514,1,1,,17389746,4993,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1602,588514,1,1,,26751532,4993,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1603,588515,1,1,,17389746,4993,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1604,588515,1,1,,26751532,4993,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1605,588516,1,1,,17389746,4993,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1606,588516,1,1,,26751532,4993,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1607,588519,1,2,,92124196,4993,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1608,588519,1,2,,92125099,4993,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1609,588526,1,1,,17389746,4993,Inconclusive,325495553.0,9971.0,39.8107,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1610,588526,1,1,,26751532,4993,Inconclusive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1611,588527,1,1,,17389746,4993,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1612,588527,1,1,,26751532,4993,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1613,588532,1,1,,17389746,4993,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1614,588532,1,1,,26751532,4993,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1615,588533,1,1,,17389746,4993,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1616,588533,1,1,,26751532,4993,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1617,588534,1,1,,17389746,4993,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1618,588534,1,1,,26751532,4993,Inconclusive,216409690.0,5467.0,44.6684,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1619,588535,1,1,,17389746,4993,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1620,588535,1,1,,26751532,4993,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1621,588536,1,1,,17389746,4993,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1622,588536,1,1,,26751532,4993,Inconclusive,216409692.0,5468.0,39.8107,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1623,588537,1,1,,17389746,4993,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1624,588537,1,1,,26751532,4993,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1625,588541,1,1,,17389746,4993,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1626,588541,1,1,,26751532,4993,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1627,588543,1,1,,17389746,4993,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1628,588543,1,1,,26751532,4993,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1629,588544,1,1,,17389746,4993,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1630,588544,1,1,,26751532,4993,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1631,588545,1,1,,17389746,4993,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1632,588545,1,1,,26751532,4993,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1633,588546,1,1,,17389746,4993,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1634,588546,1,1,,26751532,4993,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1635,588547,1,1,,17389746,4993,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1636,588547,1,1,,26751532,4993,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1637,588549,1,1,,56422411,4993,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1638,588550,1,1,,855854,4993,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
1639,588579,1,1,,11112140,4993,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1640,588579,1,1,,56422411,4993,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1641,588579,1,1,,104171273,4993,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1642,588579,1,1,,124881960,4993,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1643,588579,1,1,,124881963,4993,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1644,588579,1,1,,124881964,4993,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1645,588590,1,1,,56422411,4993,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1646,588590,1,1,,124881963,4993,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1647,588590,1,1,,124881964,4993,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1648,588591,1,1,,56422411,4993,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1649,588621,1,1,,56422411,4993,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1650,588627,1,1,,56422411,4993,Active,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1651,588664,1,2,,56422411,4993,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1652,588664,1,2,,56422411,4993,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1653,588674,1,2,,56422411,4993,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1654,588675,1,1,,56422411,4993,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1655,588676,1,1,,56422411,4993,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1656,588685,1,1,,855854,4993,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
1657,588689,1,1,,56422411,4993,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1658,588692,2,1,,56422411,4993,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1659,588726,1,2,,56422411,4993,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1660,588727,1,1,,56422411,4993,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1661,588795,1,1,,56422411,4993,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1662,588795,1,1,,124881963,4993,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1663,588795,1,1,,124881964,4993,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1664,588812,1,1,,17389746,4993,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1665,588812,1,1,1.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1666,588812,1,1,2.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1667,588812,1,1,3.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1668,588812,1,1,4.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1669,588812,1,1,5.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1670,588812,1,1,6.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1671,588812,1,1,7.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1672,588812,1,1,8.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1673,588812,1,1,9.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1674,588812,1,1,10.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1675,588812,1,1,11.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1676,588812,1,1,12.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1677,588812,1,1,13.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1678,588812,1,1,14.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1679,588812,1,1,15.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1680,588812,1,1,16.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1681,588812,1,1,17.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1682,588812,1,1,18.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1683,588812,1,1,19.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1684,588812,1,1,20.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1685,588812,1,1,21.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1686,588812,1,1,22.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1687,588812,1,1,23.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1688,588812,1,1,24.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1689,588812,1,1,25.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1690,588812,1,1,26.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1691,588812,1,1,27.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1692,588812,1,1,28.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1693,588812,1,1,29.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1694,588812,1,1,30.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1695,588812,1,1,31.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1696,588812,1,1,32.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1697,588812,1,1,33.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1698,588812,1,1,34.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1699,588812,1,1,35.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1700,588812,1,1,36.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1701,588812,1,1,37.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1702,588812,1,1,38.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1703,588812,1,1,39.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1704,588812,1,1,40.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1705,588812,1,1,41.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1706,588812,1,1,42.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1707,588812,1,1,43.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1708,588812,1,1,44.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1709,588812,1,1,45.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1710,588812,1,1,46.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1711,588812,1,1,47.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1712,588812,1,1,48.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1713,588812,1,1,49.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1714,588812,1,1,50.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1715,588812,1,1,51.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1716,588812,1,1,52.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1717,588812,1,1,53.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1718,588812,1,1,54.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1719,588812,1,1,55.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1720,588812,1,1,56.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1721,588812,1,1,57.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1722,588812,1,1,58.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1723,588812,1,1,59.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1724,588812,1,1,60.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1725,588812,1,1,61.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1726,588812,1,1,62.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1727,588812,1,1,63.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1728,588812,1,1,64.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1729,588812,1,1,65.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1730,588812,1,1,66.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1731,588812,1,1,67.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1732,588812,1,1,68.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1733,588812,1,1,69.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1734,588812,1,1,70.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1735,588812,1,1,71.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1736,588812,1,1,72.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1737,588812,1,1,73.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1738,588812,1,1,74.0,17389746,4993,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1739,588812,1,1,75.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1740,588812,1,1,76.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1741,588812,1,1,77.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1742,588812,1,1,78.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1743,588812,1,1,79.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1744,588812,1,1,80.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1745,588812,1,1,81.0,17389746,4993,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1746,588813,1,1,,17389746,4993,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1747,588813,1,1,1.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1748,588813,1,1,2.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1749,588813,1,1,3.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1750,588813,1,1,4.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1751,588813,1,1,5.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1752,588813,1,1,6.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1753,588813,1,1,7.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1754,588813,1,1,8.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1755,588813,1,1,9.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1756,588813,1,1,10.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1757,588813,1,1,11.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1758,588813,1,1,12.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1759,588813,1,1,13.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1760,588813,1,1,14.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1761,588813,1,1,15.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1762,588813,1,1,16.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1763,588813,1,1,17.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1764,588813,1,1,18.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1765,588813,1,1,19.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1766,588813,1,1,20.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1767,588813,1,1,21.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1768,588813,1,1,22.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1769,588813,1,1,23.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1770,588813,1,1,24.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1771,588813,1,1,25.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1772,588813,1,1,26.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1773,588813,1,1,27.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1774,588813,1,1,28.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1775,588813,1,1,29.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1776,588813,1,1,30.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1777,588813,1,1,31.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1778,588813,1,1,32.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1779,588813,1,1,33.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1780,588813,1,1,34.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1781,588813,1,1,35.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1782,588813,1,1,36.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1783,588813,1,1,37.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1784,588813,1,1,38.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1785,588813,1,1,39.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1786,588813,1,1,40.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1787,588813,1,1,41.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1788,588813,1,1,42.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1789,588813,1,1,43.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1790,588813,1,1,44.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1791,588813,1,1,45.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1792,588813,1,1,46.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1793,588813,1,1,47.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1794,588813,1,1,48.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1795,588813,1,1,49.0,17389746,4993,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1796,588813,1,1,50.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1797,588813,1,1,51.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1798,588813,1,1,52.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1799,588813,1,1,53.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1800,588813,1,1,54.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1801,588813,1,1,55.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1802,588813,1,1,56.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1803,588813,1,1,57.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1804,588813,1,1,58.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1805,588813,1,1,59.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1806,588813,1,1,60.0,17389746,4993,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1807,588813,1,1,61.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1808,588813,1,1,62.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1809,588813,1,1,63.0,17389746,4993,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1810,588813,1,1,64.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1811,588813,1,1,65.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1812,588813,1,1,66.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1813,588813,1,1,67.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1814,588813,1,1,68.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1815,588813,1,1,69.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1816,588813,1,1,70.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1817,588813,1,1,71.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1818,588813,1,1,72.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1819,588813,1,1,73.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1820,588813,1,1,74.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1821,588813,1,1,75.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1822,588813,1,1,76.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1823,588813,1,1,77.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1824,588813,1,1,78.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1825,588813,1,1,79.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1826,588813,1,1,80.0,17389746,4993,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1827,588813,1,1,81.0,17389746,4993,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1828,588814,1,3,,56422411,4993,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1829,588819,1,4,,56422411,4993,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1830,588834,2,1,,17389746,4993,Active,325651834.0,3757.0,39.8107,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1831,588834,2,1,,26751532,4993,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1832,588850,1,1,,56422411,4993,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1833,588852,1,3,,56422411,4993,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1834,588855,1,1,,56422411,4993,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1835,588855,1,1,,124881963,4993,Inconclusive,18418623.0,4088.0,35.4813,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1836,588856,1,1,,56422411,4993,Inactive,,,2.2387,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1837,588856,1,1,,124881963,4993,Inactive,,,1.5849,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1838,596016,1,4,,103165594,4993,Unspecified,,,,,Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs immediately after infection followed by reinoculated into fresh HFF monolayers measured after 48 hrs by RT-PCR analysis,Other,21428405.0,
1839,596017,1,4,,103165594,4993,Unspecified,,,,,Antiparasitic activity against clindamycin-resistant Toxoplasma gondii 4 infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs immediately after infection followed by reinoculated into fresh HFF monolayers measured after 48 hrs by RT-PCR analysis,Other,21428405.0,
1840,596083,1,4,,103165594,4993,Unspecified,,,,,Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs after 6 hrs infection followed by reinoculated into fresh HFF monolayers measured after 48 hrs by RT-PCR analysis,Other,21428405.0,
1841,596084,1,4,,103165594,4993,Unspecified,,,,,Antiparasitic activity against clindamycin-resistant Toxoplasma gondii 4 infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs after 6 hrs infection followed by reinoculated into fresh HFF monolayers measured after 48 hrs by RT-PCR analysis,Other,21428405.0,
1842,601638,5,2,,103165594,4993,Active,,,0.023,EC50,Antimalarial activity against Plasmodium falciparum 3D7 infected in human A positive erythrocytes by [3H]hypoxanthine uptake assay in presence of serum in medium,Confirmatory,21517059.0,
1843,601644,1,4,,103165594,4993,Unspecified,,,,,Plasma protein binding in human by albumin chromatographic method,Other,21517059.0,
1844,602118,1,4,,103165594,4993,Active,,,,,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.",Other,22096101.0,
1845,602119,3,2,,103165594,4993,Active,,,0.00215,IC50,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration",Confirmatory,22096101.0,
1846,602123,1,1,,56422411,4993,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1847,602141,1,1,,56422411,4993,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1848,602156,1,1,,131332476,4993,Active,,,0.002152,IC50,Novartis GNF Liver Stage Dataset: Malariabox Annotation,Other,22096101.0,
1849,602162,1,1,,56422411,4993,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1850,602163,1,1,,56422411,4993,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1851,602179,1,2,,56422411,4993,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1852,602229,1,1,,56422411,4993,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1853,602233,1,1,,56422411,4993,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1854,602244,1,2,,56422411,4993,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1855,602247,1,2,,56422411,4993,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1856,602248,1,2,,56422411,4993,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1857,602250,1,2,,56422411,4993,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1858,602252,1,1,,56422411,4993,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1859,602252,1,1,,56422411,4993,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1860,602261,1,1,,56422411,4993,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1861,602274,1,2,,56422411,4993,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1862,602276,1,1,,855854,4993,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,Screening,,
1863,602277,1,1,,855854,4993,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,Screening,,
1864,602281,1,1,,56422411,4993,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1865,602281,1,1,,56422411,4993,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1866,602310,1,2,,56422411,4993,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1867,602310,1,2,,124881963,4993,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1868,602313,1,1,,56422411,4993,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1869,602314,1,2,,92124196,4993,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1870,602314,1,2,,92125099,4993,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1871,602329,1,1,,56422411,4993,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1872,602332,1,1,,11112140,4993,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1873,602332,1,1,,56422411,4993,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1874,602332,1,1,,104171273,4993,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1875,602332,1,1,,124881960,4993,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1876,602332,1,1,,124881963,4993,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1877,602340,1,2,,56422411,4993,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1878,602342,2,1,,56422411,4993,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1879,602346,1,1,,56422411,4993,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1880,602363,1,1,,56422411,4993,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1881,602393,1,1,,56422411,4993,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1882,602396,1,2,,56422411,4993,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1883,602399,1,2,,56422411,4993,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1884,602405,1,1,,56422411,4993,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1885,602410,1,1,,56422411,4993,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1886,602412,1,2,,56422411,4993,Inactive,195969650.0,259249.0,,,Re-confirmation screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1887,602429,1,1,,56422411,4993,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1888,602438,1,1,,56422411,4993,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1889,602440,1,1,,56422411,4993,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1890,602449,1,2,,56422411,4993,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1891,602481,1,1,,56422411,4993,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1892,605732,1,4,,103165594,4993,Active,,,0.028999999999999998,IC50,Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as decrease in parasitemia after 72 hrs,Confirmatory,21644570.0,
1893,605733,1,3,,103165594,4993,Unspecified,,,10.0,IC50,Antimalarial activity against Plasmodium falciparum W2 infected in human erythrocytes assessed as decrease in parasitemia after 72 hrs,Confirmatory,21644570.0,
1894,607059,3,2,,103165594,4993,Active,,,29.5,IC50,Antimalarial activity against mefloquine-resistant Plasmodium falciparum W2 after 48 hrs by LDH assay,Confirmatory,21644541.0,
1895,607060,3,4,,103165594,4993,Active,,,1.146,IC50,Antimalarial activity against Plasmodium falciparum HB3,Confirmatory,21644541.0,
1896,607061,3,3,,103165594,4993,Active,,,0.019,IC50,Antimalarial activity against Plasmodium falciparum NF54,Confirmatory,21644541.0,
1897,607062,3,2,,103165594,4993,Active,,,0.06,IC50,Antimalarial activity against Plasmodium falciparum FC27,Confirmatory,21644541.0,
1898,607063,3,2,,103165594,4993,Active,,,0.012,IC50,Antimalarial activity against Plasmodium falciparum FCR3,Confirmatory,21644541.0,
1899,607064,3,2,,103165594,4993,Active,,,0.06,IC50,Antimalarial activity against Plasmodium falciparum Mad20,Confirmatory,21644541.0,
1900,607065,3,2,,103165594,4993,Active,,,9.9,IC50,Antimalarial activity against Plasmodium falciparum K1,Confirmatory,21644541.0,
1901,616030,3,2,,103165594,4993,Active,,,7.1,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,21741131.0,
1902,616032,3,2,,103165594,4993,Active,,,1.1,IC50,Antiparasitic activity against Toxoplasma gondii PRU tachyzoites harboring beta-Gal gene infected in human HFF cells after 72 hrs by microtiter plate based assay,Confirmatory,21741131.0,
1903,616033,3,2,,103165594,4993,Unspecified,,,50.0,CC50,Cytotoxicity against human HFF cells after 72 hrs by MTT assay,Confirmatory,21741131.0,
1904,623870,1,1,,56422411,4993,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1905,623870,1,1,,56422411,4993,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1906,623877,1,1,,56422411,4993,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1907,623901,1,1,,56422411,4993,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1908,624030,1,2,,104171273,4993,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1909,624031,1,2,,104171273,4993,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
1910,624032,1,2,,104171273,4993,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
1911,624037,1,3,,56422411,4993,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1912,624038,1,3,,56422411,4993,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1913,624040,1,3,,56422411,4993,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1914,624044,1,2,,104171273,4993,Active,8393992.0,24660.0,9.9924,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1915,624111,1,1,,56422411,4993,Inactive,195969650.0,259249.0,,,Counter-screen against parental HEK293 cells for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1916,624114,1,1,,56422411,4993,Inactive,195969650.0,259249.0,,,Counter-screen against parental HEK293 cells for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1917,624115,1,1,,56422411,4993,Inactive,195969650.0,259249.0,,,Counter-screen against parental HEK293 cells for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1918,624125,1,4,,56422411,4993,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1919,624126,1,3,,56422411,4993,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1920,624127,1,2,,56422411,4993,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1921,624156,1,1,,85788820,4993,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1922,624168,1,1,,56422411,4993,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1923,624169,1,1,,56422411,4993,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1924,624170,1,1,,56422411,4993,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1925,624170,1,1,,104171273,4993,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1926,624171,1,1,,56422411,4993,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1927,624172,1,1,,56422411,4993,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1928,624172,1,1,,104171273,4993,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1929,624173,1,3,,56422411,4993,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1930,624173,1,3,,104171273,4993,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1931,624178,1,1,,56422411,4993,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1932,624178,1,1,,124881963,4993,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1933,624178,1,1,,124881964,4993,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1934,624202,1,1,,56422411,4993,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1935,624202,1,1,,124881963,4993,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1936,624202,1,1,,124881964,4993,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1937,624204,1,2,,56422411,4993,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1938,624246,1,1,,56422411,4993,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1939,624256,1,2,,56422411,4993,Active,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1940,624263,1,1,,56422411,4993,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1941,624263,1,1,,56422411,4993,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1942,624263,1,1,,124881963,4993,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1943,624263,1,1,,124881963,4993,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1944,624263,1,1,,124881964,4993,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1945,624263,1,1,,124881964,4993,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1946,624267,1,2,,56422411,4993,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1947,624267,1,2,,56422411,4993,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1948,624268,1,3,,56422411,4993,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1949,624288,1,1,,56422411,4993,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1950,624296,1,1,,855854,4993,Inconclusive,7705682.0,51053.0,5.1735,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1951,624296,1,1,,56422411,4993,Inactive,7705682.0,51053.0,2.9093,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1952,624296,1,1,,104171273,4993,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1953,624297,1,1,,855854,4993,Inconclusive,7705682.0,51053.0,6.5131,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1954,624297,1,1,,56422411,4993,Inconclusive,7705682.0,51053.0,0.1636,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1955,624297,1,1,,104171273,4993,Inconclusive,7705682.0,51053.0,13.3359,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1956,624304,1,2,,56422411,4993,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1957,624330,1,2,,56422411,4993,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1958,624349,1,2,,92124196,4993,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1959,624349,1,2,,92125099,4993,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1960,624349,1,2,,92307603,4993,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1961,624349,1,2,,121362394,4993,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1962,624349,1,2,,121362770,4993,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1963,624352,1,1,,56422411,4993,Active,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1964,624354,1,1,,56422411,4993,Active,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1965,624377,1,1,,855854,4993,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1966,624414,1,1,,56422411,4993,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1967,624414,1,1,,124881963,4993,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1968,624414,1,1,,124881964,4993,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1969,624415,1,2,,56422411,4993,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1970,624416,1,1,,855854,4993,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1971,624417,1,1,,56422411,4993,Inconclusive,1724069.0,2740.0,28.1838,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1972,624418,1,1,,56422411,4993,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1973,624463,1,1,,56422411,4993,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1974,624464,1,1,,56422411,4993,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1975,624465,1,1,,56422411,4993,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1976,624466,1,3,,855854,4993,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1977,624467,1,1,,855854,4993,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1978,624483,1,1,,56422411,4993,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1979,625279,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1980,625280,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1981,625281,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1982,625282,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1983,625283,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1984,625284,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1985,625285,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1986,625286,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1987,625287,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1988,625288,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1989,625289,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1990,625290,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1991,625291,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1992,625292,1,3,,103165594,4993,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1993,640997,1,4,,103165594,4993,Unspecified,,,,,Inhibition of Plasmodium falciparum DHFR assessed as oxidation of NADPH to NADP+ at 10 uM after 15 mins spectrophotometric assay,Other,22192590.0,
1994,641000,3,2,,103165594,4993,Active,,,0.02,IC50,Inhibition of Plasmodium falciparum DHFR assessed as oxidation of NADPH to NADP+ after 15 mins spectrophotometric assay,Confirmatory,22192590.0,
1995,651560,1,1,,56422411,4993,Active,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1996,651572,1,2,,855854,4993,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1997,651580,1,1,,56422411,4993,Inactive,40254439.0,2034.0,,,Single concentration confirmation of uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1998,651582,1,1,,56422411,4993,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1999,651589,1,1,,56422411,4993,Active,4504385.0,3091.0,,,Single concentration confirmation of HIF-2a Inhibitors in a HIF-1a counterscreen in human MiAPaCa-2 Cells luciferase reporter assay,Screening,,
2000,651602,1,1,,855854,4993,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2001,651602,1,1,,855854,4993,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2002,651602,1,1,,855854,4993,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2003,651610,2,1,,855854,4993,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2004,651631,4,1,,144203883,4993,Active,269849759.0,7157.0,8.4127,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2005,651631,4,1,,144209032,4993,Inconclusive,269849759.0,7157.0,49.2994,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2006,651631,4,1,,144210449,4993,Inconclusive,269849759.0,7157.0,61.1306,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2007,651632,4,1,,144203883,4993,Inactive,296439460.0,79915.0,21.1317,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2008,651632,4,1,,144209032,4993,Inactive,296439460.0,79915.0,62.0642,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2009,651632,4,1,,144210449,4993,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2010,651633,4,1,,144203883,4993,Active,,,10.5909,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2011,651633,4,1,,144209032,4993,Active,,,12.3834,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2012,651633,4,1,,144210449,4993,Inconclusive,,,21.6899,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2013,651634,4,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2014,651634,4,1,,144209032,4993,Inconclusive,,,69.6372,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2015,651634,4,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2016,651635,1,3,,11112140,4993,Inconclusive,171543895.0,6311.0,8.9125,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2017,651635,1,3,,56422411,4993,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2018,651636,1,1,,56422411,4993,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2019,651640,1,1,,855854,4993,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2020,651644,1,1,,56422411,4993,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2021,651647,1,1,,56422411,4993,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2022,651654,1,1,,56422411,4993,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2023,651658,1,1,,855854,4993,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2024,651660,1,1,,56422411,4993,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2025,651661,2,1,,855854,4993,Active,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2026,651687,1,1,,56422411,4993,Active,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2027,651699,1,1,,56422411,4993,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2028,651699,1,1,,56422411,4993,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2029,651700,1,2,,56422411,4993,Active,1709543.0,52.0,16.5,IC50_Mean,"Dose response confirmation of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Confirmatory,,
2030,651702,1,2,,56422411,4993,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2031,651704,2,1,,855854,4993,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2032,651704,2,1,,56422411,4993,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2033,651710,1,1,,855854,4993,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2034,651711,2,1,,855854,4993,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2035,651718,1,2,,855854,4993,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2036,651719,1,2,,855854,4993,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
2037,651723,1,1,,56422411,4993,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2038,651724,1,1,,56422411,4993,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2039,651725,1,1,,56422411,4993,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2040,651741,1,1,,17389746,4993,Inconclusive,20149576.0,4780.0,37.578,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2041,651741,1,1,,144203883,4993,Inconclusive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2042,651743,1,1,,17389746,4993,Inconclusive,269849759.0,7157.0,31.6228,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2043,651743,1,1,,26751532,4993,Inconclusive,269849759.0,7157.0,35.4813,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2044,651749,1,1,,17389746,4993,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2045,651749,1,1,,26751532,4993,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2046,651751,1,1,,17389746,4993,Inactive,5702233.0,84385.0,50.1187,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2047,651751,1,1,,26751532,4993,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2048,651754,1,1,,17389746,4993,Inconclusive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
2049,651755,1,1,,17389746,4993,Inconclusive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
2050,651757,1,1,,17389746,4993,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
2051,651758,1,1,,17389746,4993,Inactive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
2052,651768,1,2,,56422411,4993,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2053,651777,1,1,,17389746,4993,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2054,651777,1,1,,26751532,4993,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2055,651778,1,1,,17389746,4993,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2056,651778,1,1,,26751532,4993,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2057,651800,1,1,,855854,4993,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2058,651802,1,1,,17389746,4993,Inconclusive,49066040.0,6097.0,29.8493,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2059,651819,1,1,,56422411,4993,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2060,651820,1,1,,855854,4993,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2061,651820,1,1,,56422411,4993,Inconclusive,,,10.0,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2062,651821,2,4,,855854,4993,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2063,651828,1,2,,121362394,4993,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2064,651838,1,1,,17389746,4993,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2065,651838,1,1,,26751532,4993,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2066,651838,1,1,1.0,17389746,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2067,651838,1,1,1.0,26751532,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2068,651838,1,1,2.0,17389746,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2069,651838,1,1,2.0,26751532,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2070,651838,1,1,3.0,17389746,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2071,651838,1,1,3.0,26751532,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2072,651838,1,1,4.0,17389746,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2073,651838,1,1,4.0,26751532,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2074,651838,1,1,5.0,17389746,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2075,651838,1,1,5.0,26751532,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2076,651838,1,1,6.0,17389746,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2077,651838,1,1,6.0,26751532,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2078,651838,1,1,7.0,17389746,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2079,651838,1,1,7.0,26751532,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2080,651838,1,1,8.0,17389746,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2081,651838,1,1,8.0,26751532,4993,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2082,651957,1,1,,855854,4993,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2083,651958,1,1,,855854,4993,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2084,651965,1,1,,56422411,4993,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2085,651965,1,1,,124881963,4993,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2086,651965,1,1,,124881964,4993,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2087,651999,1,1,,56422411,4993,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2088,652005,1,1,,56422411,4993,Inactive,4757714.0,52.0,32.9,IC50_Mean,"Dose response confirmation of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, in an orthogonal absorbance-based assay",Confirmatory,,
2089,652006,1,1,,56422411,4993,Inactive,224586929.0,26191.0,80.0,IC50_Mean,"Dose response confirmation of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, in a fluorescence-based, Lymphoid Phosphatase (PTPN22, LYP-1) selectivity Assay",Confirmatory,,
2090,652010,1,1,,855854,4993,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2091,652017,1,1,,855854,4993,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2092,652025,1,1,,56422411,4993,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2093,652039,1,1,,855854,4993,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2094,652048,1,2,,56422411,4993,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2095,652048,1,2,,144203883,4993,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2096,652051,1,1,,56422411,4993,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2097,652051,1,1,,144203883,4993,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2098,652054,1,1,,56422411,4993,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2099,652067,1,4,,855854,4993,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2100,652104,1,1,,56422411,4993,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2101,652105,1,1,,56422411,4993,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2102,652106,1,1,,56422411,4993,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2103,652106,1,1,,124881963,4993,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2104,652106,1,1,,124881964,4993,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2105,652115,1,1,,855854,4993,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2106,652126,1,3,,855854,4993,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2107,652154,1,1,,855854,4993,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2108,652162,2,1,,855854,4993,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2109,652163,1,1,,855854,4993,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2110,652163,1,1,,56422411,4993,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2111,652197,1,1,,855854,4993,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2112,652257,1,1,,855854,4993,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2113,668287,2,2,,103165594,4993,Active,,,0.8,IC50,Antitoxoplasmic activity against Toxoplasma gondii PRU tachyzoites infected in human HFF cells assessed as beta-galactosidase activity after 72 hrs by colorimetric assay,Confirmatory,22608675.0,
2114,668289,2,2,,103165594,4993,Active,,,7.1,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,22608675.0,
2115,668908,2,2,,103165594,4993,Active,,,0.8,IC50,Antimicrobial activity against tachyzoites of Toxoplasma gondii expressing PRU-beta-Gal gene infected in HFF after 72 hrs by colorimetric microtiter assay,Confirmatory,21852132.0,
2116,671160,7,2,,103165594,4993,Active,118992.0,1719.0,6.0,IC50,Inhibition of human DHFR,Confirmatory,22739090.0,
2117,671160,7,2,,103165594,4993,Active,118992.0,573971.0,6.0,IC50,Inhibition of human DHFR,Confirmatory,22739090.0,
2118,671161,4,1,,103165594,4993,Active,,,6.6,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,22739090.0,
2119,671162,7,2,,103165594,4993,Active,729370.0,,0.2,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,22739090.0,
2120,683338,2,4,,103165594,4993,Active,,,0.01,IC50,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in red blood cells after 72 hrs by parasitic LDH assay,Confirmatory,24900509.0,
2121,683344,2,3,,103165594,4993,Active,,,18.2,IC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay,Confirmatory,24900509.0,
2122,683345,2,3,,103165594,4993,Inconclusive,,,,IC50,Cytotoxicity against pig LLC-PK11 cells after 48 hrs by neutral red assay,Confirmatory,24900509.0,
2123,683346,2,3,,103165594,4993,Inconclusive,,,,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay,Confirmatory,24900509.0,
2124,683347,1,4,,103165594,4993,Unspecified,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for chloroquine-sensitive Plasmodium falciparum D6",Other,24900509.0,
2125,683369,1,3,,103165594,4993,Inactive,,,,,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in red blood cells up to 19 uM after 72 hrs by parasitic LDH assay,Other,24900509.0,
2126,683712,2,2,,103165594,4993,Active,,,1.03,IC50,Antimalarial activity against liver stages of Plasmodium cynomolgi infected in human HepG2 cells assessed as growth inhibition of hepatic parasite after 3 days,Confirmatory,22122518.0,
2127,685500,2,2,,103165594,4993,Unspecified,,,10.0,IC50,HARVARD: Cytotoxicity in HepG2 cell line,Confirmatory,22586124.0,
2128,685501,2,2,,103165594,4993,Active,,,0.0047,IC50,HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells,Confirmatory,22586124.0,
2129,686920,1,1,,855854,4993,Active,,,5.12,AbsAC35_uM,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2130,686940,1,1,,855854,4993,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2131,686961,1,1,,56422411,4993,Inactive,4758208.0,1845.0,80.0,IC50_VHR1 (OMFP)_Mean,"Dose response confirmation of uHTS small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, in a fluorescence-based, VHR-1 (dual specificity phosphatase 3) selectivity assay",Confirmatory,,
2132,686962,1,1,,162163291,4993,Active,1709543.0,52.0,14.73,IC50_LMPTP(OMFP)_Mean,"SAR confirmation of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Confirmatory,,
2133,686963,1,1,,162163291,4993,Inactive,4757714.0,52.0,23.6,IC50_LMPTP(pNPP)_Mean,"SAR confirmation of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, in an orthogonal absorbance-based assay",Confirmatory,,
2134,686964,1,1,,855854,4993,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2135,686970,1,2,,56422411,4993,Active,49168486.0,3417.0,0.8199,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2136,686970,1,2,,124881964,4993,Active,49168486.0,3417.0,3.1623,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2137,686971,1,2,,56422411,4993,Active,,,1.1582,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2138,686971,1,2,,124881964,4993,Active,,,1.0,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2139,686977,2,1,,49698727,4993,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
2140,686978,1,1,,56422411,4993,Active,79154014.0,55775.0,0.6513,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2141,686978,1,1,,124881960,4993,Active,79154014.0,55775.0,0.4611,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2142,686978,1,1,,124881963,4993,Active,79154014.0,55775.0,0.2818,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2143,686978,1,1,,124881964,4993,Active,79154014.0,55775.0,0.2818,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2144,686978,1,1,,144203883,4993,Active,79154014.0,55775.0,0.5309,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2145,686979,1,1,,56422411,4993,Inconclusive,79154014.0,55775.0,0.8199,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2146,686979,1,1,,124881960,4993,Active,79154014.0,55775.0,1.2995,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2147,686979,1,1,,124881963,4993,Active,79154014.0,55775.0,0.7943,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2148,686979,1,1,,124881964,4993,Active,79154014.0,55775.0,3.1623,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2149,686979,1,1,,144203883,4993,Active,79154014.0,55775.0,0.9441,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2150,686992,2,1,,855854,4993,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2151,686996,1,1,,855854,4993,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2152,687014,1,1,,855854,4993,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2153,687016,1,1,,855854,4993,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2154,687125,1,4,,103165594,4993,Active,,,0.00895,IC50,OSM: Inhibition of Plasmodium falciparum 3D7 growth. IC50 values determined from 21 point dose response curves. Avery Group Griffith.,Confirmatory,,
2155,687127,1,4,,103165594,4993,Active,,,0.0332,IC50,OSM: Inhibition of Plasmodium falciparum 3D7 growth using a SYBR green I fluorescence based assay. GSK Tres Cantos.,Confirmatory,,
2156,687142,1,4,,103165594,4993,Active,,,13.921,IC50,OSM: HEK293 cytotoxicity assay. IC50 values determined from 21 point dose response curves. Avery Group Griffith.,Confirmatory,,
2157,687145,1,4,,103165594,4993,Active,,,11.9,IC50,OSM: Inhibition of Plasmodium falciparum K1 growth. IC50 values determined from 21 point dose response curves. Avery Group Griffith.,Confirmatory,,
2158,700779,1,3,,103165594,4993,Unspecified,,,,,Selectivity ratio of IC50 for Plasmodium falciparum Dd2 to IC50 for Plasmodium falciparum 3D7A,Other,24900481.0,
2159,700784,2,4,,103165594,4993,Active,,,0.02,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7A assessed as inhibition of [3H]hypoxanthine incorporation incubated for 24 hrs prior to [3H]hypoxanthine addition measured after 24 hrs by beta scintillation counting,Confirmatory,24900481.0,
2160,700786,2,4,,103165594,4993,Unspecified,,,40.0,IC50,Antiplasmodial activity against Plasmodium falciparum Dd2 assessed as inhibition of [3H]hypoxanthine incorporation incubated for 24 hrs prior to [3H]hypoxanthine addition measured after 24 hrs by beta scintillation counting,Confirmatory,24900481.0,
2161,700787,4,5,,103165594,4993,Inconclusive,112816.0,3358.0,,IC50,Inhibition of human 5HT2c receptor expressed in CHO-K1 cells assessed as inhibition of 5HT-induced calcium influx measured up to 30 secs by aequorin luminescence assay,Confirmatory,24900481.0,
2162,700788,1,3,,103165594,4993,Inconclusive,,,,,Selectivity ratio of IC50 for plasmodium falciparum 3D7A to IC50 for human 5HT2c receptor,Other,24900481.0,
2163,708404,1,2,,103165594,4993,Unspecified,,,,,Antiparasitic activity against Leishmania mexicana promastigotes assessed as parasite growth at 50 ug/mL,Other,22946585.0,
2164,708411,3,1,,103165594,4993,Unspecified,,,,,Toxicity against human MRC5 cells assessed as growth inhibition,Other,22946585.0,
2165,708606,1,2,,103165594,4993,Unspecified,,,,,Antiparasitic activity against Leishmania major promastigotes assessed as parasite growth at 50 ug/mL,Other,22946585.0,
2166,720504,1,1,,56422411,4993,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2167,720508,1,1,,855854,4993,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2168,720509,1,1,,855854,4993,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2169,720511,1,1,,855854,4993,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2170,720513,1,1,,56422411,4993,Inactive,,,,AbsAC40_uM,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_Dose_CherryPick_Activity_Set6,Confirmatory,,
2171,720514,1,1,,56422411,4993,Active,,,23.01,AC50_uM,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2172,720516,2,1,,144203883,4993,Inconclusive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2173,720516,2,1,,144209032,4993,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2174,720516,2,1,,144210449,4993,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2175,720532,1,1,,11112140,4993,Active,420597.0,,7.0795,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2176,720532,1,1,,124881960,4993,Active,420597.0,,15.8489,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2177,720532,1,1,,144203883,4993,Active,420597.0,,14.1254,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2178,720533,1,1,,11112140,4993,Inconclusive,,,10.0,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2179,720533,1,1,,124881960,4993,Inconclusive,,,31.6228,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2180,720533,1,1,,144203883,4993,Inconclusive,,,14.1254,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2181,720542,1,2,,56422411,4993,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2182,720543,1,1,,855854,4993,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2183,720551,1,2,,56422411,4993,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2184,720552,2,1,,144203883,4993,Active,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2185,720552,2,1,,144209032,4993,Inconclusive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2186,720552,2,1,,144210449,4993,Active,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2187,720553,1,2,,56422411,4993,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2188,720554,1,3,,121362394,4993,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2189,720570,1,1,,855854,4993,Active,,,26.0,Max_Activity_Conc_uM,Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent TC71 mammalian cell cytotoxity  Measured in Cell-Based System Using Plate Reader - 7014-04_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2190,720579,2,1,,56422411,4993,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2191,720579,2,1,,124881960,4993,Inconclusive,222762.0,3707576.0,17.7828,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2192,720579,2,1,,124881963,4993,Active,222762.0,3707576.0,8.9125,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2193,720579,2,1,,124881964,4993,Inconclusive,222762.0,3707576.0,50.1187,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2194,720580,1,1,,56422411,4993,Inconclusive,222762.0,3707576.0,28.1838,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2195,720580,1,1,,124881960,4993,Inconclusive,222762.0,3707576.0,22.3872,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2196,720580,1,1,,124881963,4993,Inconclusive,222762.0,3707576.0,8.9125,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2197,720580,1,1,,124881964,4993,Inconclusive,222762.0,3707576.0,28.1838,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2198,720582,1,1,,855854,4993,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2199,720586,1,1,,855854,4993,Inactive,169655958.0,,,AbsAC35_uM,Fluorescence polarization acridine orange assay to identify DNA binding small molcules Measured in Biochemical System Using Plate Reader - 7014-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2200,720587,1,1,,855854,4993,Active,,,8.71,AbsAC35_uM,Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent A673 mammalian cell cytotoxity  Measured in Cell-Based System Using Plate Reader - 7014-03_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2201,720588,1,1,,855854,4993,Active,,,15.9,AbsAC35_uM,HEK293 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-01_Inhibitor_Dose_CherryPick_Activity_Set3,Confirmatory,,
2202,720589,1,1,,855854,4993,Active,,,6.43,AbsAC35_uM,HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_CherryPick_Activity_Set3,Confirmatory,,
2203,720596,1,1,,855854,4993,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2204,720634,2,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2205,720634,2,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2206,720634,2,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2207,720635,2,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2208,720635,2,1,,144209032,4993,Inconclusive,,,31.1058,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2209,720635,2,1,,144210449,4993,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2210,720636,1,1,,17389746,4993,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2211,720636,1,1,,144203883,4993,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2212,720637,2,1,,144203883,4993,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2213,720637,2,1,,144209032,4993,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2214,720637,2,1,,144210449,4993,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2215,720641,1,2,,92307603,4993,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2216,720647,1,2,,855854,4993,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2217,720648,1,1,,855854,4993,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2218,720652,1,1,,17389746,4993,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2219,720653,1,1,,17389746,4993,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2220,720653,1,1,,26751532,4993,Active,,,11.2202,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2221,720659,1,1,,17389746,4993,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2222,720659,1,1,,26751532,4993,Inconclusive,325495557.0,8856.0,50.1187,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2223,720674,2,2,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2224,720674,2,2,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2225,720674,2,2,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2226,720675,2,2,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2227,720675,2,2,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2228,720675,2,2,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2229,720678,2,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2230,720678,2,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2231,720678,2,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2232,720679,2,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2233,720679,2,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2234,720679,2,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2235,720680,2,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2236,720680,2,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2237,720680,2,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2238,720681,2,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2239,720681,2,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2240,720681,2,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2241,720682,2,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2242,720682,2,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2243,720682,2,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2244,720683,2,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2245,720683,2,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2246,720683,2,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2247,720684,2,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2248,720684,2,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2249,720684,2,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2250,720685,2,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2251,720685,2,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2252,720685,2,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2253,720686,2,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2254,720686,2,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2255,720686,2,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2256,720687,2,2,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2257,720687,2,2,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2258,720687,2,2,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2259,720691,4,1,,144203883,4993,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2260,720691,4,1,,144209032,4993,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2261,720691,4,1,,144210449,4993,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2262,720692,3,1,,144203883,4993,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2263,720692,3,1,,144209032,4993,Inconclusive,311348376.0,2908.0,22.2047,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2264,720692,3,1,,144210449,4993,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2265,720693,3,1,,144203883,4993,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2266,720693,3,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2267,720693,3,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2268,720700,1,4,,855854,4993,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2269,720702,1,1,,855854,4993,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2270,720704,1,4,,855854,4993,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2271,720707,1,2,,56422411,4993,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2272,720708,1,2,,56422411,4993,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2273,720709,1,2,,56422411,4993,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2274,720711,1,2,,56422411,4993,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2275,720717,1,3,,92124196,4993,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2276,720717,1,3,,92125099,4993,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2277,720717,1,3,,92307603,4993,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2278,720719,2,1,,144203883,4993,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2279,720719,2,1,,144209032,4993,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2280,720719,2,1,,144210449,4993,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2281,720725,2,1,,144203883,4993,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2282,720725,2,1,,144209032,4993,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2283,720725,2,1,,144210449,4993,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2284,722357,1,2,,103165594,4993,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.4",Other,23168082.0,
2285,722361,1,2,,103165594,4993,Active,,,,,Solubility in octanol at pH 7.4,Other,23168082.0,
2286,722362,1,4,,103165594,4993,Active,,,0.07,IC50,Antimalarial activity against chloroquine-susceptible Plasmodium falciparum D10 asexual erythrocyte forms after 48 hrs by parasite LDH assay,Confirmatory,23168082.0,
2287,722363,1,2,,103165594,4993,Active,,,,,Aqueous solubility in pH 7.4 PBS buffer at 37 degC incubated for 24 hrs by HPLC method,Other,23168082.0,
2288,722364,1,2,,103165594,4993,Unspecified,,,,,"Partition coefficient, log D of the compound using n-octanol/PBS buffer system at pH 7.4 by HPLC method",Other,23168082.0,
2289,722365,1,2,,103165594,4993,Unspecified,,,,,"Partition coefficient, log D of the compound using n-octanol/PBS buffer system at pH 5.5 by HPLC method",Other,23168082.0,
2290,722366,1,2,,103165594,4993,Active,,,,,Solubility in octanol at pH 5.5,Other,23168082.0,
2291,722367,1,2,,103165594,4993,Active,,,,,Aqueous solubility in pH 5.5 PBS buffer at 37 degC incubated for 24 hrs by HPLC method,Other,23168082.0,
2292,728296,1,2,,103165594,4993,Active,,,,,Antiparasitic activity against tachyzoites of Toxoplasma gondii RH type 1 infected in HFF cells incubated for 24 hrs followed by compound washout measured after 72 hrs by beta-galactoside reporter assay,Other,23470217.0,
2293,733054,1,3,,103165594,4993,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Other,23352268.0,
2294,733061,1,3,,103165594,4993,Unspecified,,,,EC50,Antitubercular activity against Mycobacterium tuberculosis H37Rv by BacTiter-Gl Microbial Cell Viability assay,Confirmatory,23352268.0,
2295,733062,1,3,,103165594,4993,Unspecified,,,,EC50,Antitubercular activity against Mycobacterium tuberculosis H37Rv by microdilution alamar Blue broth assay,Confirmatory,23352268.0,
2296,741699,1,3,,103165594,4993,Unspecified,,,168.27599999999998,IC50,SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay.,Confirmatory,,
2297,741702,1,3,,103165594,4993,Unspecified,,,1012.14,IC50,SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.,Confirmatory,,
2298,741703,1,3,,103165594,4993,Unspecified,,,120.524,IC50,SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.,Confirmatory,,
2299,741707,1,3,,103165594,4993,Unspecified,,,975.936,IC50,SANGER: Inhibition of human NCI-H1694 cell growth in a cell viability assay.,Confirmatory,,
2300,741711,1,3,,103165594,4993,Unspecified,,,1715.61,IC50,SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.,Confirmatory,,
2301,741714,1,3,,103165594,4993,Unspecified,,,1691.02,IC50,SANGER: Inhibition of human NCI-H1838 cell growth in a cell viability assay.,Confirmatory,,
2302,741715,1,3,,103165594,4993,Unspecified,,,234.15900000000002,IC50,SANGER: Inhibition of human NCI-H187 cell growth in a cell viability assay.,Confirmatory,,
2303,741716,1,3,,103165594,4993,Unspecified,,,261.01,IC50,SANGER: Inhibition of human NCI-H1882 cell growth in a cell viability assay.,Confirmatory,,
2304,741717,1,3,,103165594,4993,Active,,,21.8274,IC50,SANGER: Inhibition of human NCI-H1963 cell growth in a cell viability assay.,Confirmatory,,
2305,741724,1,3,,103165594,4993,Unspecified,,,1055.5,IC50,SANGER: Inhibition of human NCI-H2081 cell growth in a cell viability assay.,Confirmatory,,
2306,741726,1,3,,103165594,4993,Active,,,6.06338,IC50,SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay.,Confirmatory,,
2307,741727,1,3,,103165594,4993,Unspecified,,,3757.84,IC50,SANGER: Inhibition of human NCI-H2107 cell growth in a cell viability assay.,Confirmatory,,
2308,741729,1,3,,103165594,4993,Active,,,47.2411,IC50,SANGER: Inhibition of human NCI-H2126 cell growth in a cell viability assay.,Confirmatory,,
2309,741730,1,3,,103165594,4993,Unspecified,,,1584.11,IC50,SANGER: Inhibition of human NCI-H2141 cell growth in a cell viability assay.,Confirmatory,,
2310,741732,1,3,,103165594,4993,Unspecified,,,312.85,IC50,SANGER: Inhibition of human NCI-H2171 cell growth in a cell viability assay.,Confirmatory,,
2311,741733,1,3,,103165594,4993,Unspecified,,,69.2837,IC50,SANGER: Inhibition of human NCI-H2196 cell growth in a cell viability assay.,Confirmatory,,
2312,741734,1,3,,103165594,4993,Unspecified,,,646.8290000000001,IC50,SANGER: Inhibition of human NCI-H2227 cell growth in a cell viability assay.,Confirmatory,,
2313,741736,1,3,,103165594,4993,Unspecified,,,2173.7,IC50,SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay.,Confirmatory,,
2314,741738,1,3,,103165594,4993,Active,,,6.54481,IC50,SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay.,Confirmatory,,
2315,741746,1,3,,103165594,4993,Unspecified,,,1260.18,IC50,SANGER: Inhibition of human NCI-H322M cell growth in a cell viability assay.,Confirmatory,,
2316,741747,1,3,,103165594,4993,Unspecified,,,1083.23,IC50,SANGER: Inhibition of human NCI-H345 cell growth in a cell viability assay.,Confirmatory,,
2317,741751,1,3,,103165594,4993,Unspecified,,,12587.9,IC50,SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay.,Confirmatory,,
2318,741753,1,3,,103165594,4993,Unspecified,,,156.249,IC50,SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay.,Confirmatory,,
2319,741756,1,3,,103165594,4993,Active,,,34.0757,IC50,SANGER: Inhibition of human NCI-H524 cell growth in a cell viability assay.,Confirmatory,,
2320,741757,1,3,,103165594,4993,Active,,,7.92007,IC50,SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay.,Confirmatory,,
2321,741760,1,3,,103165594,4993,Active,,,26.2846,IC50,SANGER: Inhibition of human NCI-H64 cell growth in a cell viability assay.,Confirmatory,,
2322,741763,1,3,,103165594,4993,Unspecified,,,215.888,IC50,SANGER: Inhibition of human NCI-H69 cell growth in a cell viability assay.,Confirmatory,,
2323,741764,1,3,,103165594,4993,Unspecified,,,311.01599999999996,IC50,SANGER: Inhibition of human NCI-H716 cell growth in a cell viability assay.,Confirmatory,,
2324,741765,1,3,,103165594,4993,Unspecified,,,3531.4,IC50,SANGER: Inhibition of human NCI-H719 cell growth in a cell viability assay.,Confirmatory,,
2325,741766,1,3,,103165594,4993,Active,,,23.125999999999998,IC50,SANGER: Inhibition of human NCI-H720 cell growth in a cell viability assay.,Confirmatory,,
2326,741768,1,3,,103165594,4993,Unspecified,,,163.21200000000002,IC50,SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay.,Confirmatory,,
2327,741769,1,3,,103165594,4993,Unspecified,,,242.31599999999997,IC50,SANGER: Inhibition of human NCI-H748 cell growth in a cell viability assay.,Confirmatory,,
2328,741771,1,3,,103165594,4993,Active,,,9.1147,IC50,SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay.,Confirmatory,,
2329,741773,1,3,,103165594,4993,Unspecified,,,2926.05,IC50,SANGER: Inhibition of human NCI-H889 cell growth in a cell viability assay.,Confirmatory,,
2330,741775,1,3,,103165594,4993,Active,,,14.7387,IC50,SANGER: Inhibition of human NCI-SNU-1 cell growth in a cell viability assay.,Confirmatory,,
2331,741776,1,3,,103165594,4993,Unspecified,,,370.015,IC50,SANGER: Inhibition of human NCI-SNU-16 cell growth in a cell viability assay.,Confirmatory,,
2332,741777,1,3,,103165594,4993,Unspecified,,,727.688,IC50,SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay.,Confirmatory,,
2333,741778,1,3,,103165594,4993,Active,,,1.50168,IC50,SANGER: Inhibition of human NEC8 cell growth in a cell viability assay.,Confirmatory,,
2334,741779,1,3,,103165594,4993,Unspecified,,,4780.43,IC50,SANGER: Inhibition of human NH-12 cell growth in a cell viability assay.,Confirmatory,,
2335,741780,1,3,,103165594,4993,Active,,,43.7897,IC50,SANGER: Inhibition of human NKM-1 cell growth in a cell viability assay.,Confirmatory,,
2336,741781,1,3,,103165594,4993,Unspecified,,,353.065,IC50,SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay.,Confirmatory,,
2337,741782,1,3,,103165594,4993,Active,,,21.5035,IC50,SANGER: Inhibition of human NOMO-1 cell growth in a cell viability assay.,Confirmatory,,
2338,741783,1,3,,103165594,4993,Active,,,6.6593,IC50,SANGER: Inhibition of human NOS-1 cell growth in a cell viability assay.,Confirmatory,,
2339,741784,1,4,,103165594,4993,Unspecified,,,234.56599999999997,IC50,SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay.,Confirmatory,,
2340,741790,1,3,,103165594,4993,Active,,,8.50007,IC50,SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay.,Confirmatory,,
2341,741791,1,3,,103165594,4993,Unspecified,,,1246.8,IC50,SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay.,Confirmatory,,
2342,741794,1,3,,103165594,4993,Unspecified,,,453.202,IC50,SANGER: Inhibition of human OMC-1 cell growth in a cell viability assay.,Confirmatory,,
2343,741795,1,3,,103165594,4993,Active,,,9.858880000000001,IC50,SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay.,Confirmatory,,
2344,741796,1,3,,103165594,4993,Active,,,22.079,IC50,SANGER: Inhibition of human OPM-2 cell growth in a cell viability assay.,Confirmatory,,
2345,741797,1,3,,103165594,4993,Active,,,2.613,IC50,SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay.,Confirmatory,,
2346,741799,1,3,,103165594,4993,Active,,,4.15327,IC50,SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay.,Confirmatory,,
2347,741803,1,3,,103165594,4993,Unspecified,,,348.499,IC50,SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay.,Confirmatory,,
2348,741804,1,3,,103165594,4993,Unspecified,,,4796.97,IC50,SANGER: Inhibition of human P31-FUJ cell growth in a cell viability assay.,Confirmatory,,
2349,741811,1,3,,103165594,4993,Active,,,14.5868,IC50,SANGER: Inhibition of human PF-382 cell growth in a cell viability assay.,Confirmatory,,
2350,741814,1,3,,103165594,4993,Active,,,2.86137,IC50,SANGER: Inhibition of human PSN1 cell growth in a cell viability assay.,Confirmatory,,
2351,741815,1,3,,103165594,4993,Active,,,6.606,IC50,SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay.,Confirmatory,,
2352,741816,1,3,,103165594,4993,Unspecified,,,348.087,IC50,SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay.,Confirmatory,,
2353,741819,1,3,,103165594,4993,Unspecified,,,9670.27,IC50,SANGER: Inhibition of human REH cell growth in a cell viability assay.,Confirmatory,,
2354,741821,1,3,,103165594,4993,Unspecified,,,563.516,IC50,SANGER: Inhibition of human RH-1 cell growth in a cell viability assay.,Confirmatory,,
2355,741823,1,3,,103165594,4993,Unspecified,,,52.0854,IC50,SANGER: Inhibition of human RKO cell growth in a cell viability assay.,Confirmatory,,
2356,741824,1,3,,103165594,4993,Unspecified,,,1649.03,IC50,SANGER: Inhibition of human RL cell growth in a cell viability assay.,Confirmatory,,
2357,741825,1,3,,103165594,4993,Active,,,15.6774,IC50,SANGER: Inhibition of human RL95-2 cell growth in a cell viability assay.,Confirmatory,,
2358,741829,1,3,,103165594,4993,Active,,,14.5558,IC50,SANGER: Inhibition of human RPMI-6666 cell growth in a cell viability assay.,Confirmatory,,
2359,741831,1,3,,103165594,4993,Unspecified,,,97.4035,IC50,SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay.,Confirmatory,,
2360,741832,1,3,,103165594,4993,Active,,,8.116010000000001,IC50,SANGER: Inhibition of human RPMI-8402 cell growth in a cell viability assay.,Confirmatory,,
2361,741833,1,3,,103165594,4993,Active,,,9.69698,IC50,SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay.,Confirmatory,,
2362,741834,1,3,,103165594,4993,Unspecified,,,438.277,IC50,SANGER: Inhibition of human RS4-11 cell growth in a cell viability assay.,Confirmatory,,
2363,741838,1,3,,103165594,4993,Unspecified,,,199.85,IC50,SANGER: Inhibition of human RXF393 cell growth in a cell viability assay.,Confirmatory,,
2364,741839,1,3,,103165594,4993,Unspecified,,,105.62200000000001,IC50,SANGER: Inhibition of human Raji cell growth in a cell viability assay.,Confirmatory,,
2365,741840,1,3,,103165594,4993,Active,,,5.63854,IC50,SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay.,Confirmatory,,
2366,741843,1,3,,103165594,4993,Unspecified,,,95.5406,IC50,SANGER: Inhibition of human SBC-1 cell growth in a cell viability assay.,Confirmatory,,
2367,741847,1,3,,103165594,4993,Active,,,1.8413400000000002,IC50,SANGER: Inhibition of human SCC-3 cell growth in a cell viability assay.,Confirmatory,,
2368,741850,1,3,,103165594,4993,Active,,,16.8699,IC50,SANGER: Inhibition of human SCH cell growth in a cell viability assay.,Confirmatory,,
2369,741851,1,3,,103165594,4993,Unspecified,,,185.335,IC50,SANGER: Inhibition of human SCLC-21H cell growth in a cell viability assay.,Confirmatory,,
2370,741852,1,3,,103165594,4993,Unspecified,,,158.188,IC50,SANGER: Inhibition of human SF126 cell growth in a cell viability assay.,Confirmatory,,
2371,741853,1,3,,103165594,4993,Active,,,3.6011900000000003,IC50,SANGER: Inhibition of human SF268 cell growth in a cell viability assay.,Confirmatory,,
2372,741855,1,3,,103165594,4993,Active,,,2.5460599999999998,IC50,SANGER: Inhibition of human SF539 cell growth in a cell viability assay.,Confirmatory,,
2373,741856,1,3,,103165594,4993,Unspecified,,,203.593,IC50,SANGER: Inhibition of human SH-4 cell growth in a cell viability assay.,Confirmatory,,
2374,741857,1,3,,103165594,4993,Active,,,26.8118,IC50,SANGER: Inhibition of human SHP-77 cell growth in a cell viability assay.,Confirmatory,,
2375,741858,1,3,,103165594,4993,Active,,,7.98428,IC50,SANGER: Inhibition of human SIG-M5 cell growth in a cell viability assay.,Confirmatory,,
2376,741859,1,3,,103165594,4993,Unspecified,,,5018.08,IC50,SANGER: Inhibition of human SIMA cell growth in a cell viability assay.,Confirmatory,,
2377,741861,1,3,,103165594,4993,Active,,,3.7742699999999996,IC50,SANGER: Inhibition of human SJSA-1 cell growth in a cell viability assay.,Confirmatory,,
2378,741864,1,3,,103165594,4993,Unspecified,,,549.761,IC50,SANGER: Inhibition of human SK-LMS-1 cell growth in a cell viability assay.,Confirmatory,,
2379,741866,1,3,,103165594,4993,Unspecified,,,455.403,IC50,SANGER: Inhibition of human SK-MEL-1 cell growth in a cell viability assay.,Confirmatory,,
2380,741867,1,3,,103165594,4993,Unspecified,,,490.005,IC50,SANGER: Inhibition of human SK-MEL-2 cell growth in a cell viability assay.,Confirmatory,,
2381,741875,1,3,,103165594,4993,Unspecified,,,705.7139999999999,IC50,SANGER: Inhibition of human SK-MM-2 cell growth in a cell viability assay.,Confirmatory,,
2382,741877,1,3,,103165594,4993,Unspecified,,,106.655,IC50,SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay.,Confirmatory,,
2383,741878,1,3,,103165594,4993,Unspecified,,,3143.55,IC50,SANGER: Inhibition of human SK-N-FI cell growth in a cell viability assay.,Confirmatory,,
2384,741879,1,3,,103165594,4993,Active,,,1.23989,IC50,SANGER: Inhibition of human SK-NEP-1 cell growth in a cell viability assay.,Confirmatory,,
2385,741881,1,3,,103165594,4993,Unspecified,,,54.3506,IC50,SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay.,Confirmatory,,
2386,741882,1,3,,103165594,4993,Unspecified,,,2622.02,IC50,SANGER: Inhibition of human SK-UT-1 cell growth in a cell viability assay.,Confirmatory,,
2387,741884,1,3,,103165594,4993,Unspecified,,,179.767,IC50,SANGER: Inhibition of human SKM-1 cell growth in a cell viability assay.,Confirmatory,,
2388,741886,1,3,,103165594,4993,Active,,,20.2085,IC50,SANGER: Inhibition of human SNB75 cell growth in a cell viability assay.,Confirmatory,,
2389,741892,1,3,,103165594,4993,Unspecified,,,666.877,IC50,SANGER: Inhibition of human SNU-C1 cell growth in a cell viability assay.,Confirmatory,,
2390,741894,1,3,,103165594,4993,Active,,,16.5014,IC50,SANGER: Inhibition of human SR cell growth in a cell viability assay.,Confirmatory,,
2391,741895,1,3,,103165594,4993,Active,,,9.30824,IC50,SANGER: Inhibition of human ST486 cell growth in a cell viability assay.,Confirmatory,,
2392,741896,1,3,,103165594,4993,Active,,,10.8472,IC50,SANGER: Inhibition of human SU-DHL-1 cell growth in a cell viability assay.,Confirmatory,,
2393,741897,1,3,,103165594,4993,Unspecified,,,2585.21,IC50,SANGER: Inhibition of human SUP-T1 cell growth in a cell viability assay.,Confirmatory,,
2394,741910,1,3,,103165594,4993,Unspecified,,,1264.71,IC50,SANGER: Inhibition of human SW684 cell growth in a cell viability assay.,Confirmatory,,
2395,741914,1,3,,103165594,4993,Unspecified,,,775.668,IC50,SANGER: Inhibition of human SW872 cell growth in a cell viability assay.,Confirmatory,,
2396,741917,1,3,,103165594,4993,Unspecified,,,283.345,IC50,SANGER: Inhibition of human SW954 cell growth in a cell viability assay.,Confirmatory,,
2397,741918,1,3,,103165594,4993,Unspecified,,,286.052,IC50,SANGER: Inhibition of human SW962 cell growth in a cell viability assay.,Confirmatory,,
2398,741926,1,3,,103165594,4993,Unspecified,,,1895.32,IC50,SANGER: Inhibition of human TALL-1 cell growth in a cell viability assay.,Confirmatory,,
2399,741929,1,3,,103165594,4993,Active,,,9.917639999999999,IC50,SANGER: Inhibition of human TE-1 cell growth in a cell viability assay.,Confirmatory,,
2400,741935,1,3,,103165594,4993,Active,,,3.60362,IC50,SANGER: Inhibition of human 697 cell growth in a cell viability assay.,Confirmatory,,
2401,741938,1,3,,103165594,4993,Active,,,25.8085,IC50,SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay.,Confirmatory,,
2402,741941,1,3,,103165594,4993,Unspecified,,,72.5809,IC50,SANGER: Inhibition of human A101D cell growth in a cell viability assay.,Confirmatory,,
2403,741945,1,3,,103165594,4993,Active,,,25.9982,IC50,SANGER: Inhibition of human A253 cell growth in a cell viability assay.,Confirmatory,,
2404,741947,1,3,,103165594,4993,Active,,,9.44155,IC50,SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay.,Confirmatory,,
2405,741949,1,3,,103165594,4993,Unspecified,,,53.0337,IC50,SANGER: Inhibition of human A388 cell growth in a cell viability assay.,Confirmatory,,
2406,741950,1,3,,103165594,4993,Active,,,15.7541,IC50,SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay.,Confirmatory,,
2407,741953,1,3,,103165594,4993,Unspecified,,,1582.39,IC50,SANGER: Inhibition of human A498 cell growth in a cell viability assay.,Confirmatory,,
2408,741959,1,3,,103165594,4993,Active,,,2.2999099999999997,IC50,SANGER: Inhibition of human ACN cell growth in a cell viability assay.,Confirmatory,,
2409,741961,1,3,,103165594,4993,Active,,,1.18544,IC50,SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay.,Confirmatory,,
2410,741962,1,3,,103165594,4993,Unspecified,,,655.7560000000001,IC50,SANGER: Inhibition of human AM-38 cell growth in a cell viability assay.,Confirmatory,,
2411,741964,1,3,,103165594,4993,Active,,,19.533,IC50,SANGER: Inhibition of human ARH-77 cell growth in a cell viability assay.,Confirmatory,,
2412,741965,1,3,,103165594,4993,Active,,,1.7841,IC50,SANGER: Inhibition of human ATN-1 cell growth in a cell viability assay.,Confirmatory,,
2413,741969,1,3,,103165594,4993,Active,,,25.3678,IC50,SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay.,Confirmatory,,
2414,741970,1,3,,103165594,4993,Unspecified,,,321.389,IC50,SANGER: Inhibition of human BB49-HNC cell growth in a cell viability assay.,Confirmatory,,
2415,741971,1,3,,103165594,4993,Active,,,26.9007,IC50,SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay.,Confirmatory,,
2416,741972,1,3,,103165594,4993,Active,,,5.09805,IC50,SANGER: Inhibition of human BC-1 cell growth in a cell viability assay.,Confirmatory,,
2417,741973,1,3,,103165594,4993,Active,,,19.4777,IC50,SANGER: Inhibition of human BC-3 cell growth in a cell viability assay.,Confirmatory,,
2418,741975,1,3,,103165594,4993,Active,,,7.773639999999999,IC50,SANGER: Inhibition of human BE-13 cell growth in a cell viability assay.,Confirmatory,,
2419,741981,1,3,,103165594,4993,Active,,,20.9473,IC50,SANGER: Inhibition of human BL-41 cell growth in a cell viability assay.,Confirmatory,,
2420,741982,1,3,,103165594,4993,Active,,,14.6394,IC50,SANGER: Inhibition of human BL-70 cell growth in a cell viability assay.,Confirmatory,,
2421,741986,1,3,,103165594,4993,Unspecified,,,1045.89,IC50,SANGER: Inhibition of human BT-474 cell growth in a cell viability assay.,Confirmatory,,
2422,741988,1,3,,103165594,4993,Active,,,12.6933,IC50,SANGER: Inhibition of human BV-173 cell growth in a cell viability assay.,Confirmatory,,
2423,741989,1,3,,103165594,4993,Unspecified,,,1732.01,IC50,SANGER: Inhibition of human Becker cell growth in a cell viability assay.,Confirmatory,,
2424,741993,1,3,,103165594,4993,Unspecified,,,1158.71,IC50,SANGER: Inhibition of human C2BBe1 cell growth in a cell viability assay.,Confirmatory,,
2425,741996,1,3,,103165594,4993,Unspecified,,,1028.59,IC50,SANGER: Inhibition of human C8166 cell growth in a cell viability assay.,Confirmatory,,
2426,741997,1,3,,103165594,4993,Unspecified,,,322.504,IC50,SANGER: Inhibition of human CA46 cell growth in a cell viability assay.,Confirmatory,,
2427,742001,1,3,,103165594,4993,Unspecified,,,937.805,IC50,SANGER: Inhibition of human CAL-148 cell growth in a cell viability assay.,Confirmatory,,
2428,742010,1,3,,103165594,4993,Unspecified,,,129.734,IC50,SANGER: Inhibition of human TE-10 cell growth in a cell viability assay.,Confirmatory,,
2429,742012,1,3,,103165594,4993,Active,,,42.9679,IC50,SANGER: Inhibition of human TE-12 cell growth in a cell viability assay.,Confirmatory,,
2430,742013,1,3,,103165594,4993,Unspecified,,,656.582,IC50,SANGER: Inhibition of human TE-15 cell growth in a cell viability assay.,Confirmatory,,
2431,742014,1,3,,103165594,4993,Unspecified,,,876.695,IC50,SANGER: Inhibition of human TE-441-T cell growth in a cell viability assay.,Confirmatory,,
2432,742015,1,3,,103165594,4993,Active,,,44.9105,IC50,SANGER: Inhibition of human TE-5 cell growth in a cell viability assay.,Confirmatory,,
2433,742016,1,3,,103165594,4993,Active,,,41.544,IC50,SANGER: Inhibition of human TE-6 cell growth in a cell viability assay.,Confirmatory,,
2434,742017,1,3,,103165594,4993,Unspecified,,,454.20599999999996,IC50,SANGER: Inhibition of human TE-8 cell growth in a cell viability assay.,Confirmatory,,
2435,742018,1,3,,103165594,4993,Unspecified,,,1085.29,IC50,SANGER: Inhibition of human TE-9 cell growth in a cell viability assay.,Confirmatory,,
2436,742020,1,3,,103165594,4993,Unspecified,,,1703.57,IC50,SANGER: Inhibition of human TGBC1TKB cell growth in a cell viability assay.,Confirmatory,,
2437,742022,1,3,,103165594,4993,Active,,,34.2129,IC50,SANGER: Inhibition of human TGW cell growth in a cell viability assay.,Confirmatory,,
2438,742023,1,3,,103165594,4993,Unspecified,,,1435.91,IC50,SANGER: Inhibition of human THP-1 cell growth in a cell viability assay.,Confirmatory,,
2439,742025,1,3,,103165594,4993,Active,,,7.41598,IC50,SANGER: Inhibition of human TK10 cell growth in a cell viability assay.,Confirmatory,,
2440,742027,1,3,,103165594,4993,Unspecified,,,1512.27,IC50,SANGER: Inhibition of human TUR cell growth in a cell viability assay.,Confirmatory,,
2441,742031,1,3,,103165594,4993,Active,,,5.12568,IC50,SANGER: Inhibition of human U-266 cell growth in a cell viability assay.,Confirmatory,,
2442,742032,1,3,,103165594,4993,Active,,,42.6885,IC50,SANGER: Inhibition of human U-698-M cell growth in a cell viability assay.,Confirmatory,,
2443,742033,1,3,,103165594,4993,Unspecified,,,1192.23,IC50,SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay.,Confirmatory,,
2444,742036,1,3,,103165594,4993,Active,,,3.8445099999999996,IC50,SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay.,Confirmatory,,
2445,742038,1,3,,103165594,4993,Unspecified,,,695.6360000000001,IC50,SANGER: Inhibition of human UACC-812 cell growth in a cell viability assay.,Confirmatory,,
2446,742042,1,3,,103165594,4993,Active,,,15.1673,IC50,SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay.,Confirmatory,,
2447,742046,1,3,,103165594,4993,Unspecified,,,107.68799999999999,IC50,SANGER: Inhibition of human WSU-NHL cell growth in a cell viability assay.,Confirmatory,,
2448,742050,1,3,,103165594,4993,Unspecified,,,850.301,IC50,SANGER: Inhibition of human YT cell growth in a cell viability assay.,Confirmatory,,
2449,742052,1,3,,103165594,4993,Unspecified,,,394.41,IC50,SANGER: Inhibition of human no-10 cell growth in a cell viability assay.,Confirmatory,,
2450,742053,1,3,,103165594,4993,Unspecified,,,1515.61,IC50,SANGER: Inhibition of human no-11 cell growth in a cell viability assay.,Confirmatory,,
2451,742056,1,3,,103165594,4993,Unspecified,,,731.297,IC50,SANGER: Inhibition of human CAS-1 cell growth in a cell viability assay.,Confirmatory,,
2452,742058,1,3,,103165594,4993,Active,,,9.38931,IC50,SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay.,Confirmatory,,
2453,742059,1,3,,103165594,4993,Active,,,5.70501,IC50,SANGER: Inhibition of human CESS cell growth in a cell viability assay.,Confirmatory,,
2454,742061,1,3,,103165594,4993,Active,,,17.456,IC50,SANGER: Inhibition of human CGTH-W-1 cell growth in a cell viability assay.,Confirmatory,,
2455,742063,1,3,,103165594,4993,Unspecified,,,69.0102,IC50,SANGER: Inhibition of human CHP-126 cell growth in a cell viability assay.,Confirmatory,,
2456,742066,1,3,,103165594,4993,Active,,,2.4603200000000003,IC50,SANGER: Inhibition of human CMK cell growth in a cell viability assay.,Confirmatory,,
2457,742068,1,3,,103165594,4993,Active,,,3.9992099999999997,IC50,SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay.,Confirmatory,,
2458,742069,1,3,,103165594,4993,Active,,,32.1459,IC50,SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay.,Confirmatory,,
2459,742073,1,3,,103165594,4993,Active,,,6.75597,IC50,SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay.,Confirmatory,,
2460,742076,1,3,,103165594,4993,Unspecified,,,128.655,IC50,SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay.,Confirmatory,,
2461,742077,1,3,,103165594,4993,Unspecified,,,2014.58,IC50,SANGER: Inhibition of human COLO-824 cell growth in a cell viability assay.,Confirmatory,,
2462,742078,1,3,,103165594,4993,Active,,,7.27998,IC50,SANGER: Inhibition of human COLO-829 cell growth in a cell viability assay.,Confirmatory,,
2463,742081,1,3,,103165594,4993,Active,,,6.37367,IC50,SANGER: Inhibition of human COR-L279 cell growth in a cell viability assay.,Confirmatory,,
2464,742082,1,3,,103165594,4993,Unspecified,,,260.0,IC50,SANGER: Inhibition of human COR-L88 cell growth in a cell viability assay.,Confirmatory,,
2465,742084,1,3,,103165594,4993,Unspecified,,,1228.76,IC50,SANGER: Inhibition of human CP66-MEL cell growth in a cell viability assay.,Confirmatory,,
2466,742086,1,3,,103165594,4993,Active,,,47.2233,IC50,SANGER: Inhibition of human CPC-N cell growth in a cell viability assay.,Confirmatory,,
2467,742087,1,3,,103165594,4993,Active,,,18.7089,IC50,SANGER: Inhibition of human CRO-AP2 cell growth in a cell viability assay.,Confirmatory,,
2468,742088,1,3,,103165594,4993,Active,,,27.66,IC50,SANGER: Inhibition of human CTB-1 cell growth in a cell viability assay.,Confirmatory,,
2469,742089,1,3,,103165594,4993,Active,,,2.47632,IC50,SANGER: Inhibition of human CTV-1 cell growth in a cell viability assay.,Confirmatory,,
2470,742090,1,3,,103165594,4993,Unspecified,,,2674.49,IC50,SANGER: Inhibition of human CW-2 cell growth in a cell viability assay.,Confirmatory,,
2471,742096,1,3,,103165594,4993,Unspecified,,,113.855,IC50,SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay.,Confirmatory,,
2472,742101,1,3,,103165594,4993,Unspecified,,,1315.07,IC50,SANGER: Inhibition of human D-247MG cell growth in a cell viability assay.,Confirmatory,,
2473,742102,1,3,,103165594,4993,Unspecified,,,531.389,IC50,SANGER: Inhibition of human D-263MG cell growth in a cell viability assay.,Confirmatory,,
2474,742103,1,4,,103165594,4993,Unspecified,,,3285.09,IC50,SANGER: Inhibition of human D-283MED cell growth in a cell viability assay.,Confirmatory,,
2475,742104,1,3,,103165594,4993,Unspecified,,,1729.11,IC50,SANGER: Inhibition of human D-336MG cell growth in a cell viability assay.,Confirmatory,,
2476,742105,1,3,,103165594,4993,Unspecified,,,615.6569999999999,IC50,SANGER: Inhibition of human D-392MG cell growth in a cell viability assay.,Confirmatory,,
2477,742107,1,3,,103165594,4993,Unspecified,,,480.315,IC50,SANGER: Inhibition of human D-502MG cell growth in a cell viability assay.,Confirmatory,,
2478,742108,1,3,,103165594,4993,Unspecified,,,1497.16,IC50,SANGER: Inhibition of human D-542MG cell growth in a cell viability assay.,Confirmatory,,
2479,742110,1,3,,103165594,4993,Active,,,34.3685,IC50,SANGER: Inhibition of human DB cell growth in a cell viability assay.,Confirmatory,,
2480,742112,1,3,,103165594,4993,Active,,,3.93456,IC50,SANGER: Inhibition of human DEL cell growth in a cell viability assay.,Confirmatory,,
2481,742113,1,3,,103165594,4993,Active,,,14.5501,IC50,SANGER: Inhibition of human DG-75 cell growth in a cell viability assay.,Confirmatory,,
2482,742114,1,3,,103165594,4993,Unspecified,,,997.137,IC50,SANGER: Inhibition of human DJM-1 cell growth in a cell viability assay.,Confirmatory,,
2483,742116,1,3,,103165594,4993,Unspecified,,,58.5922,IC50,SANGER: Inhibition of human DMS-114 cell growth in a cell viability assay.,Confirmatory,,
2484,742117,1,3,,103165594,4993,Active,,,43.4122,IC50,SANGER: Inhibition of human DMS-153 cell growth in a cell viability assay.,Confirmatory,,
2485,742120,1,3,,103165594,4993,Unspecified,,,176.479,IC50,SANGER: Inhibition of human DMS-79 cell growth in a cell viability assay.,Confirmatory,,
2486,742121,1,3,,103165594,4993,Unspecified,,,816.2689999999999,IC50,SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay.,Confirmatory,,
2487,742123,1,3,,103165594,4993,Active,,,4.98034,IC50,SANGER: Inhibition of human DSH1 cell growth in a cell viability assay.,Confirmatory,,
2488,742125,1,3,,103165594,4993,Active,,,21.5903,IC50,SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay.,Confirmatory,,
2489,742128,1,3,,103165594,4993,Active,,,32.4147,IC50,SANGER: Inhibition of human Daudi cell growth in a cell viability assay.,Confirmatory,,
2490,742131,1,3,,103165594,4993,Unspecified,,,495.504,IC50,SANGER: Inhibition of human EB-3 cell growth in a cell viability assay.,Confirmatory,,
2491,742132,1,3,,103165594,4993,Unspecified,,,1590.07,IC50,SANGER: Inhibition of human EB2 cell growth in a cell viability assay.,Confirmatory,,
2492,742133,1,3,,103165594,4993,Unspecified,,,424.866,IC50,SANGER: Inhibition of human EC-GI-10 cell growth in a cell viability assay.,Confirmatory,,
2493,742135,1,3,,103165594,4993,Active,,,2.56176,IC50,SANGER: Inhibition of human ECC12 cell growth in a cell viability assay.,Confirmatory,,
2494,742136,1,3,,103165594,4993,Active,,,37.0717,IC50,SANGER: Inhibition of human ECC4 cell growth in a cell viability assay.,Confirmatory,,
2495,742143,1,3,,103165594,4993,Unspecified,,,245.218,IC50,SANGER: Inhibition of human EKVX cell growth in a cell viability assay.,Confirmatory,,
2496,742144,1,3,,103165594,4993,Active,,,12.4054,IC50,SANGER: Inhibition of human EM-2 cell growth in a cell viability assay.,Confirmatory,,
2497,742146,1,3,,103165594,4993,Active,,,0.1229,IC50,SANGER: Inhibition of human ES1 cell growth in a cell viability assay.,Confirmatory,,
2498,742147,1,3,,103165594,4993,Unspecified,,,175.229,IC50,SANGER: Inhibition of human ES3 cell growth in a cell viability assay.,Confirmatory,,
2499,742148,1,3,,103165594,4993,Active,,,3.11718,IC50,SANGER: Inhibition of human ES4 cell growth in a cell viability assay.,Confirmatory,,
2500,742149,1,3,,103165594,4993,Unspecified,,,2654.42,IC50,SANGER: Inhibition of human ES5 cell growth in a cell viability assay.,Confirmatory,,
2501,742150,1,3,,103165594,4993,Active,,,17.2354,IC50,SANGER: Inhibition of human ES6 cell growth in a cell viability assay.,Confirmatory,,
2502,742151,1,3,,103165594,4993,Active,,,14.7937,IC50,SANGER: Inhibition of human ES7 cell growth in a cell viability assay.,Confirmatory,,
2503,742152,1,3,,103165594,4993,Active,,,0.8966700000000001,IC50,SANGER: Inhibition of human ES8 cell growth in a cell viability assay.,Confirmatory,,
2504,742154,1,3,,103165594,4993,Active,,,4.10377,IC50,SANGER: Inhibition of human ETK-1 cell growth in a cell viability assay.,Confirmatory,,
2505,742155,1,3,,103165594,4993,Unspecified,,,1542.94,IC50,SANGER: Inhibition of human EVSA-T cell growth in a cell viability assay.,Confirmatory,,
2506,742156,1,3,,103165594,4993,Active,,,1.3730799999999999,IC50,SANGER: Inhibition of human EW-1 cell growth in a cell viability assay.,Confirmatory,,
2507,742157,1,3,,103165594,4993,Unspecified,,,2589.3,IC50,SANGER: Inhibition of human EW-11 cell growth in a cell viability assay.,Confirmatory,,
2508,742158,1,3,,103165594,4993,Unspecified,,,1138.93,IC50,SANGER: Inhibition of human EW-12 cell growth in a cell viability assay.,Confirmatory,,
2509,742159,1,3,,103165594,4993,Unspecified,,,401.79,IC50,SANGER: Inhibition of human EW-13 cell growth in a cell viability assay.,Confirmatory,,
2510,742160,1,3,,103165594,4993,Active,,,15.8034,IC50,SANGER: Inhibition of human EW-16 cell growth in a cell viability assay.,Confirmatory,,
2511,742161,1,3,,103165594,4993,Unspecified,,,332.537,IC50,SANGER: Inhibition of human EW-18 cell growth in a cell viability assay.,Confirmatory,,
2512,742162,1,3,,103165594,4993,Unspecified,,,113.374,IC50,SANGER: Inhibition of human EW-22 cell growth in a cell viability assay.,Confirmatory,,
2513,742163,1,3,,103165594,4993,Unspecified,,,54.2712,IC50,SANGER: Inhibition of human EW-24 cell growth in a cell viability assay.,Confirmatory,,
2514,742164,1,3,,103165594,4993,Unspecified,,,245.35299999999998,IC50,SANGER: Inhibition of human EW-3 cell growth in a cell viability assay.,Confirmatory,,
2515,742166,1,3,,103165594,4993,Active,,,27.6103,IC50,SANGER: Inhibition of human EoL-1-cell cell growth in a cell viability assay.,Confirmatory,,
2516,742172,1,3,,103165594,4993,Unspecified,,,2118.02,IC50,SANGER: Inhibition of human GAK cell growth in a cell viability assay.,Confirmatory,,
2517,742174,1,3,,103165594,4993,Unspecified,,,1047.86,IC50,SANGER: Inhibition of human GB-1 cell growth in a cell viability assay.,Confirmatory,,
2518,742175,1,3,,103165594,4993,Active,,,21.6245,IC50,SANGER: Inhibition of human GCIY cell growth in a cell viability assay.,Confirmatory,,
2519,742177,1,3,,103165594,4993,Active,,,42.3362,IC50,SANGER: Inhibition of human GDM-1 cell growth in a cell viability assay.,Confirmatory,,
2520,742178,1,3,,103165594,4993,Unspecified,,,585.6709999999999,IC50,SANGER: Inhibition of human GI-1 cell growth in a cell viability assay.,Confirmatory,,
2521,742179,1,3,,103165594,4993,Active,,,1.40272,IC50,SANGER: Inhibition of human GI-ME-N cell growth in a cell viability assay.,Confirmatory,,
2522,742181,1,3,,103165594,4993,Active,,,33.1382,IC50,SANGER: Inhibition of human GOTO cell growth in a cell viability assay.,Confirmatory,,
2523,742183,1,3,,103165594,4993,Active,,,0.70882,IC50,SANGER: Inhibition of human GR-ST cell growth in a cell viability assay.,Confirmatory,,
2524,742184,1,3,,103165594,4993,Unspecified,,,1939.03,IC50,SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay.,Confirmatory,,
2525,742188,1,3,,103165594,4993,Active,,,4.74112,IC50,SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay.,Confirmatory,,
2526,742189,1,3,,103165594,4993,Active,,,5.65396,IC50,SANGER: Inhibition of human HC-1 cell growth in a cell viability assay.,Confirmatory,,
2527,742191,1,3,,103165594,4993,Unspecified,,,143.33700000000002,IC50,SANGER: Inhibition of human HCC1187 cell growth in a cell viability assay.,Confirmatory,,
2528,742195,1,3,,103165594,4993,Active,,,38.506,IC50,SANGER: Inhibition of human HCC1599 cell growth in a cell viability assay.,Confirmatory,,
2529,742199,1,3,,103165594,4993,Unspecified,,,97.5804,IC50,SANGER: Inhibition of human HCC2157 cell growth in a cell viability assay.,Confirmatory,,
2530,742200,1,3,,103165594,4993,Unspecified,,,134.969,IC50,SANGER: Inhibition of human HCC2218 cell growth in a cell viability assay.,Confirmatory,,
2531,742201,1,3,,103165594,4993,Active,,,5.78443,IC50,SANGER: Inhibition of human HCC2998 cell growth in a cell viability assay.,Confirmatory,,
2532,742205,1,3,,103165594,4993,Unspecified,,,1228.43,IC50,SANGER: Inhibition of human HCE-T cell growth in a cell viability assay.,Confirmatory,,
2533,742208,1,3,,103165594,4993,Active,,,11.9151,IC50,SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay.,Confirmatory,,
2534,742209,1,3,,103165594,4993,Unspecified,,,443.413,IC50,SANGER: Inhibition of human HDLM-2 cell growth in a cell viability assay.,Confirmatory,,
2535,742211,1,3,,103165594,4993,Active,,,2.6703,IC50,SANGER: Inhibition of human HEL cell growth in a cell viability assay.,Confirmatory,,
2536,742213,1,3,,103165594,4993,Active,,,24.4542,IC50,SANGER: Inhibition of human HH cell growth in a cell viability assay.,Confirmatory,,
2537,742214,1,3,,103165594,4993,Unspecified,,,301.879,IC50,SANGER: Inhibition of human HL-60 cell growth in a cell viability assay.,Confirmatory,,
2538,742219,1,3,,103165594,4993,Active,,,5.023219999999999,IC50,SANGER: Inhibition of human HOP-62 cell growth in a cell viability assay.,Confirmatory,,
2539,742226,1,3,,103165594,4993,Active,,,29.3816,IC50,SANGER: Inhibition of human HT cell growth in a cell viability assay.,Confirmatory,,
2540,742230,1,3,,103165594,4993,Active,,,6.803160000000001,IC50,SANGER: Inhibition of human HT-144 cell growth in a cell viability assay.,Confirmatory,,
2541,742235,1,3,,103165594,4993,Active,,,12.0862,IC50,SANGER: Inhibition of human HUTU-80 cell growth in a cell viability assay.,Confirmatory,,
2542,742246,1,3,,103165594,4993,Unspecified,,,2019.73,IC50,SANGER: Inhibition of human IM-9 cell growth in a cell viability assay.,Confirmatory,,
2543,742247,1,3,,103165594,4993,Unspecified,,,967.668,IC50,SANGER: Inhibition of human IMR-5 cell growth in a cell viability assay.,Confirmatory,,
2544,742249,1,3,,103165594,4993,Active,,,4.33289,IC50,SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay.,Confirmatory,,
2545,742250,1,3,,103165594,4993,Unspecified,,,611.102,IC50,SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay.,Confirmatory,,
2546,742251,1,3,,103165594,4993,Active,,,16.0905,IC50,SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay.,Confirmatory,,
2547,742252,1,3,,103165594,4993,Active,,,11.3937,IC50,SANGER: Inhibition of human IST-SL2 cell growth in a cell viability assay.,Confirmatory,,
2548,742253,1,3,,103165594,4993,Active,,,2.21925,IC50,SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay.,Confirmatory,,
2549,742255,1,3,,103165594,4993,Unspecified,,,77.0279,IC50,SANGER: Inhibition of human JAR cell growth in a cell viability assay.,Confirmatory,,
2550,742257,1,3,,103165594,4993,Unspecified,,,980.555,IC50,SANGER: Inhibition of human JVM-2 cell growth in a cell viability assay.,Confirmatory,,
2551,742258,1,3,,103165594,4993,Unspecified,,,694.117,IC50,SANGER: Inhibition of human JVM-3 cell growth in a cell viability assay.,Confirmatory,,
2552,742259,1,4,,103165594,4993,Active,,,10.946,IC50,SANGER: Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay.,Confirmatory,,
2553,742260,1,3,,103165594,4993,Active,,,25.6743,IC50,SANGER: Inhibition of human K-562 cell growth in a cell viability assay.,Confirmatory,,
2554,742261,1,3,,103165594,4993,Unspecified,,,4369.83,IC50,SANGER: Inhibition of human K052 cell growth in a cell viability assay.,Confirmatory,,
2555,742262,1,3,,103165594,4993,Unspecified,,,228.955,IC50,SANGER: Inhibition of human K5 cell growth in a cell viability assay.,Confirmatory,,
2556,742263,1,3,,103165594,4993,Active,,,12.0162,IC50,SANGER: Inhibition of human KALS-1 cell growth in a cell viability assay.,Confirmatory,,
2557,742264,1,3,,103165594,4993,Active,,,33.1938,IC50,SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay.,Confirmatory,,
2558,742265,1,3,,103165594,4993,Active,,,18.1968,IC50,SANGER: Inhibition of human KARPAS-422 cell growth in a cell viability assay.,Confirmatory,,
2559,742266,1,3,,103165594,4993,Unspecified,,,130.313,IC50,SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay.,Confirmatory,,
2560,742267,1,4,,103165594,4993,Unspecified,,,1573.6,IC50,SANGER: Inhibition of human KASUMI-1 cell growth in a cell viability assay.,Confirmatory,,
2561,742268,1,3,,103165594,4993,Active,,,10.1932,IC50,SANGER: Inhibition of human KE-37 cell growth in a cell viability assay.,Confirmatory,,
2562,742269,1,3,,103165594,4993,Unspecified,,,808.64,IC50,SANGER: Inhibition of human KG-1 cell growth in a cell viability assay.,Confirmatory,,
2563,742270,1,3,,103165594,4993,Unspecified,,,83.8672,IC50,SANGER: Inhibition of human KGN cell growth in a cell viability assay.,Confirmatory,,
2564,742271,1,3,,103165594,4993,Unspecified,,,146.389,IC50,SANGER: Inhibition of human KINGS-1 cell growth in a cell viability assay.,Confirmatory,,
2565,742273,1,3,,103165594,4993,Active,,,11.9609,IC50,SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay.,Confirmatory,,
2566,742274,1,3,,103165594,4993,Active,,,2.32343,IC50,SANGER: Inhibition of human KM12 cell growth in a cell viability assay.,Confirmatory,,
2567,742275,1,3,,103165594,4993,Unspecified,,,137.487,IC50,SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay.,Confirmatory,,
2568,742276,1,3,,103165594,4993,Unspecified,,,1299.06,IC50,SANGER: Inhibition of human KMS-12-PE cell growth in a cell viability assay.,Confirmatory,,
2569,742277,1,3,,103165594,4993,Unspecified,,,1210.61,IC50,SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay.,Confirmatory,,
2570,742279,1,3,,103165594,4993,Unspecified,,,1974.82,IC50,SANGER: Inhibition of human KNS-81-FD cell growth in a cell viability assay.,Confirmatory,,
2571,742283,1,3,,103165594,4993,Unspecified,,,2223.29,IC50,SANGER: Inhibition of human KP-N-YN cell growth in a cell viability assay.,Confirmatory,,
2572,742284,1,3,,103165594,4993,Unspecified,,,221.801,IC50,SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay.,Confirmatory,,
2573,742285,1,3,,103165594,4993,Unspecified,,,62.2762,IC50,SANGER: Inhibition of human KS-1 cell growth in a cell viability assay.,Confirmatory,,
2574,742287,1,3,,103165594,4993,Active,,,15.6448,IC50,SANGER: Inhibition of human KU812 cell growth in a cell viability assay.,Confirmatory,,
2575,742288,1,3,,103165594,4993,Active,,,22.6497,IC50,SANGER: Inhibition of human KURAMOCHI cell growth in a cell viability assay.,Confirmatory,,
2576,742289,1,3,,103165594,4993,Unspecified,,,725.706,IC50,SANGER: Inhibition of human KY821 cell growth in a cell viability assay.,Confirmatory,,
2577,742299,1,3,,103165594,4993,Active,,,36.2422,IC50,SANGER: Inhibition of human L-363 cell growth in a cell viability assay.,Confirmatory,,
2578,742300,1,3,,103165594,4993,Unspecified,,,339.805,IC50,SANGER: Inhibition of human L-428 cell growth in a cell viability assay.,Confirmatory,,
2579,742301,1,3,,103165594,4993,Active,,,10.4899,IC50,SANGER: Inhibition of human L-540 cell growth in a cell viability assay.,Confirmatory,,
2580,742302,1,3,,103165594,4993,Active,,,2.6634,IC50,SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay.,Confirmatory,,
2581,742303,1,3,,103165594,4993,Unspecified,,,349.782,IC50,SANGER: Inhibition of human LAN-6 cell growth in a cell viability assay.,Confirmatory,,
2582,742304,1,3,,103165594,4993,Unspecified,,,710.409,IC50,SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay.,Confirmatory,,
2583,742305,1,3,,103165594,4993,Unspecified,,,670.227,IC50,SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay.,Confirmatory,,
2584,742306,1,3,,103165594,4993,Unspecified,,,175.804,IC50,SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay.,Confirmatory,,
2585,742307,1,3,,103165594,4993,Unspecified,,,2489.19,IC50,SANGER: Inhibition of human LB373-MEL-D cell growth in a cell viability assay.,Confirmatory,,
2586,742308,1,3,,103165594,4993,Unspecified,,,66.5904,IC50,SANGER: Inhibition of human LB647-SCLC cell growth in a cell viability assay.,Confirmatory,,
2587,742309,1,3,,103165594,4993,Unspecified,,,608.754,IC50,SANGER: Inhibition of human LB771-HNC cell growth in a cell viability assay.,Confirmatory,,
2588,742310,1,3,,103165594,4993,Unspecified,,,540.249,IC50,SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay.,Confirmatory,,
2589,742311,1,3,,103165594,4993,Unspecified,,,791.19,IC50,SANGER: Inhibition of human LB996-RCC cell growth in a cell viability assay.,Confirmatory,,
2590,742312,1,3,,103165594,4993,Active,,,41.7752,IC50,SANGER: Inhibition of human LC-1F cell growth in a cell viability assay.,Confirmatory,,
2591,742313,1,3,,103165594,4993,Active,,,45.2608,IC50,SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay.,Confirmatory,,
2592,742314,1,3,,103165594,4993,Active,,,27.2238,IC50,SANGER: Inhibition of human LC4-1 cell growth in a cell viability assay.,Confirmatory,,
2593,742319,1,3,,103165594,4993,Unspecified,,,309.503,IC50,SANGER: Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay.,Confirmatory,,
2594,742320,1,3,,103165594,4993,Active,,,10.9408,IC50,SANGER: Inhibition of human LOUCY cell growth in a cell viability assay.,Confirmatory,,
2595,742321,1,3,,103165594,4993,Active,,,13.0142,IC50,SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay.,Confirmatory,,
2596,742322,1,3,,103165594,4993,Unspecified,,,117.149,IC50,SANGER: Inhibition of human LP-1 cell growth in a cell viability assay.,Confirmatory,,
2597,742323,1,3,,103165594,4993,Active,,,18.3115,IC50,SANGER: Inhibition of human LS-1034 cell growth in a cell viability assay.,Confirmatory,,
2598,742324,1,3,,103165594,4993,Unspecified,,,1496.95,IC50,SANGER: Inhibition of human LS-123 cell growth in a cell viability assay.,Confirmatory,,
2599,742325,1,3,,103165594,4993,Active,,,0.83681,IC50,SANGER: Inhibition of human LS-411N cell growth in a cell viability assay.,Confirmatory,,
2600,742326,1,3,,103165594,4993,Unspecified,,,71.982,IC50,SANGER: Inhibition of human LS-513 cell growth in a cell viability assay.,Confirmatory,,
2601,742327,1,3,,103165594,4993,Unspecified,,,304.776,IC50,SANGER: Inhibition of human LU-134-A cell growth in a cell viability assay.,Confirmatory,,
2602,742329,1,3,,103165594,4993,Active,,,11.1257,IC50,SANGER: Inhibition of human LU-139 cell growth in a cell viability assay.,Confirmatory,,
2603,742330,1,3,,103165594,4993,Unspecified,,,368.296,IC50,SANGER: Inhibition of human LU-165 cell growth in a cell viability assay.,Confirmatory,,
2604,742331,1,4,,103165594,4993,Active,,,11.0465,IC50,SANGER: Inhibition of human LU-65 cell growth in a cell viability assay.,Confirmatory,,
2605,742333,1,3,,103165594,4993,Unspecified,,,1224.49,IC50,SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay.,Confirmatory,,
2606,742337,1,3,,103165594,4993,Unspecified,,,3356.95,IC50,SANGER: Inhibition of human MC-CAR cell growth in a cell viability assay.,Confirmatory,,
2607,742339,1,3,,103165594,4993,Active,,,17.8945,IC50,SANGER: Inhibition of human MC116 cell growth in a cell viability assay.,Confirmatory,,
2608,742341,1,3,,103165594,4993,Unspecified,,,1521.36,IC50,SANGER: Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay.,Confirmatory,,
2609,742350,1,3,,103165594,4993,Active,,,11.7684,IC50,SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay.,Confirmatory,,
2610,742356,1,3,,103165594,4993,Unspecified,,,673.4789999999999,IC50,SANGER: Inhibition of human MFH-ino cell growth in a cell viability assay.,Confirmatory,,
2611,742357,1,3,,103165594,4993,Unspecified,,,2148.27,IC50,SANGER: Inhibition of human MFM-223 cell growth in a cell viability assay.,Confirmatory,,
2612,742359,1,3,,103165594,4993,Unspecified,,,93.7384,IC50,SANGER: Inhibition of human MHH-CALL-2 cell growth in a cell viability assay.,Confirmatory,,
2613,742361,1,3,,103165594,4993,Active,,,13.7098,IC50,SANGER: Inhibition of human MHH-NB-11 cell growth in a cell viability assay.,Confirmatory,,
2614,742362,1,3,,103165594,4993,Unspecified,,,60.3948,IC50,SANGER: Inhibition of human MHH-PREB-1 cell growth in a cell viability assay.,Confirmatory,,
2615,742368,1,3,,103165594,4993,Active,,,11.4642,IC50,SANGER: Inhibition of human ML-2 cell growth in a cell viability assay.,Confirmatory,,
2616,742369,1,3,,103165594,4993,Unspecified,,,2227.89,IC50,SANGER: Inhibition of human MLMA cell growth in a cell viability assay.,Confirmatory,,
2617,742370,1,3,,103165594,4993,Unspecified,,,2900.41,IC50,SANGER: Inhibition of human MMAC-SF cell growth in a cell viability assay.,Confirmatory,,
2618,742371,1,3,,103165594,4993,Unspecified,,,1029.46,IC50,SANGER: Inhibition of human MN-60 cell growth in a cell viability assay.,Confirmatory,,
2619,742372,1,3,,103165594,4993,Unspecified,,,66.3344,IC50,SANGER: Inhibition of human MOLT-13 cell growth in a cell viability assay.,Confirmatory,,
2620,742373,1,3,,103165594,4993,Active,,,15.1432,IC50,SANGER: Inhibition of human MOLT-16 cell growth in a cell viability assay.,Confirmatory,,
2621,742374,1,3,,103165594,4993,Active,,,5.43463,IC50,SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay.,Confirmatory,,
2622,742375,1,4,,103165594,4993,Active,,,16.2862,IC50,SANGER: Inhibition of human MONO-MAC-6 cell growth in a cell viability assay.,Confirmatory,,
2623,742376,1,3,,103165594,4993,Unspecified,,,1204.66,IC50,SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay.,Confirmatory,,
2624,742377,1,3,,103165594,4993,Unspecified,,,175.567,IC50,SANGER: Inhibition of human MRK-nu-1 cell growth in a cell viability assay.,Confirmatory,,
2625,742378,1,3,,103165594,4993,Unspecified,,,2183.73,IC50,SANGER: Inhibition of human MS-1 cell growth in a cell viability assay.,Confirmatory,,
2626,742379,1,3,,103165594,4993,Active,,,7.643039999999999,IC50,SANGER: Inhibition of human MSTO-211H cell growth in a cell viability assay.,Confirmatory,,
2627,742380,1,3,,103165594,4993,Active,,,11.3977,IC50,SANGER: Inhibition of human MV-4-11 cell growth in a cell viability assay.,Confirmatory,,
2628,742381,1,3,,103165594,4993,Active,,,26.7358,IC50,SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay.,Confirmatory,,
2629,742382,1,3,,103165594,4993,Unspecified,,,1077.41,IC50,SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay.,Confirmatory,,
2630,742383,1,3,,103165594,4993,Active,,,7.56148,IC50,SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay.,Confirmatory,,
2631,742385,1,4,,103165594,4993,Unspecified,,,4111.24,IC50,SANGER: Inhibition of human Mo-T cell growth in a cell viability assay.,Confirmatory,,
2632,742386,1,3,,103165594,4993,Active,,,19.8316,IC50,SANGER: Inhibition of human NALM-6 cell growth in a cell viability assay.,Confirmatory,,
2633,742387,1,3,,103165594,4993,Active,,,22.5464,IC50,SANGER: Inhibition of human NB1 cell growth in a cell viability assay.,Confirmatory,,
2634,742388,1,3,,103165594,4993,Unspecified,,,1756.12,IC50,SANGER: Inhibition of human NB10 cell growth in a cell viability assay.,Confirmatory,,
2635,742389,1,3,,103165594,4993,Unspecified,,,1777.98,IC50,SANGER: Inhibition of human NB12 cell growth in a cell viability assay.,Confirmatory,,
2636,742390,1,3,,103165594,4993,Unspecified,,,888.698,IC50,SANGER: Inhibition of human NB13 cell growth in a cell viability assay.,Confirmatory,,
2637,742391,1,3,,103165594,4993,Active,,,21.1673,IC50,SANGER: Inhibition of human NB14 cell growth in a cell viability assay.,Confirmatory,,
2638,742392,1,3,,103165594,4993,Unspecified,,,1191.57,IC50,SANGER: Inhibition of human NB17 cell growth in a cell viability assay.,Confirmatory,,
2639,742393,1,3,,103165594,4993,Unspecified,,,1260.95,IC50,SANGER: Inhibition of human NB5 cell growth in a cell viability assay.,Confirmatory,,
2640,742394,1,3,,103165594,4993,Unspecified,,,1385.61,IC50,SANGER: Inhibition of human NB6 cell growth in a cell viability assay.,Confirmatory,,
2641,742395,1,3,,103165594,4993,Unspecified,,,619.6419999999999,IC50,SANGER: Inhibition of human NB69 cell growth in a cell viability assay.,Confirmatory,,
2642,742396,1,3,,103165594,4993,Unspecified,,,1641.73,IC50,SANGER: Inhibition of human NB7 cell growth in a cell viability assay.,Confirmatory,,
2643,742398,1,3,,103165594,4993,Active,,,6.9346,IC50,SANGER: Inhibition of human NCCIT cell growth in a cell viability assay.,Confirmatory,,
2644,742400,1,3,,103165594,4993,Unspecified,,,699.663,IC50,SANGER: Inhibition of human NCI-H1092 cell growth in a cell viability assay.,Confirmatory,,
2645,742401,1,3,,103165594,4993,Unspecified,,,915.895,IC50,SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay.,Confirmatory,,
2646,742402,1,3,,103165594,4993,Unspecified,,,1840.47,IC50,SANGER: Inhibition of human NCI-H128 cell growth in a cell viability assay.,Confirmatory,,
2647,742403,1,3,,103165594,4993,Unspecified,,,72.5771,IC50,SANGER: Inhibition of human NCI-H1299 cell growth in a cell viability assay.,Confirmatory,,
2648,742404,1,3,,103165594,4993,Unspecified,,,64.9466,IC50,SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay.,Confirmatory,,
2649,742405,1,3,,103165594,4993,Unspecified,,,322.91900000000004,IC50,SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay.,Confirmatory,,
2650,742406,1,3,,103165594,4993,Unspecified,,,238.81,IC50,SANGER: Inhibition of human NCI-H1395 cell growth in a cell viability assay.,Confirmatory,,
2651,742407,1,3,,103165594,4993,Unspecified,,,122.495,IC50,SANGER: Inhibition of human NCI-H1417 cell growth in a cell viability assay.,Confirmatory,,
2652,742408,1,3,,103165594,4993,Unspecified,,,2478.87,IC50,SANGER: Inhibition of human NCI-H1436 cell growth in a cell viability assay.,Confirmatory,,
2653,742410,1,3,,103165594,4993,Unspecified,,,979.877,IC50,SANGER: Inhibition of human NCI-H1522 cell growth in a cell viability assay.,Confirmatory,,
2654,743012,3,1,,144203883,4993,Active,,,0.5956,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2655,743012,3,1,,144209032,4993,Active,,,0.1389,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2656,743012,3,1,,144210449,4993,Active,,,0.2731,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2657,743014,3,1,,144203883,4993,Active,,,0.6682,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2658,743014,3,1,,144209032,4993,Active,,,0.1963,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2659,743014,3,1,,144210449,4993,Active,,,0.1087,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2660,743015,3,1,,144203883,4993,Active,,,1.496,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2661,743015,3,1,,144209032,4993,Active,,,0.3916,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2662,743015,3,1,,144210449,4993,Active,,,0.2169,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2663,743033,3,1,,144203883,4993,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2664,743033,3,1,,144209032,4993,Inconclusive,,,12.4866,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2665,743033,3,1,,144210449,4993,Inconclusive,,,30.8956,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2666,743035,2,1,,144203883,4993,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2667,743035,2,1,,144209032,4993,Active,124375976.0,367.0,39.4861,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2668,743035,2,1,,144210449,4993,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2669,743036,2,1,,144203883,4993,Inconclusive,124375976.0,367.0,6.007000000000001,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2670,743036,2,1,,144209032,4993,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2671,743036,2,1,,144210449,4993,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2672,743040,3,1,,144203883,4993,Active,124375976.0,367.0,4.2163,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2673,743040,3,1,,144209032,4993,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2674,743040,3,1,,144210449,4993,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2675,743041,3,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2676,743041,3,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2677,743041,3,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2678,743042,3,1,,144203883,4993,Inconclusive,124375976.0,367.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2679,743042,3,1,,144209032,4993,Active,124375976.0,367.0,49.2994,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2680,743042,3,1,,144210449,4993,Inconclusive,124375976.0,367.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2681,743053,2,1,,144203883,4993,Active,124375976.0,367.0,5.35378,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2682,743053,2,1,,144209032,4993,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2683,743053,2,1,,144210449,4993,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2684,743054,2,1,,144203883,4993,Inconclusive,124375976.0,367.0,25.1151,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2685,743054,2,1,,144209032,4993,Active,124375976.0,367.0,57.4789,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2686,743054,2,1,,144210449,4993,Inconclusive,124375976.0,367.0,61.1306,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2687,743063,2,1,,144203883,4993,Inconclusive,124375976.0,367.0,0.268325,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2688,743063,2,1,,144209032,4993,Inconclusive,124375976.0,367.0,45.5978,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2689,743063,2,1,,144210449,4993,Inconclusive,124375976.0,367.0,52.8725,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2690,743064,3,1,,144203883,4993,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2691,743064,3,1,,144209032,4993,Active,,,62.0642,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2692,743064,3,1,,144210449,4993,Inconclusive,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2693,743065,3,1,,144203883,4993,Active,399498506.0,24831.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2694,743065,3,1,,144209032,4993,Active,399498506.0,24831.0,6.2064,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2695,743065,3,1,,144210449,4993,Active,399498506.0,24831.0,9.6885,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2696,743066,3,1,,144203883,4993,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2697,743066,3,1,,144209032,4993,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2698,743066,3,1,,144210449,4993,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2699,743067,2,1,,144203883,4993,Inconclusive,399498506.0,24831.0,10.5909,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2700,743067,2,1,,144209032,4993,Active,399498506.0,24831.0,5.97276,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2701,743067,2,1,,144210449,4993,Active,399498506.0,24831.0,7.40614,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2702,743069,2,1,,144203883,4993,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2703,743069,2,1,,144209032,4993,Inconclusive,348019627.0,2099.0,62.5812,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2704,743069,2,1,,144210449,4993,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2705,743074,2,1,,144203883,4993,Inconclusive,,,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2706,743074,2,1,,144209032,4993,Active,,,7.0217,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2707,743074,2,1,,144210449,4993,Inconclusive,,,24.5412,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2708,743075,2,1,,144203883,4993,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2709,743075,2,1,,144209032,4993,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2710,743075,2,1,,144210449,4993,Inactive,348019627.0,2099.0,0.7761,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2711,743077,2,1,,144203883,4993,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2712,743077,2,1,,144209032,4993,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2713,743077,2,1,,144210449,4993,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2714,743078,2,1,,144203883,4993,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2715,743078,2,1,,144209032,4993,Inconclusive,348019627.0,2099.0,39.4861,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2716,743078,2,1,,144210449,4993,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2717,743079,3,1,,144203883,4993,Inconclusive,348019627.0,2099.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2718,743079,3,1,,144209032,4993,Inconclusive,348019627.0,2099.0,62.0642,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2719,743079,3,1,,144210449,4993,Inconclusive,348019627.0,2099.0,34.3762,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2720,743080,3,1,,144203883,4993,Active,348019627.0,2099.0,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2721,743080,3,1,,144209032,4993,Inconclusive,348019627.0,2099.0,55.3148,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2722,743080,3,1,,144210449,4993,Inconclusive,348019627.0,2099.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2723,743081,3,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2724,743081,3,1,,144209032,4993,Inconclusive,,,55.3148,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2725,743081,3,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2726,743083,3,1,,144203883,4993,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2727,743083,3,1,,144209032,4993,Active,119597822.0,1588.0,55.3148,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2728,743083,3,1,,144210449,4993,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2729,743084,3,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2730,743084,3,1,,144209032,4993,Inconclusive,,,69.6372,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2731,743084,3,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2732,743085,3,1,,144203883,4993,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2733,743085,3,1,,144209032,4993,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2734,743085,3,1,,144210449,4993,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2735,743086,3,1,,144203883,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2736,743086,3,1,,144209032,4993,Inconclusive,,,7.8134,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2737,743086,3,1,,144210449,4993,Inconclusive,,,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2738,743091,2,1,,144203883,4993,Active,348019627.0,2099.0,26.6032,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2739,743091,2,1,,144209032,4993,Inconclusive,348019627.0,2099.0,60.6515,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2740,743091,2,1,,144210449,4993,Inconclusive,348019627.0,2099.0,48.5577,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2741,743094,3,1,,144203883,4993,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2742,743094,3,1,,144209032,4993,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2743,743094,3,1,,144210449,4993,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2744,743122,2,1,,144203883,4993,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2745,743122,2,1,,144209032,4993,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2746,743122,2,1,,144210449,4993,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2747,743126,1,1,,855854,4993,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2748,743139,2,1,,144203883,4993,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2749,743139,2,1,,144209032,4993,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2750,743139,2,1,,144210449,4993,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2751,743140,2,1,,144203883,4993,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2752,743140,2,1,,144209032,4993,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2753,743140,2,1,,144210449,4993,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2754,743191,3,1,,144209032,4993,Inconclusive,216409692.0,5468.0,55.7756,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2755,743191,3,1,,144210449,4993,Inconclusive,216409692.0,5468.0,17.3739,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2756,743191,3,1,,170464930,4993,Inconclusive,216409692.0,5468.0,33.4889,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2757,743194,3,1,,144209032,4993,Inconclusive,,,0.1572,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2758,743194,3,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2759,743194,3,1,,170464930,4993,Inconclusive,,,21.13,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2760,743199,2,1,,144209032,4993,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2761,743199,2,1,,144210449,4993,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2762,743199,2,1,,170464930,4993,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2763,743202,4,1,,144209032,4993,Inconclusive,20149576.0,4780.0,3.1106,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2764,743202,4,1,,144210449,4993,Inconclusive,20149576.0,4780.0,1.9331,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2765,743202,4,1,,170464930,4993,Inconclusive,20149576.0,4780.0,10.5901,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2766,743203,3,1,,144209032,4993,Inconclusive,,,1.7492,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2767,743203,3,1,,144210449,4993,Inconclusive,,,1.7229,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2768,743203,3,1,,170464930,4993,Active,,,5.3076,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2769,743209,3,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2770,743209,3,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2771,743209,3,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2772,743210,4,1,,144209032,4993,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2773,743210,4,1,,144210449,4993,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2774,743210,4,1,,170464930,4993,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2775,743211,3,1,,144209032,4993,Inconclusive,,,15.7197,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2776,743211,3,1,,144210449,4993,Inconclusive,,,10.9622,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2777,743211,3,1,,170464930,4993,Inconclusive,,,14.9589,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2778,743212,3,1,,144209032,4993,Inconclusive,216409690.0,5467.0,62.5812,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2779,743212,3,1,,144210449,4993,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2780,743212,3,1,,170464930,4993,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2781,743213,3,1,,144209032,4993,Inconclusive,,,11.1287,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2782,743213,3,1,,144210449,4993,Inconclusive,,,24.5412,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2783,743213,3,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2784,743215,3,1,,144209032,4993,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2785,743215,3,1,,144210449,4993,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2786,743215,3,1,,170464930,4993,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2787,743217,3,1,,144209032,4993,Inconclusive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2788,743217,3,1,,144210449,4993,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2789,743217,3,1,,170464930,4993,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2790,743218,3,1,,144209032,4993,Inconclusive,,,2.7954,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2791,743218,3,1,,144210449,4993,Inconclusive,,,15.4845,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2792,743218,3,1,,170464930,4993,Inconclusive,,,10.5901,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2793,743219,3,1,,144209032,4993,Active,20149576.0,4780.0,8.1191,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2794,743219,3,1,,144210449,4993,Inconclusive,20149576.0,4780.0,7.695880000000001,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2795,743219,3,1,,170464930,4993,Inconclusive,20149576.0,4780.0,16.7842,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2796,743220,3,1,,144209032,4993,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2797,743220,3,1,,144210449,4993,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2798,743220,3,1,,170464930,4993,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2799,743221,3,1,,144209032,4993,Active,,,24.914,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2800,743221,3,1,,144210449,4993,Inconclusive,,,13.8006,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2801,743221,3,1,,170464930,4993,Inconclusive,,,21.13,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2802,743222,3,1,,144209032,4993,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2803,743222,3,1,,144210449,4993,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2804,743222,3,1,,170464930,4993,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2805,743223,3,1,,144209032,4993,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2806,743223,3,1,,144210449,4993,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2807,743223,3,1,,170464930,4993,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2808,743224,3,1,,144209032,4993,Inconclusive,,,15.7197,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2809,743224,3,1,,144210449,4993,Active,,,17.3739,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2810,743224,3,1,,170464930,4993,Inconclusive,,,23.7083,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2811,743225,3,1,,144209032,4993,Inconclusive,,,19.7899,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2812,743225,3,1,,144210449,4993,Inconclusive,,,24.5412,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2813,743225,3,1,,170464930,4993,Inconclusive,,,18.9959,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2814,743226,2,1,,144209032,4993,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2815,743226,2,1,,144210449,4993,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2816,743226,2,1,,170464930,4993,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2817,743227,2,1,,144209032,4993,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2818,743227,2,1,,144210449,4993,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2819,743227,2,1,,170464930,4993,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2820,743228,3,1,,144209032,4993,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2821,743228,3,1,,144210449,4993,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2822,743228,3,1,,170464930,4993,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2823,743238,1,1,,855854,4993,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2824,743239,2,1,,144209032,4993,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2825,743239,2,1,,144210449,4993,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2826,743239,2,1,,170464930,4993,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2827,743240,2,1,,144209032,4993,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2828,743240,2,1,,144210449,4993,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2829,743240,2,1,,170464930,4993,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2830,743241,2,1,,144209032,4993,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2831,743241,2,1,,144210449,4993,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2832,743241,2,1,,170464930,4993,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2833,743242,2,1,,144209032,4993,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2834,743242,2,1,,144210449,4993,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2835,743242,2,1,,170464930,4993,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2836,743244,1,1,,144203883,4993,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2837,743247,1,2,,855854,4993,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2838,743247,1,2,,56422411,4993,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2839,743255,1,1,,56422411,4993,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2840,743266,1,2,,56422411,4993,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2841,743268,1,1,,172080651,4993,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
2842,743269,1,1,,855854,4993,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2843,743269,1,1,,855854,4993,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2844,743270,1,1,,172080651,4993,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2845,743271,1,1,,172080651,4993,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
2846,743272,1,1,,172080651,4993,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
2847,743279,1,2,,56422411,4993,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2848,743288,1,1,,17389746,4993,Active,,,10.0,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2849,743288,1,1,,26751532,4993,Active,,,12.5893,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2850,743292,1,1,,17389746,4993,Inconclusive,,,31.6228,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2851,743292,1,1,,26751532,4993,Active,,,28.1838,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2852,743309,1,2,,162163291,4993,Inactive,224586929.0,26191.0,80.0,IC50_LYP (OMFP)_Mean,"SAR confirmation of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, in a fluorescence-based, Lymphoid Phosphatase (PTPN22, LYP-1) selectivity Assay",Confirmatory,,
2853,743310,1,2,,162163291,4993,Inactive,4758208.0,1845.0,80.0,IC50_VHR1 (OMFP)_Mean,"SAR confirmation of uHTS small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, in a fluorescence-based, VHR-1 (dual specificity phosphatase 3) selectivity assay",Confirmatory,,
2854,743322,2,1,,174006175,4993,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2855,743323,2,1,,174006175,4993,Inactive,,,13.3244,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2856,743324,2,1,,174006175,4993,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2857,743325,2,1,,174006175,4993,Inactive,,,,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2858,743326,2,1,,174006175,4993,Inactive,,,,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2859,743327,2,1,,174006175,4993,Inactive,,,,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2860,743344,1,1,,174006175,4993,Inactive,,,10.5839,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2861,743345,1,1,,174006175,4993,Inactive,,,0.1332,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2862,743346,1,1,,174006175,4993,Inactive,,,0.0015,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
2863,743347,1,1,,174006175,4993,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2864,743364,1,2,,174006175,4993,Inactive,,,,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (3D7) proliferation (acoustic dispense),Confirmatory,,
2865,743365,1,2,,174006175,4993,Inactive,,,0.0033,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (DD2) proliferation (acoustic dispense),Confirmatory,,
2866,743366,1,2,,174006175,4993,Inactive,,,,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (HB3) proliferation (acoustic dispense),Confirmatory,,
2867,743397,1,1,,855854,4993,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2868,743398,1,1,,855854,4993,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2869,743398,1,1,,56422411,4993,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2870,747607,1,1,,103165594,4993,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR,Other,23627352.0,
2871,747608,1,1,,103165594,4993,Active,,,0.15,IC50,Inhibition of Mycobacterium avium DHFR,Confirmatory,23627352.0,
2872,747609,1,1,,103165594,4993,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Mycobacterium avium DHFR,Other,23627352.0,
2873,747610,2,3,,103165594,4993,Active,118998.0,,2.4,IC50,Inhibition of Pneumocystis carinii DHFR,Confirmatory,23627352.0,
2874,747611,2,3,,103165594,4993,Active,81871579.0,24312.0,1.5,IC50,Inhibition of rat liver DHFR,Confirmatory,23627352.0,
2875,747612,1,1,,103165594,4993,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant DHFR to IC50 for Pneumocystis jirovecii recombinant DHFR,Other,23627352.0,
2876,747613,1,1,,103165594,4993,Active,,,0.13,IC50,Inhibition of Pneumocystis jirovecii recombinant DHFR,Confirmatory,23627352.0,
2877,747614,2,3,,103165594,4993,Active,118992.0,1719.0,0.4,IC50,Inhibition of human recombinant DHFR,Confirmatory,,
2878,747614,2,3,,103165594,4993,Active,118992.0,573971.0,0.4,IC50,Inhibition of human recombinant DHFR,Confirmatory,,
2879,748916,1,2,,103165594,4993,Unspecified,,,100.0,IC50,Antiplasmodial activity against Plasmodium falciparum VS/1 expressing DHFR quadruple mutation by [3H]-hypoxanthine incorporation assay,Confirmatory,23587422.0,
2880,748917,1,1,,103165594,4993,Active,,,0.057999999999999996,IC50,Antiplasmodial activity against wild type Plasmodium falciparum TM4 by [3H]-hypoxanthine incorporation assay,Confirmatory,23587422.0,
2881,772515,1,2,,103165594,4993,Unspecified,,,,,Antimalarial activity against gametocytic stage of Plasmodium berghei infected in blood assessed as inhibition of ookinete formation at 10 uM after 24 hrs by Giemsa staining-based microscopic analysis relative to control,Other,23927658.0,
2882,772516,1,1,,103165594,4993,Unspecified,,,,,Antimalarial activity against mature gametocytic stage of Plasmodium falciparum assessed as inhibition of mature gamete exflagellation at 10 uM incubated for 24 hrs prior to exflagellation induction at 21 degC measured after 20 mins by microscopic analysis relative to control,Other,23927658.0,
2883,772517,1,1,,103165594,4993,Active,,,1.0,IC50,Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin,Confirmatory,23927658.0,
2884,774658,1,1,,103165594,4993,Active,,,0.013999999999999999,IC50,Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 after 72 hrs by image-based HTS assay,Confirmatory,23927763.0,
2885,774659,1,1,,103165594,4993,Unspecified,,,,,Antimalarial activity against late (4 to 5) gametocytic stage of Plasmodium falciparum at 120 uM after 72 hrs by image-based HTS assay relative to control,Other,23927763.0,
2886,774662,1,1,,103165594,4993,Unspecified,,,,,Antimalarial activity against early (1 to 3) gametocytic stage of Plasmodium falciparum at 120 uM after 72 hrs by image-based HTS assay relative to control,Other,23927763.0,
2887,977599,1,1,,103165594,4993,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2888,977602,1,2,,103165594,4993,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2889,977611,3,1,,208013433,4993,Active,,,0.91,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,24210757.0,
2890,1053175,2,1,,178126462,4993,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
2891,1053188,2,1,,56422411,4993,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2892,1053197,1,1,,855854,4993,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
2893,1058954,1,2,,103165594,4993,Active,,,,,Unbound plasma concentration in ddY mouse at 5 mg/kg,Other,24238901.0,
2894,1058955,1,1,,103165594,4993,Active,,,,,Plasma concentration in ddY mouse at 5 mg/kg,Other,24238901.0,
2895,1058956,2,3,,103165594,4993,Active,189046191.0,20517.0,3.6,Ki,Inhibition of mouse Oct1 transfected in HEK293 cells assessed as uptake of [14C]-TEA preincubated for 15 mins by liquid scintillation counting analysis,Confirmatory,24238901.0,
2896,1058957,2,3,,103165594,4993,Active,162416236.0,67473.0,0.145,Ki,Inhibition of mouse Mate1 transfected in HEK293 cells assessed as uptake of [14C]-TEA preincubated for 15 mins by liquid scintillation counting analysis,Confirmatory,24238901.0,
2897,1059657,1,1,,103165594,4993,Unspecified,,,,,Selectivity ratio of IC50 for DHFR (unknown origin) to IC50 for Toxoplasma gondii DHFR,Other,24470841.0,
2898,1059659,1,1,,103165594,4993,Active,,,3.9,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,24470841.0,
2899,1059660,1,1,,103165594,4993,Active,,,0.57,IC50,Antibacterial activity against tachyzoite stage of Toxoplasma gondii PHdeltaHX infected in human TerT cells measured after 4 days,Confirmatory,24470841.0,
2900,1069174,1,1,,103165594,4993,Active,,,,IC50,Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 7 days by BacTiter-Glo assay,Confirmatory,24412719.0,
2901,1071102,1,1,,103165594,4993,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by broth microdilution assay,Other,24268596.0,
2902,1071104,1,1,,103165594,4993,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate Alamar blue assay,Other,24268596.0,
2903,1071117,1,1,,103165594,4993,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 25 ug/ml after 7 days by microplate Alamar blue assay relative to control,Other,24268596.0,
2904,1071118,1,1,,103165594,4993,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 50 ug/ml after 7 days by microplate Alamar blue assay relative to control,Other,24268596.0,
2905,1071119,1,1,,103165594,4993,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 100 ug/ml after 7 days by microplate Alamar blue assay relative to control,Other,24268596.0,
2906,1071659,1,1,,103165594,4993,Unspecified,,,,EC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by Alamar Blue staining-based broth microdilution assay,Confirmatory,24472146.0,
2907,1077195,1,1,,103165594,4993,Unspecified,,,,,"Selectivity index, ratio of IC50 for CHO cells to IC50 for asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF54",Other,24602791.0,
2908,1077196,3,1,,103165594,4993,Unspecified,,,271.0,IC50,Cytotoxicity against CHO cells after 48 hrs by MTT assay,Confirmatory,24602791.0,
2909,1077197,1,1,,103165594,4993,Unspecified,,,,,"Resistance index, ratio of IC50 for asexual erythrocytic stage of chloroquine-resistant Plasmodium falciparum Dd2 to IC50 for asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF54",Other,24602791.0,
2910,1077198,1,2,,103165594,4993,Unspecified,,,60.7,IC50,Antiplasmodial activity against asexual erythrocytic stage of chloroquine-resistant Plasmodium falciparum Dd2 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay,Confirmatory,24602791.0,
2911,1077199,1,1,,103165594,4993,Active,,,33.0,IC50,Antiplasmodial activity against asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF54 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay,Confirmatory,24602791.0,
2912,1079931,1,1,,103165594,4993,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
2913,1079932,1,1,,103165594,4993,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
2914,1079933,1,1,,103165594,4993,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
2915,1079934,1,1,,103165594,4993,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
2916,1079935,1,1,,103165594,4993,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
2917,1079936,1,1,,103165594,4993,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
2918,1079937,1,1,,103165594,4993,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
2919,1079938,1,1,,103165594,4993,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
2920,1079939,1,1,,103165594,4993,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
2921,1079940,1,1,,103165594,4993,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
2922,1079941,1,1,,103165594,4993,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
2923,1079942,1,1,,103165594,4993,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
2924,1079943,1,1,,103165594,4993,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
2925,1079944,1,1,,103165594,4993,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
2926,1079945,1,1,,103165594,4993,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
2927,1079946,1,1,,103165594,4993,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
2928,1079947,1,1,,103165594,4993,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
2929,1079948,1,1,,103165594,4993,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
2930,1079949,1,1,,103165594,4993,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
2931,1117298,1,2,,170464930,4993,Inactive,,,31.6228,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
2932,1117301,1,2,,170464930,4993,Inactive,,,1.2589,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
2933,1117302,1,2,,170464930,4993,Inactive,,,22.3872,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
2934,1117303,1,2,,170464930,4993,Inactive,,,1.78,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
2935,1117304,1,2,,170464930,4993,Active,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
2936,1117305,1,2,,170464930,4993,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
2937,1117310,1,1,,170464930,4993,Inactive,,,31.6228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
2938,1117311,1,1,,170464930,4993,Inactive,,,1.2589299999999999,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
2939,1117312,1,1,,170464930,4993,Active,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
2940,1117314,1,1,,170464930,4993,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
2941,1117315,1,1,,170464930,4993,Inactive,,,22.3872,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
2942,1117318,1,1,,170464930,4993,Inactive,,,1.7782799999999999,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
2943,1117319,1,2,,855854,4993,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
2944,1117319,1,2,,855854,4993,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
2945,1117325,1,1,,170464930,4993,Active,,,0.86,IC50,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-IC50,Confirmatory,,
2946,1117326,1,1,,170464930,4993,Active,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
2947,1117327,1,1,,170464930,4993,Active,,,0.0677,IC50,alkaline phosphatase stimulation in WNT3A conditioned C2C12 cells-IC50,Confirmatory,,
2948,1117328,1,1,,170464930,4993,Inactive,,,,,human p70S6K1 kinase inhibition-screen,Screening,,
2949,1117329,1,1,,170464930,4993,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
2950,1117336,1,1,,170464930,4993,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
2951,1117340,1,1,,170464930,4993,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
2952,1117341,1,1,,170464930,4993,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
2953,1117342,1,1,,170464930,4993,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
2954,1117343,1,1,,170464930,4993,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
2955,1117346,1,1,,170464930,4993,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
2956,1117347,1,1,,170464930,4993,Inactive,,,10.0,IC50,Decreased HeLa cell count-IC50,Confirmatory,,
2957,1117348,1,1,,170464930,4993,Inactive,,,10.0,IC50,Increased HeLa cells in S-phase-IC50,Confirmatory,,
2958,1117349,1,1,,170464930,4993,Inactive,,,10.0,IC50,Increased HeLa cells with 2N DNA content-IC50,Confirmatory,,
2959,1117350,1,1,,170464930,4993,Inactive,,,10.0,IC50,Increased chromatin condensation in HeLa cells-IC50,Confirmatory,,
2960,1117351,1,1,,170464930,4993,Inactive,,,10.0,IC50,Increased HeLa cells with 4N DNA content-IC50,Confirmatory,,
2961,1117353,1,1,,170464930,4993,Inactive,,,,,human KDR kinase inhibition-screen,Screening,,
2962,1117354,1,1,,170464930,4993,Inactive,,,,,human JAK2 kinase inhibition-screen,Screening,,
2963,1117355,1,1,,170464930,4993,Inactive,,,,,human GSK3B kinase inhibition-screen,Screening,,
2964,1117356,1,1,,170464930,4993,Inactive,,,,,human FLT3 kinase inhibition-screen,Screening,,
2965,1118337,3,1,,103165594,4993,Active,,,0.0133,IC50,Antimalarial activity against schizont stage of chloroquine-susceptible Plasmodium falciparum 3D7 infected in erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs by scintillation counting analysis,Confirmatory,,
2966,1118338,3,1,,103165594,4993,Active,,,0.0021,IC50,Antimalarial activity against schizont stage of chloroquine-susceptible Plasmodium falciparum 3D7 infected in erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 96 hrs by scintillation counting analysis,Confirmatory,,
2967,1118339,3,1,,103165594,4993,Active,,,0.0104,IC50,Antimalarial activity against schizont stage of chloroquine-resistant Plasmodium falciparum W2 infected in erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs by scintillation counting analysis,Confirmatory,,
2968,1118340,3,1,,103165594,4993,Active,,,0.0023,IC50,Antimalarial activity against schizont stage of chloroquine-resistant Plasmodium falciparum W2 infected in erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 96 hrs by scintillation counting analysis,Confirmatory,,
2969,1118341,3,1,,103165594,4993,Active,,,0.0146,IC50,Antimalarial activity against schizont stage of atovaquone-resistant Plasmodium falciparum Tm90C2b infected in erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs by scintillation counting analysis,Confirmatory,,
2970,1118342,3,1,,103165594,4993,Active,,,0.0014,IC50,Antimalarial activity against schizont stage of atovaquone-resistant Plasmodium falciparum Tm90C2b infected in erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 96 hrs by scintillation counting analysis,Confirmatory,,
2971,1118351,1,1,,103165594,4993,Active,,,0.24,IC50,Antitoxoplasma activity against Toxoplasma gondii RH tachyzoites isolated from human brain assessed as parasite growth inhibition after 24 hrs by hematoxylin-eosin staining based light microscopy,Confirmatory,,
2972,1118352,1,1,,103165594,4993,Active,,,0.12,IC50,Antitoxoplasma activity against Toxoplasma gondii RH tachyzoites isolated from human brain assessed as parasite growth inhibition after 48 hrs by hematoxylin-eosin staining based light microscopy,Confirmatory,,
2973,1118353,1,1,,103165594,4993,Inconclusive,,,,LD50,Cytotoxicity against rhesus monkey LLC-MK2 cells assessed as cell viability after 48 hrs by MTS assay,Confirmatory,,
2974,1118354,1,1,,103165594,4993,Inconclusive,,,,LD50,Cytotoxicity against concanavalin A stimulated BALB/c mouse splenocytes after 72 hrs by alamar blue dye based plate reader analysis,Confirmatory,,
2975,1134958,1,1,,103165594,4993,Unspecified,,,,,"Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 20 mg/kg, sc single dose after 72 hrs of infection",Other,117107.0,
2976,1134959,1,1,,103165594,4993,Unspecified,,,,,"Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 10 mg/kg, sc single dose after 72 hrs of infection",Other,117107.0,
2977,1134960,1,1,,103165594,4993,Unspecified,,,,,"Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 5 mg/kg, sc single dose after 72 hrs of infection",Other,117107.0,
2978,1134961,1,1,,103165594,4993,Unspecified,,,,,"Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 2.5 mg/kg, sc single dose after 72 hrs of infection",Other,117107.0,
2979,1134962,1,1,,103165594,4993,Unspecified,,,,,"Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 1.25 mg/kg, sc single dose after 72 hrs of infection",Other,117107.0,
2980,1135018,1,1,,103165594,4993,Unspecified,,,,,"Antimalarial activity against chloroquine-resistant, pyrimethamine-sensitive Plasmodium falciparum Vietnam Oak Knoll in Aotus monkey assessed as dose required to >50% cures compound treated for 7 days",Other,117107.0,
2981,1135019,1,1,,103165594,4993,Unspecified,,,,,"Toxicity in chloroquine-sensitive, pyrimethamine-resistant Plasmodium falciparum Malayan Camp CH/Q infected in Aotus monkey compound treated for 7 days",Other,117107.0,
2982,1135021,1,1,,103165594,4993,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum Vietnam Oak Knoll in po once daily dosed Owl monkey assessed as curative dose compound treated for 7 days,Other,117107.0,
2983,1135023,1,1,,103165594,4993,Unspecified,,,,,Antimalarial activity against Plasmodium vivax New Guinea Chesson in po once daily dosed Owl monkey assessed as curative dose compound treated for 7 days,Other,117107.0,
2984,1135040,1,1,,103165594,4993,Unspecified,,,,,Toxicity in Owl monkey administered as po qd for 7 days,Other,117107.0,
2985,1143938,1,1,,103165594,4993,Unspecified,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 20 mg/kg, sc administered 72 hrs after infection relative to control",Other,102792.0,
2986,1143939,1,1,,103165594,4993,Unspecified,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 10 mg/kg, sc administered 72 hrs after infection relative to control",Other,102792.0,
2987,1143940,1,1,,103165594,4993,Unspecified,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 5 mg/kg, sc administered 72 hrs after infection relative to control",Other,102792.0,
2988,1143941,1,1,,103165594,4993,Unspecified,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 2.5 mg/kg, sc administered 72 hrs after infection relative to control",Other,102792.0,
2989,1143942,1,1,,103165594,4993,Unspecified,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 1.25 mg/kg, sc administered 72 hrs after infection relative to control",Other,102792.0,
2990,1143943,1,1,,103165594,4993,Active,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 640 mg/kg, sc administered 72 hrs after infection",Other,102792.0,
2991,1143944,1,1,,103165594,4993,Active,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 320 mg/kg, sc administered 72 hrs after infection",Other,102792.0,
2992,1143945,1,1,,103165594,4993,Active,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 160 mg/kg, sc administered 72 hrs after infection",Other,102792.0,
2993,1143946,1,1,,103165594,4993,Active,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 80 mg/kg, sc administered 72 hrs after infection",Other,102792.0,
2994,1143947,1,1,,103165594,4993,Active,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 40 mg/kg, sc administered 72 hrs after infection",Other,102792.0,
2995,1143951,1,1,,103165594,4993,Unspecified,,,,,"Toxicity in Plasmodium berghei infected mouse assessed as mortality at 320 mg/kg, sc administered 72 hrs after infection measured after 2 to 5 days",Other,102792.0,
2996,1143952,1,1,,103165594,4993,Unspecified,,,,,"Toxicity in Plasmodium berghei infected mouse assessed as mortality at 640 mg/kg, sc administered 72 hrs after infection measured after 2 to 5 days",Other,102792.0,
2997,1143953,1,1,,103165594,4993,Unspecified,,,,,Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as daily dose required to suppression of 90% parasite infection administered with diet for 6 days,Other,102792.0,
2998,1143954,1,1,,103165594,4993,Unspecified,,,,,Ratio of quinine hydrochloride SD90 to compound SD90 for trophozoite-induced Plasmodium berghei infected in mouse assessed as daily dose required to suppression of 90% parasite infection administered with diet for 6 days,Other,102792.0,
2999,1143981,1,1,,103165594,4993,Active,,,,,"Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 320 mg/kg, sc administered 72 hrs after infection",Other,102792.0,
3000,1143983,1,1,,103165594,4993,Unspecified,,,,,"Toxicity in sporozoite-induced Plasmodium gallinaceum infected white leghorn chicken assessed as mortality at 320 mg/kg, sc administered 72 hrs after infection measured up to 6 days",Other,102792.0,
3001,1143987,1,1,,103165594,4993,Active,,,,,"Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 160 mg/kg, sc administered 72 hrs after infection",Other,102792.0,
3002,1143993,1,1,,103165594,4993,Active,,,,,"Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 80 mg/kg, sc administered 72 hrs after infection",Other,102792.0,
3003,1143999,1,1,,103165594,4993,Active,,,,,"Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 40 mg/kg, sc administered 72 hrs after infection",Other,102792.0,
3004,1144004,1,1,,103165594,4993,Active,,,,,"Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 20 mg/kg, sc administered 72 hrs after infection",Other,102792.0,
3005,1144009,1,1,,103165594,4993,Active,,,,,"Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 10 mg/kg, sc administered 72 hrs after infection",Other,102792.0,
3006,1145671,1,1,,103165594,4993,Active,,,0.008,IC50,Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth,Confirmatory,137981.0,
3007,1145672,1,1,,103165594,4993,Active,,,10.5,IC50,Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth,Confirmatory,137981.0,
3008,1145673,1,1,,103165594,4993,Unspecified,,,,,"Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 to IC50 for sensitive Streptococcus faecium ATCC 8043",Other,137981.0,
3009,1145674,1,1,,103165594,4993,Active,,,5.1,IC50,Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction,Confirmatory,137981.0,
3010,1145675,1,1,,103165594,4993,Active,,,0.24,IC50,Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth,Confirmatory,137981.0,
3011,1145676,1,1,,103165594,4993,Unspecified,,,,,"Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 to IC50 for sensitive Lactobacillus casei ATCC 7469",Other,137981.0,
3012,1145677,1,1,,103165594,4993,Active,,,4.0,IC50,Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction,Confirmatory,137981.0,
3013,1145678,1,1,,103165594,4993,Active,,,12.0,IC50,Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth,Confirmatory,137981.0,
3014,1145679,1,1,,103165594,4993,Unspecified,,,,,"Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 to IC50 for sensitive Pediococcus cerevisiae ATCC 808",Other,137981.0,
3015,1145680,1,1,,103165594,4993,Unspecified,,,76.0,IC50,Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth,Confirmatory,137981.0,
3016,1145681,1,1,,103165594,4993,Inactive,,,,,Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid,Other,137981.0,
3017,1145682,1,1,,103165594,4993,Inactive,,,,,Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid,Other,137981.0,
3018,1145683,1,1,,103165594,4993,Inactive,,,,,Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid,Other,137981.0,
3019,1145684,1,1,,103165594,4993,Inactive,,,,,Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid,Other,137981.0,
3020,1145685,1,1,,103165594,4993,Inactive,,,,,Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid,Other,137981.0,
3021,1145686,1,1,,103165594,4993,Inactive,,,,,Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid,Other,137981.0,
3022,1145687,1,1,,103165594,4993,Active,,,,,Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth in presence of p-aminobenzoic acid,Other,137981.0,
3023,1145688,1,1,,103165594,4993,Unspecified,,,,,Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as active dose required to increase of 100% in mean survival time,Other,137981.0,
3024,1145689,1,1,,103165594,4993,Unspecified,,,,,Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as dose required to survivors for period of 60 days,Other,137981.0,
3025,1148778,1,1,,103165594,4993,Unspecified,,,,,Antimalarial activity against Plasmodium berghei KBG13 infected in mouse assessed as minimum dose required for disease cures,Other,775088.0,
3026,1148781,1,1,,103165594,4993,Unspecified,,,,,Toxicity in mouse infected with Plasmodium berghei KBG13 assessed as animal death at 2 times minimum curative dose,Other,775088.0,
3027,1155422,3,1,,103165594,4993,Active,,,0.028260000000000004,IC50,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 after 72 hrs by SYBR I method,Confirmatory,24914738.0,
3028,1155423,3,1,,103165594,4993,Active,,,8.55842,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 72 hrs by SYBR I method,Confirmatory,24914738.0,
3029,1155470,1,1,,103165594,4993,Active,,,10.0417,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR I method,Confirmatory,24914738.0,
3030,1155471,1,1,,103165594,4993,Active,,,15.3797,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR I method,Confirmatory,24914738.0,
3031,1155472,1,1,,103165594,4993,Active,,,0.01085,IC50,Antiplasmodial activity against Plasmodium falciparum SB1 after 72 hrs by SYBR I method,Confirmatory,24914738.0,
3032,1155473,1,2,,103165594,4993,Active,,,13.8386,IC50,Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR I method,Confirmatory,24914738.0,
3033,1159387,1,2,,103165594,4993,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
3034,1159389,1,2,,103165594,4993,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
3035,1159390,1,2,,103165594,4993,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
3036,1159509,1,1,,144209032,4993,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3037,1159509,1,1,,144210449,4993,Inconclusive,119626539.0,4790.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3038,1159509,1,1,,170464930,4993,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3039,1159515,1,1,,144209032,4993,Inconclusive,,,55.7756,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3040,1159515,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3041,1159515,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3042,1159516,1,1,,144209032,4993,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3043,1159516,1,1,,144210449,4993,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3044,1159516,1,1,,170464930,4993,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3045,1159517,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3046,1159517,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3047,1159517,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3048,1159518,1,1,,144209032,4993,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3049,1159518,1,1,,144210449,4993,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3050,1159518,1,1,,170464930,4993,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3051,1159519,1,1,,144209032,4993,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3052,1159519,1,1,,144210449,4993,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3053,1159519,1,1,,170464930,4993,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3054,1159520,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3055,1159520,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3056,1159520,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3057,1159521,1,1,,144209032,4993,Inconclusive,15928672.0,19885.0,34.9013,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3058,1159521,1,1,,144210449,4993,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3059,1159521,1,1,,170464930,4993,Inconclusive,15928672.0,19885.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3060,1159523,1,1,,144209032,4993,Inconclusive,15928672.0,19885.0,40.6919,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3061,1159523,1,1,,144210449,4993,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3062,1159523,1,1,,170464930,4993,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3063,1159524,1,1,,56422411,4993,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3064,1159524,1,1,,124881960,4993,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3065,1159525,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3066,1159525,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3067,1159525,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3068,1159526,1,1,,144209032,4993,Inconclusive,119627033.0,3725.0,44.3041,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3069,1159526,1,1,,144210449,4993,Inconclusive,119627033.0,3725.0,43.6412,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3070,1159526,1,1,,170464930,4993,Inconclusive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3071,1159527,1,1,,144209032,4993,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3072,1159527,1,1,,144210449,4993,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3073,1159527,1,1,,170464930,4993,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3074,1159528,1,1,,144209032,4993,Inconclusive,119627033.0,3725.0,41.8258,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3075,1159528,1,1,,144210449,4993,Active,119627033.0,3725.0,33.3603,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3076,1159528,1,1,,170464930,4993,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3077,1159529,1,1,,144209032,4993,Inconclusive,,,22.2047,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3078,1159529,1,1,,144210449,4993,Inconclusive,,,21.8724,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3079,1159529,1,1,,170464930,4993,Inconclusive,,,15.089,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3080,1159531,1,1,,144209032,4993,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3081,1159531,1,1,,144210449,4993,Inconclusive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3082,1159531,1,1,,170464930,4993,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3083,1159550,3,1,,252402850,4993,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
3084,1159551,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3085,1159551,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3086,1159551,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3087,1159552,1,1,,144209032,4993,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3088,1159552,1,1,,144210449,4993,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3089,1159552,1,1,,170464930,4993,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3090,1159553,2,1,,144209032,4993,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3091,1159553,2,1,,144210449,4993,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3092,1159553,2,1,,170464930,4993,Inconclusive,325495463.0,5914.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3093,1159555,1,1,,144209032,4993,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3094,1159555,1,1,,144210449,4993,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3095,1159555,1,1,,170464930,4993,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3096,1159580,2,1,,268734694,4993,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3097,1159583,2,1,,178126462,4993,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
3098,1159606,1,1,,56422411,4993,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
3099,1159607,2,1,,312309710,4993,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
3100,1159614,1,2,,170464930,4993,Inactive,22328079.0,2581.0,0.7079,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
3101,1159620,1,1,,103165594,4993,Active,,,,,Summary of drug indications.,Other,,
3102,1174521,1,1,,103165594,4993,Active,,,0.01,IC50,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 assessed as inhibition of parasite growth after 72 hrs by parasite LDH release assay,Confirmatory,25462261.0,
3103,1174524,1,1,,103165594,4993,Inactive,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as inhibition of parasite growth up to 19 uM after 72 hrs by parasite LDH release assay,Other,25462261.0,
3104,1174526,1,1,,103165594,4993,Inconclusive,,,,IC50,Cytotoxicity against African green monkey Vero cells after 72 hrs by neutral red assay,Confirmatory,25462261.0,
3105,1182742,1,1,,103165594,4993,Active,,,0.0283,IC50,Antiplasmodial activity against Plasmodium falciparum NF54 by SYBR-green based assay,Confirmatory,25007124.0,
3106,1182743,1,1,,103165594,4993,Active,,,8.5584,IC50,Antiplasmodial activity against Plasmodium falciparum K1 by SYBR-green based assay,Confirmatory,25007124.0,
3107,1182789,1,2,,103165594,4993,Active,,,10.0417,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 harboring mutations conferring drug-resistance by SYBR-green based assay,Confirmatory,25007124.0,
3108,1182790,1,1,,103165594,4993,Active,,,15.3797,IC50,Antiplasmodial activity against Plasmodium falciparum W2 harboring mutations conferring drug-resistance by SYBR-green based assay,Confirmatory,25007124.0,
3109,1182791,1,1,,103165594,4993,Active,,,0.0109,IC50,Antiplasmodial activity against Plasmodium falciparum SB1-A6 harboring mutations conferring drug-resistance by SYBR-green based assay,Confirmatory,25007124.0,
3110,1182792,1,2,,103165594,4993,Active,,,13.8386,IC50,Antiplasmodial activity against Plasmodium falciparum Dd2 harboring mutations conferring drug-resistance by SYBR-green based assay,Confirmatory,25007124.0,
3111,1182793,1,1,,103165594,4993,Unspecified,,,,,"Resistance index, ratio of IC50 for Plasmodium falciparum K1 to IC50 for Plasmodium falciparum NF54",Other,25007124.0,
3112,1182794,1,1,,103165594,4993,Unspecified,,,,,"Resistance index, ratio of IC50 for Plasmodium falciparum 7G8 to IC50 for Plasmodium falciparum NF54",Other,25007124.0,
3113,1182795,1,1,,103165594,4993,Unspecified,,,,,"Resistance index, ratio of IC50 for Plasmodium falciparum W2 to IC50 for Plasmodium falciparum NF54",Other,25007124.0,
3114,1182796,1,1,,103165594,4993,Unspecified,,,,,"Resistance index, ratio of IC50 for Plasmodium falciparum Dd2 to IC50 for Plasmodium falciparum NF54",Other,25007124.0,
3115,1188166,1,1,,103165594,4993,Unspecified,,,,IC50,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by microdilution AlamarBlue broth assay,Confirmatory,25129868.0,
3116,1189129,1,1,,103165594,4993,Active,,,5.71,IC50,"DNDI: Chagas in Vitro, 96 hour",Confirmatory,,
3117,1189130,1,1,,103165594,4993,Active,,,2.51,IC50,"DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells",Confirmatory,,
3118,1189131,1,1,,103165594,4993,Unspecified,,,12.06,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in mouse macrophages (infected-amastigotes)",Confirmatory,,
3119,1189133,1,1,,103165594,4993,Active,,,6.75,IC50,"DNDI: HAT in Vitro, 72 hour",Confirmatory,,
3120,1189134,1,1,,103165594,4993,Unspecified,,,277.83,IC50,"DNDI: Leish (axenic) in Vitro, 72 hour",Confirmatory,,
3121,1189135,1,1,,103165594,4993,Unspecified,,,12.06,IC50,"DNDI: Leish (macro) in Vitro, 96 hour",Confirmatory,,
3122,1189136,1,1,,103165594,4993,Active,,,9.85,IC50,"DNDI: Malaria in Vitro, 72 hour",Confirmatory,,
3123,1190840,1,1,,103165594,4993,Active,,,0.027999999999999997,IC50,Antiplasmodial activity against Plasmodium falciparum NF54 by SYBR Green-based method,Confirmatory,25599834.0,
3124,1190841,1,1,,103165594,4993,Active,,,8.6,IC50,Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 by SYBR Green-based method,Confirmatory,25599834.0,
3125,1192798,1,1,,103165594,4993,Active,,,0.027999999999999997,IC50,Antimalarial activity against drug-sensitive Plasmodium falciparum NF54 by SYBR green-based assay,Confirmatory,25650255.0,
3126,1192799,1,1,,103165594,4993,Active,,,8.6,IC50,Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by SYBR green-based assay,Confirmatory,25650255.0,
3127,1196722,1,1,,103165594,4993,Unspecified,,,,,Antiparasitic activity against promastigote form of Leishmania mexicana MHOM/BZ/61/M379 at 100 uM after 24 hrs by haemocytometer,Other,25576738.0,
3128,1196723,1,1,,103165594,4993,Unspecified,,,100.0,IC50,Antiparasitic activity against promastigote form of Leishmania mexicana MHOM/BZ/61/M379 after 24 hrs by haemocytometer,Confirmatory,25576738.0,
3129,1196724,1,1,,103165594,4993,Inconclusive,,,,,Solubility of the compound in phosphate buffered saline at pH 7.4 by UV spectrophotometry,Other,25576738.0,
3130,1201517,1,1,,103165594,4993,Active,,,2.0,IC50,Antitoxoplasmic activity against tachyzoite stage of Toxoplasma gondii PRU transfected with beta galactosidase infected in HFF assessed as parasite growth inhibition after 96 hrs by colorimetric microtiter assay,Confirmatory,25791675.0,
3131,1201532,1,1,,103165594,4993,Active,,,2.8,IC50,Inhibition of Plasmodium falciparum DHFR after 48 hrs,Confirmatory,25791675.0,
3132,1202552,1,1,,103165594,4993,Unspecified,,,122.0,CC50,Cytotoxicity against African green monkey Vero cells after 24 hrs by MTT assay,Confirmatory,25899334.0,
3133,1202553,1,1,,103165594,4993,Unspecified,,,,,"Antiplasmodial activity against Plasmodium berghei infected in CD1 mouse assessed as reduction in parasitemia at 50 mg/kg, po administered for 4 days measured on day 4 relative to vehicle-treated control",Other,25899334.0,
3134,1202554,1,1,,103165594,4993,Unspecified,,,,,"Antiplasmodial activity against Plasmodium berghei infected in CD1 mouse assessed as survival time at 50 mg/kg, po administered for 4 days measured on day 4 relative to vehicle-treated control",Other,25899334.0,
3135,1207600,1,1,,103165594,4993,Unspecified,,,,,ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro,Other,,
3136,1207601,1,1,,103165594,4993,Unspecified,,,,,ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro,Other,,
3137,1207602,1,2,,103165594,4993,Unspecified,74959757.0,,,,ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro,Other,,
3138,1224824,1,1,,174006175,4993,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
3139,1224825,1,1,,174006175,4993,Inactive,,,8.3328,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
3140,1224834,3,1,,144209032,4993,Inconclusive,,,8.7668,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3141,1224834,3,1,,144210449,4993,Inconclusive,,,17.2289,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3142,1224834,3,1,,170464930,4993,Inconclusive,,,8.4127,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3143,1224835,1,1,,144209032,4993,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3144,1224835,1,1,,144210449,4993,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3145,1224835,1,1,,170464930,4993,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3146,1224836,1,1,,144209032,4993,Inconclusive,,,55.3148,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3147,1224836,1,1,,144210449,4993,Inconclusive,,,24.3365,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3148,1224836,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3149,1224837,1,1,,144209032,4993,Inconclusive,,,24.7082,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3150,1224837,1,1,,144210449,4993,Inconclusive,,,27.305999999999997,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3151,1224837,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3152,1224838,1,1,,144209032,4993,Active,66775687.0,9970.0,1.7492,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3153,1224838,1,1,,144210449,4993,Active,66775687.0,9970.0,3.0638,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3154,1224838,1,1,,170464930,4993,Inconclusive,66775687.0,9970.0,2.9849,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3155,1224839,1,1,,144209032,4993,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3156,1224839,1,1,,144210449,4993,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3157,1224839,1,1,,170464930,4993,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3158,1224840,3,1,,144209032,4993,Inconclusive,,,24.7082,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3159,1224840,3,1,,144210449,4993,Inconclusive,,,17.2289,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3160,1224840,3,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3161,1224841,3,1,,144209032,4993,Active,325495545.0,2101.0,6.2064,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3162,1224841,3,1,,144210449,4993,Active,325495545.0,2101.0,8.6349,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3163,1224841,3,1,,170464930,4993,Active,325495545.0,2101.0,8.4127,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3164,1224842,3,1,,144209032,4993,Inactive,325495545.0,2101.0,13.8945,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3165,1224842,3,1,,144210449,4993,Inactive,325495545.0,2101.0,12.1972,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3166,1224842,3,1,,170464930,4993,Inactive,325495545.0,2101.0,8.4127,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3167,1224843,1,1,,144209032,4993,Inconclusive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3168,1224843,1,1,,144210449,4993,Inconclusive,119601739.0,7253.0,27.305999999999997,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3169,1224843,1,1,,170464930,4993,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3170,1224844,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3171,1224844,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3172,1224844,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3173,1224845,1,1,,144209032,4993,Active,344243002.0,100757539.0,22.8913,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3174,1224845,1,1,,144210449,4993,Inconclusive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3175,1224845,1,1,,170464930,4993,Inconclusive,344243002.0,100757539.0,0.0695,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3176,1224846,1,1,,144209032,4993,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3177,1224846,1,1,,144210449,4993,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3178,1224846,1,1,,170464930,4993,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3179,1224847,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3180,1224847,1,1,,144210449,4993,Active,,,8.9762,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3181,1224847,1,1,,170464930,4993,Active,,,12.357000000000001,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3182,1224848,3,1,,144209032,4993,Active,325495545.0,2101.0,6.2064,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3183,1224848,3,1,,144210449,4993,Active,325495545.0,2101.0,8.6349,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3184,1224848,3,1,,170464930,4993,Active,325495545.0,2101.0,7.4978,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3185,1224849,3,1,,144209032,4993,Inactive,325495545.0,2101.0,6.2064,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3186,1224849,3,1,,144210449,4993,Inactive,325495545.0,2101.0,8.6349,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3187,1224849,3,1,,170464930,4993,Inactive,325495545.0,2101.0,7.4978,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3188,1224857,2,1,,170464930,4993,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3189,1224857,2,1,,174006175,4993,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3190,1224859,2,1,,170464930,4993,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3191,1224859,2,1,,174006175,4993,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3192,1224863,1,1,,176484889,4993,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3193,1224863,1,1,,316919782,4993,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3194,1224864,1,2,,316934980,4993,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
3195,1224865,1,2,,56422411,4993,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3196,1224867,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3197,1224867,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3198,1224867,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3199,1224868,1,1,,144209032,4993,Active,,,3.5192,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3200,1224868,1,1,,144210449,4993,Active,,,12.2998,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3201,1224868,1,1,,170464930,4993,Inconclusive,,,4.2527,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3202,1224869,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3203,1224869,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3204,1224869,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3205,1224870,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3206,1224870,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3207,1224870,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3208,1224871,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3209,1224871,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3210,1224871,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3211,1224872,1,1,,144209032,4993,Inconclusive,,,12.4866,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3212,1224872,1,1,,144210449,4993,Inconclusive,,,43.6412,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3213,1224872,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3214,1224873,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3215,1224873,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3216,1224873,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3217,1224874,1,1,,144209032,4993,Active,,,3.5192,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3218,1224874,1,1,,144210449,4993,Active,,,12.2998,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3219,1224874,1,1,,170464930,4993,Active,,,5.3538,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3220,1224875,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3221,1224875,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3222,1224875,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3223,1224876,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3224,1224876,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3225,1224876,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3226,1224877,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3227,1224877,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3228,1224877,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3229,1224878,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3230,1224878,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3231,1224878,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3232,1224879,1,1,,144209032,4993,Inconclusive,,,49.71,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3233,1224879,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3234,1224879,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3235,1224880,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3236,1224880,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3237,1224880,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3238,1224881,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3239,1224881,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3240,1224881,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3241,1224882,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3242,1224882,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3243,1224882,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3244,1224883,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3245,1224883,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3246,1224883,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3247,1224884,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3248,1224884,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3249,1224884,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3250,1224885,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3251,1224885,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3252,1224885,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3253,1224886,1,1,,144209032,4993,Inconclusive,,,3.5192,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3254,1224886,1,1,,144210449,4993,Inconclusive,,,12.2998,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3255,1224886,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3256,1224887,1,1,,144209032,4993,Inconclusive,,,31.3649,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3257,1224887,1,1,,144210449,4993,Inconclusive,,,54.941,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3258,1224887,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3259,1224888,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3260,1224888,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3261,1224888,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3262,1224889,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3263,1224889,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3264,1224889,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3265,1224890,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3266,1224890,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3267,1224890,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3268,1224892,1,1,,144209032,4993,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3269,1224892,1,1,,144210449,4993,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3270,1224892,1,1,,170464930,4993,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3271,1224893,1,1,,144209032,4993,Active,66775687.0,9970.0,6.08847,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3272,1224893,1,1,,144210449,4993,Active,66775687.0,9970.0,5.04574,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3273,1224893,1,1,,170464930,4993,Active,66775687.0,9970.0,3.22305,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3274,1224894,1,1,,144209032,4993,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3275,1224894,1,1,,144210449,4993,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3276,1224894,1,1,,170464930,4993,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3277,1224895,1,1,,144209032,4993,Inconclusive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3278,1224895,1,1,,144210449,4993,Inconclusive,119601739.0,7253.0,22.9752,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3279,1224895,1,1,,170464930,4993,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3280,1224896,1,1,,144209032,4993,Active,344243002.0,100757539.0,29.3767,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3281,1224896,1,1,,144210449,4993,Inconclusive,344243002.0,100757539.0,44.9878,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3282,1224896,1,1,,170464930,4993,Active,344243002.0,100757539.0,31.0393,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3283,1227098,1,1,,103165594,4993,Active,311033393.0,3073.0,3.1,IC50,Inhibition of human placental HexA using MUGS substrate incubated for 1 to 2 hrs at pH 7.0 by spectrofluorometry,Confirmatory,25984755.0,
3284,1227099,1,1,,103165594,4993,Active,311033393.0,3073.0,8.9,IC50,Inhibition of human placental HexA using MUGS substrate incubated for 1 to 2 hrs at pH 4.5 by spectrofluorometry,Confirmatory,25984755.0,
3285,1227100,1,1,,103165594,4993,Active,123081.0,3074.0,9.1,IC50,Inhibition of human placental HexB using MUGS substrate incubated for 1 to 2 hrs at pH 4.5 by spectrofluorometry,Confirmatory,25984755.0,
3286,1227101,1,1,,103165594,4993,Active,123081.0,3074.0,15.0,IC50,Inhibition of beta-N-acetylhexosaminidase (unknown origin),Confirmatory,25984755.0,
3287,1227101,1,1,,103165594,4993,Active,311033393.0,3073.0,15.0,IC50,Inhibition of beta-N-acetylhexosaminidase (unknown origin),Confirmatory,25984755.0,
3288,1227102,1,1,,103165594,4993,Active,311033393.0,3073.0,17.0,IC50,Inhibition of human placental HexA using pNPGlcNAc substrate,Confirmatory,25984755.0,
3289,1227103,1,1,,103165594,4993,Unspecified,311033393.0,3073.0,,,Chaperoning efficacy at HexA alpha G269S mutant in ATSD patient fibroblasts assessed as maximum increase in enzyme activity using MUGS substrate incubated for 1 to 2 hrs by spectrofluorometry relative to control,Other,25984755.0,
3290,1227105,1,1,,103165594,4993,Unspecified,,,,,Toxicity against ATSD patient fibroblasts assessed as reduction in cell viability up to 400 uM by almar blue assay,Other,25984755.0,
3291,1227106,1,1,,103165594,4993,Active,118992.0,1719.0,,,Inhibition of human DHFR,Other,25984755.0,
3292,1227106,1,1,,103165594,4993,Active,118992.0,573971.0,,,Inhibition of human DHFR,Other,25984755.0,
3293,1227107,1,1,,103165594,4993,Active,48429227.0,6774.0,,,Inhibition of STAT3 phosphorylation in ATSD patient fibroblasts at 100 uM,Other,25984755.0,
3294,1227108,1,1,,103165594,4993,Active,311033393.0,3073.0,,,Chaperoning efficacy at HexA alpha G269S mutant in ATSD patient fibroblasts assessed as drug level causing maximum increase in enzyme activity using MUGS substrate incubated for 1 to 2 hrs by spectrofluorometry relative to control,Other,25984755.0,
3295,1227109,1,1,,103165594,4993,Unspecified,,,,,Toxicity against ATSD patient fibroblasts assessed as reduction in beta-galactosidase activity at >400 uM,Other,25984755.0,
3296,1227110,1,1,,103165594,4993,Unspecified,,,,,Toxicity against ATSD patient fibroblasts assessed as reduction in beta-galactosidase activity at,Other,25984755.0,
3297,1227112,1,1,,103165594,4993,Active,311033393.0,3073.0,14.0,IC50,Inhibition of HexA in normal human fibroblasts using MUGS substrate incubated for 1 to 2 hrs at pH 4.5 by spectrofluorometry,Confirmatory,25984755.0,
3298,1227113,1,1,,103165594,4993,Active,311033393.0,3073.0,8.5,IC50,Inhibition of HexA alpha G269S mutant in ATSD patient fibroblasts using MUGS substrate incubated for 1 to 2 hrs at pH 4.5 by spectrofluorometry,Confirmatory,25984755.0,
3299,1227114,1,1,,103165594,4993,Active,123081.0,3074.0,4.5,IC50,Inhibition of human placental HexB using MUGS substrate incubated for 1 to 2 hrs at pH 7.0 by spectrofluorometry,Confirmatory,25984755.0,
3300,1227116,1,1,,103165594,4993,Active,311033393.0,3073.0,,,Induction of lysosomal transport of HexA alpha G269S mutant in ATSD patient fibroblasts at 11 ug/ml incubated for 5 days by Western blotting method,Other,25984755.0,
3301,1227118,1,1,,103165594,4993,Active,311033393.0,3073.0,,,Induction of lysosomal transport of HexA alpha G269S mutant in ATSD patient fibroblasts at 11 ug/ml by immunofluorescence staining method,Other,25984755.0,
3302,1227119,1,1,,103165594,4993,Active,311033393.0,3073.0,,,Induction of HexA alpha G269S mutant activity in ATSD patient fibroblasts assessed as hydrolysis of fluorescent analogue of GM2 ganglioside at 11 ug/ml incubated for 10 days by TLC method,Other,25984755.0,
3303,1227122,1,1,,103165594,4993,Active,311033393.0,3073.0,,,Induction of HexA alpha G269S mutant activity in ATSD patient fibroblasts assessed as LacCer level at 11 ug/ml incubated for 10 days by TLC method,Other,25984755.0,
3304,1227123,1,1,,103165594,4993,Active,311033393.0,3073.0,,,Induction of HexA alpha G269S mutant activity in ATSD patient fibroblasts assessed as GlcCer level at 11 ug/ml incubated for 10 days by TLC method,Other,25984755.0,
3305,1227126,1,1,,103165594,4993,Active,311033393.0,3073.0,,,Induction of wild type HexA activity in non-GM2 gangliosidosis patient fibroblasts at 33 ug/ml incubated for 5 days,Other,25984755.0,
3306,1228553,1,1,,103165594,4993,Active,,,0.068,IC50,Antimalarial activity against Plasmodium falciparum 3D7A infected in red blood cells assessed as inhibition of parasite growth after 24 hrs by [3H]hypoxanthine incorporation assay,Confirmatory,25906200.0,
3307,1228554,1,1,,103165594,4993,Unspecified,,,20.0,IC50,Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum W2 assessed as inhibition of parasite growth,Confirmatory,25906200.0,
3308,1228555,1,1,,103165594,4993,Unspecified,,,20.0,IC50,Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum V1/S assessed as inhibition of parasite growth,Confirmatory,25906200.0,
3309,1254216,1,1,,103165594,4993,Unspecified,,,,,Antiplasmodial activity against Plasmodium falciparum 3D7 infected in po dosed non-myelodepleted NOD-SCID IL2Rgammanull mouse engrafted with human erythrocytes assessed as reduction of parasitemia level administered qd for 4 days,Other,26502160.0,
3310,1259241,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3311,1259241,1,1,,144210449,4993,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3312,1259241,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3313,1259242,1,1,,144209032,4993,Inconclusive,,,55.3148,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3314,1259242,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3315,1259242,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3316,1259243,1,1,,144209032,4993,Inactive,124375976.0,367.0,7.8134,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3317,1259243,1,1,,144210449,4993,Active,124375976.0,367.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3318,1259243,1,1,,170464930,4993,Inconclusive,124375976.0,367.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3319,1259244,1,1,,144209032,4993,Active,348019627.0,2099.0,31.1058,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3320,1259244,1,1,,144210449,4993,Active,348019627.0,2099.0,48.5577,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3321,1259244,1,1,,170464930,4993,Inconclusive,348019627.0,2099.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3322,1259247,1,1,,144209032,4993,Inconclusive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3323,1259247,1,1,,144210449,4993,Active,124375976.0,367.0,56.6142,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3324,1259247,1,1,,170464930,4993,Inconclusive,124375976.0,367.0,21.1317,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3325,1259248,1,1,,144209032,4993,Active,348019627.0,2099.0,44.9616,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3326,1259248,1,1,,144210449,4993,Active,348019627.0,2099.0,48.5577,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3327,1259248,1,1,,170464930,4993,Inconclusive,348019627.0,2099.0,23.7101,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3328,1259252,1,1,,174006175,4993,Inconclusive,169655958.0,,14.818,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
3329,1259253,1,1,,174006175,4993,Active,169655958.0,,1.3207,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
3330,1259255,1,1,,174006175,4993,Inconclusive,169655958.0,,2.6351,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
3331,1259256,1,1,,174006175,4993,Active,169655958.0,,2.6351,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
3332,1259309,1,1,,178126462,4993,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3333,1259310,1,1,,104170026,4993,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3334,1259310,1,1,,321942176,4993,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3335,1259310,1,1,,332877407,4993,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3336,1259311,1,1,,178126462,4993,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3337,1259313,1,1,,56422411,4993,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3338,1259318,1,1,,855854,4993,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3339,1259325,1,2,,336954309,4993,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3340,1259344,1,1,,144203883,4993,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3341,1259355,1,1,,26751532,4993,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3342,1259356,1,1,,144203883,4993,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3343,1259364,1,1,,144209032,4993,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3344,1259364,1,1,,144210449,4993,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3345,1259364,1,1,,170464930,4993,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3346,1259365,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3347,1259365,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3348,1259365,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3349,1259366,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3350,1259366,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3351,1259366,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3352,1259367,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3353,1259367,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3354,1259367,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3355,1259368,1,1,,144209032,4993,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3356,1259368,1,1,,144210449,4993,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3357,1259368,1,1,,170464930,4993,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3358,1259369,1,1,,144209032,4993,Active,109731339.0,2737.0,17.4921,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3359,1259369,1,1,,144210449,4993,Active,109731339.0,2737.0,27.305999999999997,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3360,1259369,1,1,,170464930,4993,Inconclusive,109731339.0,2737.0,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3361,1259377,1,1,,144209032,4993,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3362,1259377,1,1,,144210449,4993,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3363,1259377,1,1,,170464930,4993,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3364,1259378,1,1,,144209032,4993,Inconclusive,54288833.0,2100.0,43.9381,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3365,1259378,1,1,,144210449,4993,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3366,1259378,1,1,,170464930,4993,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3367,1259379,1,1,,144209032,4993,Inconclusive,,,69.6372,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3368,1259379,1,1,,144210449,4993,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3369,1259379,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3370,1259380,1,1,,144209032,4993,Inconclusive,,,27.7231,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3371,1259380,1,1,,144210449,4993,Active,,,21.6899,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3372,1259380,1,1,,170464930,4993,Active,,,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3373,1259381,1,1,,144209032,4993,Inconclusive,124375976.0,367.0,22.0212,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3374,1259381,1,1,,144210449,4993,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3375,1259381,1,1,,170464930,4993,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3376,1259382,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3377,1259382,1,1,,144210449,4993,Inconclusive,,,30.6379,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3378,1259382,1,1,,170464930,4993,Inconclusive,,,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3379,1259383,1,1,,144209032,4993,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3380,1259383,1,1,,144210449,4993,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3381,1259383,1,1,,170464930,4993,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3382,1259384,1,1,,144209032,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3383,1259384,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3384,1259384,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3385,1259385,1,1,,144209032,4993,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3386,1259385,1,1,,144210449,4993,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3387,1259385,1,1,,170464930,4993,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3388,1259386,1,1,,144209032,4993,Inconclusive,,,69.6372,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3389,1259386,1,1,,144210449,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3390,1259386,1,1,,170464930,4993,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3391,1259387,1,1,,144209032,4993,Inconclusive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3392,1259387,1,1,,144210449,4993,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3393,1259387,1,1,,170464930,4993,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3394,1259388,1,1,,144209032,4993,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3395,1259388,1,1,,144210449,4993,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3396,1259388,1,1,,170464930,4993,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3397,1259389,1,1,,124637461,4993,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3398,1259390,1,1,,144209032,4993,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3399,1259390,1,1,,144210449,4993,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3400,1259390,1,1,,170464930,4993,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3401,1259391,1,1,,144209032,4993,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3402,1259391,1,1,,144210449,4993,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3403,1259391,1,1,,170464930,4993,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3404,1259392,1,1,,144209032,4993,Active,109731339.0,2737.0,17.1596,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3405,1259392,1,1,,144210449,4993,Active,109731339.0,2737.0,17.903,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3406,1259392,1,1,,170464930,4993,Active,109731339.0,2737.0,19.9496,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3407,1259393,1,1,,144209032,4993,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3408,1259393,1,1,,144210449,4993,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3409,1259393,1,1,,170464930,4993,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3410,1259394,1,1,,144209032,4993,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3411,1259394,1,1,,144210449,4993,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3412,1259394,1,1,,170464930,4993,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3413,1259395,1,1,,144209032,4993,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3414,1259395,1,1,,144210449,4993,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3415,1259395,1,1,,170464930,4993,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3416,1259396,1,1,,144209032,4993,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3417,1259396,1,1,,144210449,4993,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3418,1259396,1,1,,170464930,4993,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3419,1259400,1,1,,170464930,4993,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3420,1259401,1,1,,144209032,4993,Active,325495545.0,2101.0,12.1481,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3421,1259401,1,1,,144210449,4993,Inconclusive,325495545.0,2101.0,10.4614,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3422,1259401,1,1,,170464930,4993,Active,325495545.0,2101.0,9.43918,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3423,1259402,1,1,,144209032,4993,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3424,1259402,1,1,,144210449,4993,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3425,1259402,1,1,,170464930,4993,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3426,1259403,1,1,,144209032,4993,Active,325495545.0,2101.0,7.81343,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3427,1259403,1,1,,144210449,4993,Active,325495545.0,2101.0,9.68854,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3428,1259403,1,1,,170464930,4993,Active,325495545.0,2101.0,7.7911399999999995,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3429,1259404,1,1,,144209032,4993,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3430,1259404,1,1,,144210449,4993,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3431,1259404,1,1,,170464930,4993,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3432,1259406,1,1,,363920229,4993,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
3433,1259406,1,1,1.0,363920229,4993,Inactive,26638650.0,3778.0,0.0572019,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
3434,1259406,1,1,2.0,363920229,4993,Inactive,4758626.0,3779.0,-0.11578,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3435,1259406,1,1,3.0,363920229,4993,Inactive,5031823.0,10242.0,0.052120400000000004,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3436,1259406,1,1,4.0,363920229,4993,Inactive,26051275.0,27345.0,-0.011247100000000001,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3437,1259406,1,1,5.0,363920229,4993,Inactive,160410009.0,389816.0,-0.0171623,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3438,1259406,1,1,6.0,363920229,4993,Inactive,26638650.0,3778.0,-0.00785136,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
3439,1259406,1,1,7.0,363920229,4993,Inactive,4758626.0,3779.0,-0.00379139,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3440,1259406,1,1,8.0,363920229,4993,Inactive,5031823.0,10242.0,0.00565232,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3441,1259406,1,1,9.0,363920229,4993,Inactive,26051275.0,27345.0,-0.00455348,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3442,1259406,1,1,10.0,363920229,4993,Inactive,5031823.0,10242.0,-0.0704723,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
3443,1259407,1,1,,363898496,4993,Active,,,,,CCRIS mutagenicity studies,Other,,
3444,1259408,1,1,,363894874,4993,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
3445,1259411,1,1,,363898496,4993,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
3446,1259413,1,2,,104170026,4993,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
3447,1259415,1,1,,855854,4993,Active,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3448,1259416,1,2,,855854,4993,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3449,1259416,1,2,,173028005,4993,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3450,1259416,1,2,,340080514,4993,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3451,1259421,1,1,,173028005,4993,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3452,1259421,1,1,,340080514,4993,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3453,1259423,1,2,,354820696,4993,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3454,1259423,1,2,,354958437,4993,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3455,1259423,1,2,,355009883,4993,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
